

Publications on the Clinical Use of SIR-Spheres® microspheres

Since the first experimental patients were treated in the late 1980s, numerous reports detailing the use of SIR-Spheres microspheres have appeared in the literature. These papers have been from a variety of clinical trial and experiential settings and are presented here as a bibliography in different tumour types and in chronological order (latest first). In addition, the interim results of other studies that have as yet only been presented at scientific meetings are provided separately in each tumour type.

Review articles, technical papers and books or chapters on selective internal radiation therapy (SIRT) or radioembolisation that are useful sources of information on areas related to treating patients with SIR-Spheres microspheres are also listed, again in chronological order in each section.

Contents

Colorectal Cancer Liver Metastases.....	2
Hepatocellular Carcinoma.....	8
Neuroendocrine Tumour Liver Metastases.....	13
Breast Cancer Liver Metastases	16
Pancreatic Cancer Liver Metastases.....	16
Cholangiocarcinoma	17
Melanoma Liver Metastases	18
Lung Cancer Liver Metastases.....	18
Cervical Cancer Liver Metastases.....	18
Desmoplastic Small Round Cell Tumour Liver Metastases	19
Renal Cell Carcinoma Liver Metastases.....	19
Hemangi endothelioma Liver Metastases.....	19
Testicular Cancer Liver Metastases	19
Primary or Metastatic Soft Tissue Sarcomas of the Liver.....	19
Thyroid Cancer Liver Metastases.....	19
Liver Metastases from Cancer of Unknown Primary.....	20
Liver Tumours from Various Cancer Sources.....	20
Lung Malignancies	26
Haematological Malignancies.....	26
Primary Renal Cancer.....	26
Consensus Statements / Guidelines	27
Review Articles	29
Mechanistic Aspects of Treatment	40
Hepatic Arterial Anatomy	50
Imaging.....	53
Managing Side Effects and Complications	67
Books and Book Chapters	73

©SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd



www.sirtex.com

Sirtex Medical Limited
Level 33, 101 Miller Street
North Sydney NSW 2060
Australia
Phone: +61 2 99 64 8400
Email: info@sirtex.com

Sirtex Medical Singapore Pte Ltd
50 Science Park Road
#01-01 Science Park II
Singapore 117406
Phone: +65 6308 8370
Email: info@sirtex.com

Sirtex Medical Europe GmbH
Walter-Flex Straße 2,
D-53113 Bonn, Germany
Phone: +49 228 18 407 30
Email: info@sirtex-europe.com

Colorectal Cancer Liver Metastases

Prospective Clinical Studies in Colorectal Cancer Liver Metastases

Reid T. Integration of selective internal radiation therapy second-line: The InSIRT trial. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 10–11.

Wasan H. Selective internal radiation therapy first-line therapy – SIRFLOX and FOXFIRE. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 12–14.

Gulec SA, Pennington K, Wheeler J *et al.* Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (Chemo-SIRT) for colorectal cancer liver metastases: An in vivo double-arm-controlled phase II trial. *American Journal of Clinical Oncology* 2012 May 24; ePub doi: 10.1097/COC.0b013e3182546c50.

Fahmueller YN, Nagel D, Hoffmann RT *et al.* Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy. *BMC Cancer* 2012; **12**: 5.

Gulec SA, Suthar RR, Barot TC, Pennington K. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing ⁹⁰Y selective internal radiation therapy plus chemotherapy. *European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38**: 1289–1295.

Cosimelli M, Golfieri R, Cagol PP *et al.* Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. *British Journal of Cancer* 2010; **103**: 324–331.

Hendlisz A, Van den Eynde M, Peeters M *et al.* Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. *Journal of Clinical Oncology* 2010; **28**: 3687–3694.

van Hazel GA, Pavlakis N, Goldstein D *et al.* Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using Yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. *Journal of Clinical Oncology* 2009; **27**: 4089–4095. [see accompanying editorial by Kuebler JP under *Review Articles/ Colorectal Cancer*]

Van den Eynde M, Flamen P, El Nakadi I *et al.* Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. *Clinical Nuclear Medicine* 2008; **33**: 697–699.

Flamen P, Vanderlinden B, Delatte P *et al.* Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. *Physics in Medicine and Biology* 2008; **53**: 6591–6603.

Sharma RA, Wasan HS, Love SB *et al.* FOXFIRE: a phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases in patients with colorectal cancer. *Clinical Oncology (Royal College of Radiologists)* 2008; **20**: 261–263.

Sharma R, van Hazel G, Morgan B *et al.* Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. *Journal of Clinical Oncology* 2007; **25**: 1099–1106.

Mancini R, Carpanese L, Sciuto R *et al.* A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with ⁹⁰yttrium SIR-Spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: Preliminary results on toxicity and response rates. *In vivo* 2006; **20**: 711–714.

Lim L, Gibbs P, Yip D *et al.* A prospective evaluation of treatment with selective internal radiation therapy (SIR-Spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. *BMC Cancer* 2005; **5**: 132.

van Hazel G, Blackwell A, Anderson J *et al.* Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. *Journal of Surgical Oncology* 2004; **88**: 78–85.

Gray B, van Hazel G, Hope M *et al.* Randomised trial of SIR-Spheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. *Annals of Oncology* 2001; **12**: 1711–1720.

Abstracts on Prospective Clinical Studies in Colorectal Cancer Liver Metastases

Birlew RA, El-Rayes E, Kauh J *et al.* Longitudinal quality of life assessment of patients with hepatic metastatic colorectal adenocarcinoma after treatment with transarterial radioembolization yttrium-90 therapy. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S37 Abs. 67.

Reid TR, Roeland E, Dad S *et al.* inSIRT trial: Single-center phase II study of yttrium-90 radioactive resin microspheres in the treatment of liver-predominant metastatic colorectal adenocarcinoma after failure of first-line combination chemotherapy. *ASCO Annual Meeting 2012, Journal of Clinical Oncology* 2012; **30** (suppl): Abs. e14079.

Sofocleous CT, Kemeny NE, Pandit-Taskar N *et al.* Phase I trial of yttrium 90 resin microspheres in the treatment of colon cancer liver metastases progressing despite hepatic arterial as well as systemic chemotherapy: Preliminary results. *ASCO Gastrointestinal Cancers Symposium* 2012; Abs. 625.

Roeland E, Shimabukuro KA, Fanta PT *et al.* inSIRT trial: Single-center phase II study of yttrium-90 radioactive resin microspheres in the treatment of liver-predominant metastatic colorectal adenocarcinoma after failure of first-line combination chemotherapy. *ASCO Gastrointestinal Cancers Symposium* 2012; Abs. 685.

Rose SC, Roeland E, Shimabukuro K *et al.* Single center prospective phase II trial of yttrium-90 radioembolization for treatment of colorectal liver metastases that have failed first line chemotherapy and prior to initiation of second line chemotherapy: study design and early results. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2011; Abs. 1306.4.

Murthy R, Mahvash A, Avritscher R *et al.* SIRTUXIRI: Yttrium-90 radioembolotherapy with cetuximab & irinotecan in colorectal hepatic metastases (NCT00766220). *The 3rd Annual Symposium on Clinical Interventional Oncology (CIO)* 2011; Abs.

Cosimelli M, Mancini R, Izzo F *et al.* Immunohistochemical expression of biomarkers in patients with highly chemorefractory colorectal liver metastases (mCRC) pre and post radioembolization (RE) with yttrium-90 resin microspheres. *ASCO Gastrointestinal Cancers Symposium* 2010; Abs. 494.

van Hazel G, Turner D, GebSKI V. Impact of ⁹⁰Y resin microspheres on health-related quality of life (HRQoL) in patients with colorectal cancer (CRC) liver metastases receiving first-line chemotherapy. *ASCO Gastrointestinal Cancers Symposium* 2009; Abstract 419.

Retrospective Studies in Colorectal Cancer Liver Metastases

Sharma R, Antony S, Anderson E. Clinical benefit and potential pitfalls in combining thermal ablation and radiation therapy to treat liver metastases. *Journal of Clinical Oncology* 2013; **31**: e404-e406.

Fendler WP, Philippe Tiega DB, Ilhan H *et al.* Validation of several SUV-based parameters derived from ¹⁸F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. *Journal of Nuclear Medicine* 2013 May 31; ePub doi: 10.2967/jnumed.112.116426.

Melucci E, Cosimelli M, Carpanese L *et al.* Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensitivity after radioembolization with yttrium-90 resin microspheres. *Journal of Experimental and Clinical Cancer Research* 2013; **32**: 13.

Soydal C, Kucuk ON, Gecim EI *et al.* The prognostic value of quantitative parameters of ¹⁸F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer. *Nuclear Medicine Communications* 2013 Mar 7; ePub doi: 10.1097/MNM.0b013e32835f9427.

Bester L, Meteling B, Pocock N *et al.* Radioembolisation with yttrium-90 microspheres: An effective treatment modality for unresectable liver metastases. *Journal of Medical Imaging and Radiation Oncology* 2013; **57**: 72–80. [see sub-group analysis]

Zerizer I, Al-Nahhas A, Towey D *et al.* The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria. *European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39**: 1391–1399.

Schonewolf CA, Patel B, Gensure RH *et al.* Patterns of failure in colorectal patients with liver metastases after yttrium-90 radioembolization. *American Journal of Clinical Oncology* 2012 Dec 27; ePub doi: 10.1097/COC.0b013e318277d610.

- Wang LM, Jani AR, Hill EJ, Sharma RA. Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. *Journal of Clinical Pathology* 2013; **66**: 205–211.
- Rosenbaum CE, van den Bosch MA, Veldhuis WB *et al.* Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases. *European Radiology* 2012 Oct 31; ePub doi: 10.1007/s00330-012-2693-x.
- Bester L, Meteling B, Pocock N *et al.* Radioembolization versus standard care of hepatic metastases: Comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. *Journal of Vascular and Interventional Radiology* 2012; **23**: 96–105. [see sub-group analysis]
- Fong ZV, Palazzo F, Needleman L *et al.* Combined hepatic arterial embolization and hepatic ablation for unresectable colorectal metastases to the liver. *The American Surgeon* 2012; **78**: 1243–1248.
- Fahmueller YN, Nagel D, Hoffmann RT *et al.* Immunogenic cell death biomarkers HMGB1, RAGE and DNase indicate response to radioembolisation therapy and prognosis in colorectal cancer patients. *International Journal of Cancer* 2012 Oct 10; ePub doi: 10.1002/ijc.27894.
- Seidensticker R, Denecke T, Kraus P *et al.* Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. *Cardiovascular and Interventional Radiology* 2012; **35**: 1066–1073.
- Martin LK, Cucci A, Wei L, Rose J *et al.* Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. *Clinical Colorectal Cancer* 2012 Jan 23; ePub doi: 0.1016/j.clcc.2011.12.002.
- Hadaki M, Praseedom R, Brais R *et al.* Selective internal radiation therapy with ⁹⁰Y-SIR-Spheres microspheres for non-resectable colorectal metastases in the liver. *BMJ Case Reports* 2011; ePub doi: 10.1136/bcr.01.2011.3793.
- Kosmider S, Tan TT, Yip D *et al.* Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. *Journal of Vascular and Interventional Radiology* 2011; **22**: 780–786.
- Nace GW, Steel JL, Amesur N *et al.* Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. *International Journal of Surgical Oncology* 2011; 571261.
- Chua TC, Bester L, Saxena A, Morris DL. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. *Journal of Cancer Research Clinical Oncology* 2011; **137**: 865–873.
- Chua TC, Bester L, Akther J, Morris DL. Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres(R)) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases. *Anticancer Research* 2010; **30**: 3005–3007.
- Dudeck O, Zeile M, Wybranski C *et al.* Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. *European Radiology* 2010; **20**: 2699–2706.
- Pini S, Pinto C, Angelelli B *et al.* Multimodal sequential approach in colorectal cancer liver metastases: hepatic resection after yttrium-90 selective internal radiation therapy and cetuximab rescue treatment. *Tumori* 2010; **96**: 157–159.
- Cianni R, Urigo C, Notarianni E *et al.* Selective internal radiation therapy with SIR-Spheres for the treatment of unresectable colorectal hepatic metastases. *Cardiovascular and Interventional Radiology* 2009; **32**: 1179–1186.
- Campbell JM, Wong CO, Muzik O *et al.* Early dose response to Yttrium-90 microsphere treatment of metastatic liver cancer by a patient-specific method using single photon emission computed tomography and positron emission tomography. *International Journal of Radiation Oncology, Biology and Physics* 2009; **74**: 313–320.
- Siddiqi NH, Devlin PM. Radiation lobectomy—A minimally invasive treatment model for liver cancer: Case report. *Journal of Vascular and Interventional Radiology* 2009; **20**: 664–669.
- Jakobs TF, Hoffmann RT, Dehm K *et al.* Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. *Journal of Vascular and Interventional Radiology* 2008; **19**: 1187–1195.
- Murthy R, Eng C, Krishnan S *et al.* Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. *Journal of Vascular and Interventional Radiology* 2007; **18**: 1588–1591.

- Garrean S, Muhs A, Bui JT *et al.* Complete eradication of hepatic metastasis from colorectal cancer by Yttrium-90 SIRT. *World Journal of Gastroenterology* 2007; **13**: 3016–3019.
- Lin M, Shon IH, Wilson R *et al.* Treatment response in liver metastases following ⁹⁰Y SIR-spheres: an evaluation with PET. *Hepato-Gastroenterology* 2007; **54**: 910–912.
- Boppudi S, Wickremesekera S, Nowitz M *et al.* Evaluation of the role of CT in the assessment of response to selective internal radiation therapy in patients with colorectal liver metastases. *Australasian Radiology* 2006; **50**: 570–577.
- Kennedy A. ⁹⁰Y-microsphere brachytherapy is effective in treating unresectable colorectal liver metastases. *American Journal of Hematology/Oncology Review* October 2006; **5**: 1–5.
- Stubbs R, O'Brien I, Correia M. Selective internal radiation therapy with ⁹⁰Y-microspheres for colorectal liver metastases: single-centre experience with 100 patients. *ANZ Journal of Surgery* 2006; **76**: 696–703. [see accompanying editorial by Morris D under *Review Articles/Colorectal Cancer*]
- Kennedy A, Coldwell D, Nutting C *et al.* Resin ⁹⁰Y-microsphere brachytherapy for unresectable colorectal metastases: modern USA experience. *International Journal of Radiation Oncology, Biology and Physics* 2006; **65**: 412–425.
- Murthy R, Xiong H, Nunez R *et al.* Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: Preliminary results. *Journal of Vascular and Interventional Radiology* 2005; **16**: 937–945.
- Stubbs R, Wickremesekera S. Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases. *HPB* 2004; **6**: 133–139.
- Stubbs R, Cannan R, Mitchell A. Selective internal radiation therapy with yttrium-90 microspheres for extensive liver metastases. *Journal of Gastrointestinal Surgery* 2001; **5**: 294–302.
- Stubbs R, Cannan R, Mitchell A. Selective internal radiation therapy (SIRT) with ⁹⁰yttrium microspheres for extensive colorectal liver metastases. *Hepato-Gastroenterology* 2001; **48**: 333–337.
- Gray B, van Hazel G, Buck M *et al.* Treatment of colorectal liver metastases with SIR-Spheres plus chemotherapy. *GI Cancer* 2000; **3**: 249–257.
- Stubbs R, Cannan R, Mitchell A *et al.* An initial experience with selective internal radiation therapy (SIRT) for non-resectable colorectal liver metastases. *GI Cancer* 1999; **3**: 135–143.
- Stubbs R, Cannan R. Active treatment of colorectal hepatic metastases. *New Zealand Family Physician* 1999; **26**.
- Gray B, Anderson J, Burton M *et al.* Regression of liver metastases following treatment with yttrium-90 microspheres. *ANZ Journal of Surgery* 1992; **62**: 105–110.
- Gray B, Burton M, Kelleher D *et al.* Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate. *Journal of Surgical Oncology* 1989; **42**: 192–196.

Abstracts on Retrospective Studies in Colorectal Cancer Liver Metastases

- Kennedy AS, Ball D, Cohen SK *et al.* Safety and efficacy of ⁹⁰Y resin microspheres in elderly (≥70 years) compared to younger patients with colorectal liver metastases (mCRC). *ASCO Annual Meeting 2013, Journal of Clinical Oncology* **31** (Suppl): Abs. e14545.
- Goldin D, Berry SK, Mansoor BM *et al.* Survival after radioembolization for metastatic colorectal cancer: search for prognostic factors. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S36–37 Abs. 66.
- Lam MG, Louie JD, Abdelmaksoud M *et al.* Dose-response analysis in metastatic colorectal cancer patients treated with hepatic yttrium-90 radioembolization. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S37 Abs. 68.
- Kennedy AS, Ball D, Steven J. Cohen SJ *et al.* Safety and efficacy of resin ⁹⁰Y-microspheres in 548 patients with colorectal liver metastases progressing on systemic chemotherapy. *ASCO Gastrointestinal Cancers Symposium* 2013; Abs. 264.
- Kennedy AS, Ball D, Steven J. Cohen SJ *et al.* Hepatic imaging response to ⁹⁰Y-microsphere therapy administered for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. *ASCO Gastrointestinal Cancers Symposium* 2013; Abs. 270.
- Goldin D, Mansoor B, Berry S *et al.* Bevacizumab effects on Y-90 microsphere infusion, tumor-to-normal vascularity ratio, and survival in metastatic colorectal cancer. *15th Annual Symposium on Clinical Interventional Oncology (CIO)* 2013; Abs 13.

Lawal T, Prajapati H, El Rayes B *et al.* Salvage Yttrium-90 radioembolization after failed chemotherapy for colorectal cancer liver metastases. *American Association for the Study of Liver Diseases (AASLD) Congress, Hepatology* 2012; **56** (Suppl 1): Abs. 1380.

Sabet A, Ezziddin S, Muckle M *et al.* ¹⁸F-FDG-PET/CT in planning of selective internal radiation therapy of colorectal liver metastases. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. OP173.

Schoen M, Kant D, Dietrich J *et al.* Selective internal radiation therapy (SIRT) prior to liver resection for colorectal liver metastases. *International Hepato-Pancreato-Biliary Association Congress* 2012; Abs. C443.

Coldwell D, Schacht M, Sharma V. Differential response to radioembolization for colorectal cancer metastases to the liver in KRAS mutant patients. *World Conference on Interventional Oncology (WCIO) meeting* 2012; Abs. 48.

Kennedy AS, Ball D, Cohen SJ *et al.* USA patients receiving resin ⁹⁰Y microspheres for unresectable colorectal liver metastases: A multi-center study of 506 patients. *ASCO Annual Meeting 2012, Journal of Clinical Oncology* 2012; **30** (suppl): Abs. 3590.

Leoni C, Mosconi C, Giampalma E *et al.* Response and survival after ⁹⁰Y radioembolisation of colorectal liver metastases refractory to chemotherapy. *European Society of Radiology ECR* 2012; Abs. C-0735.

Sofocleous CT, Pandit-Taskar N, Do K *et al.* Yttrium 90 resin microspheres as a salvage treatment for colon cancer liver metastases progressing after at least two prior lines of systemic chemotherapy: preliminary results. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S70 Abs. 168.

Savin MA, Vartanian SA, Metz T *et al.* Early imaging accuracy post Y90 radioembolization for liver metastases from colorectal cancer. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S70–S71 Abs. 169.

Rosenbaum CE, Smits M, Seinstra BA *et al.* Diffusion-weighted magnetic resonance imaging for early tumor response assessment after Yttrium-90 radioembolization in patients with colorectal cancer liver metastases. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S84 Abs. 204.

Grabowski SF, Nichols EM, Kudryasheva S *et al.* The efficacy of selective internal radiation therapy (SIRT) with yttrium-90 (Y90) is enhanced when given in low volume disease and in conjunction with other liver-directed therapies. *53rd Annual Meeting of American Society for Radiation Oncology (ASTRO), International Journal of Radiation Oncology, Biology and Physics* 2011; **81** (2 Suppl): S353–S354 Abs. 2296.

Ulrich G, Zeile M, Großer OS *et al.* Does the intratumoral uptake pattern of Tc-99m-MAA allow a prediction of response to yttrium-90-radioembolization in patients with colorectal liver metastases? *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. P743.

Cove-Smith L, Wilson G. Efficacy and toxicity of selective internal radiation therapy (SIRT) with yttrium 90 microspheres for the treatment of unresectable hepatic tumours: a retrospective analysis of 58 patients. *13th World Congress on Gastrointestinal Cancer, Annals of Oncology* 2011; **22** (Suppl 5): v64 Abs. P-0150.

Paprottka PM, Hoffmann RT, Trumm CG *et al.* ⁹⁰Yttrium-radioembolization of chemotherapy-refractory colorectal cancer liver metastases. *World Conference on Interventional Oncology (WCIO) meeting* 2011; Abs. 52.

Paprottka PM, Hoffmann RT, Räßler F *et al.* ⁹⁰Yttrium-radioembolisation of chemotherapy-refractory colorectal cancer liver metastases. *European Congress of Radiology* 2011; Abs. B-160.

Cucci AR, Martin EW Jr., Bloomston M *et al.* Y-90 radioembolization in the treatment of colorectal cancer that is metastatic to the liver. *ASCO Gastrointestinal Cancers Symposium, Journal of Clinical Oncology* 2011; **29** (Suppl 4): Abs. 593.

Ju AW, Hamidi M, Bradley KA *et al.* The use of bevacizumab prior to radioembolization of colorectal liver metastases with yttrium-90 resin microspheres. *52nd Annual Meeting of American Society for Radiation Oncology (ASTRO), International Journal of Radiation Oncology, Biology and Physics* 2010; **78** (3 Suppl): S318 Abs. 2257.

Tie J, Yip D, Dowling R *et al.* Radioembolization and systemic chemotherapy in patients with hepatic metastases from primary colorectal cancer. *ESMO Congress, Ann Oncol* 2010; **21** (Suppl 8): Abs. 698.

Tie J, Kosmider S, Yip D *et al.* Selective internal radiation therapy combined with systemic chemotherapy as a first-line treatment for unresectable liver-dominant colorectal cancer. *12th World Congress on Gastrointestinal Cancer, Annals of Oncology* 2010; **21** (Suppl 7): Abs. P-0137.

Wasan HS, Gungor H, Medani H *et al.* Survival of metastatic colorectal cancer patients treated with concurrent ⁹⁰Y chemo-radioembolisation (SIRT + modified FOLFOX) after failure of all lines of conventional therapy. *12th World Congress on Gastrointestinal Cancer, Annals of Oncology* 2010; **21** (Suppl 7): Abs. P-0183.

Gibbs P, Stubbs RS, Pavlakis N *et al.* Durable disease-free survival without resection of target lesions following radioembolisation with yttrium-90 resin microspheres in patients with colorectal liver metastases. *European Multidisciplinary Colorectal Cancer Congress, Annals of Oncology* 2010; **21** (Suppl 1): i50 Abs. P95.

Sangro B, Chopitea A, Rodriguez J *et al.* Radioembolization using Y90-labeled resin microspheres (Y90-RE) as consolidation treatment after 1st-line chemotherapy (CxT) for liver metastases from colorectal cancer (CRC). *ASCO Gastrointestinal Cancers Symposium* 2010; Abs. 250.

Öz İI, Peker A, Küçük Ö *et al.* Treatment of unoperable and chemorefractory liver metastasis of colorectal cancer by yttrium-90 resin microspheres: Experience at Ankara University Medical Faculty. *European Association of Nuclear Medicine (EANM) Conference* 2009; Abs. P629.

Mutha PR, Madoff DC, Mahvash A *et al.* Extrahepatic progression of hepatic-only metastatic colorectal cancer: Impact on combinatorial (systemic + local) therapy clinical trial design. *Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2009; **26** (2S): S63 Abs. 162.

Kennedy AS, Kreuk P, Jakobs T, Dezarn WA. Effects of anti-angiogenic therapy and chemotherapy on ⁹⁰Y-microsphere treatment of colorectal liver metastases. *20th International Congress on Anti Cancer Treatment (ICACT)* 2009; Abs. IC/AB159.

Gurajala RKR, Sinha A, Chandakacharla R *et al.* A new technique for the treatment of colorectal cancer liver metastases with SIRT Yttrium-90 microspheres: A review of the first five cases. *European Association of Nuclear Medicine (EANM) Conference* 2008; Abs. PW103.

Tan TH, Kosmider S, Yip D, Gibbs P. Clinical experience of selective internal radiation therapy in combination with systemic chemotherapy as first-line therapy in patients with unresectable hepatic metastases from colorectal cancer. *ASCO Annual Meeting, Journal of Clinical Oncology* 2008; **26** (May 20 Supplement): Abs. 15080.

Kennedy A. Long-lived complete responders following radioembolization: Does this challenge the orthodox belief of disease progression? *2nd European Symposium on Liver-Directed Cancer Therapies using Microspheres* February 2008.

Stubbs R, O'Brien I, Correia M. Selective internal radiation therapy for colorectal liver metastases: single-centre experience with 100 patients. *7th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA)* 2006; Abs.

Murthy R, Habbu A, Richey S *et al.* Implications of patterns of metastases of mCRC on liver directed therapy in patients undergoing combination systemic treatment with irinotecan and cetuximab. *World Conference on Interventional Oncology (WCIO) meeting* 2006; Abs. 8130.

Rivet M. Monitoring ⁹⁰Y-SIR-Sphere treatment response with ¹⁸F-FDG-PET. *36th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine* April 2006; Abs. 14.

Kennedy A, Coldwell D, Nutting C *et al.* Liver Brachytherapy for unresectable Colorectal Metastases: US Results 2000–2004. *ASCO Gastrointestinal Cancers Symposium* 2005; Abs. 145.

Huie M, Greiner L, Thomas J *et al.* Institutional series of selective internal radiation therapy (SIRT) for liver predominant metastatic colorectal cancer. *Journal of Clinical Oncology* 2004; **22** 14S, Abs. 3665.

Geller DA, Carr BI, Amesur N *et al.* Responses in chemotherapy-refractory liver metastases from colon cancer to single dose hepatic artery ⁹⁰Y microspheres. *ASCO Annual Meeting, Proceedings of the American Society of Clinical Oncology* 2003; **22**: Abs. 1489.

Hepatocellular Carcinoma

Prospective Clinical Studies in Hepatocellular Carcinoma

Chow P, Ricke J, Malfertheiner P, Vilgrain V. Evolving clinical evidence for selective internal radiation therapy in hepatocellular carcinoma. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 30–33.

Sangro B, Bilbao JI, Boan J *et al.* Radioembolization using ⁹⁰Y-resin microspheres for patients with advanced hepatocellular carcinoma. *International Journal of Radiation Oncology, Biology and Physics* 2006; **66**: 792–800.

Lau W, Ho S, Leung T *et al.* Selective internal radiation therapy for non-resectable hepatocellular carcinoma with intraarterial infusion of 90-yttrium microspheres. *International Journal of Radiation Oncology, Biology and Physics* 1998; **40**: 583–592.

Lau W, Leung W, Ho S *et al.* Treatment of inoperable hepatocellular carcinoma with intra-hepatic arterial yttrium-90 microspheres: a phase I and II study. *British Journal of Cancer* 1994; **70**: 994–999.

Abstracts on Prospective Clinical Studies in Hepatocellular Carcinoma

Kolligs FT, Bilbao JI, Jakobs T *et al.* SIRTACE: A randomized multicentre pilot trial of selective internal radioembolisation (SIRT) with yttrium-90 microspheres versus transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC). *European Association for the Study of the Liver (EASL) Congress, Journal of Hepatology* 2013; **58** (Suppl 1): S51 Abs. 114.

Ricke J, Bulla K, Walecki J *et al.* Safety and toxicity of the combination of Y-90 radioembolization and sorafenib in advanced HCC: An interim analysis of the European multicenter trial SORAMIC. *European Association for the Study of the Liver (EASL) Congress, Journal of Hepatology* 2013; **58** (Suppl 1): S114 Abs. 268.

Irani FG, Tay K, Burgmans MC *et al.* Multi-centre phase II study of SIR-spheres plus sorafenib in patients with non-resectable hepatocellular carcinoma. The Asia-Pacific HCC trials group protocol 05 (AHCC05). *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S83–S84 Abs. 202.

Ricke J, Schuette K, I. Graziadei W *et al.* Evaluation of sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma. *ASCO Annual Meeting, Journal of Clinical Oncology* 2011; **29** (Suppl): Abs. TPS175.

Chow PK, Poon D, Win KM *et al.* Multicenter phase II study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma: The Asia-Pacific Hepatocellular Carcinoma Trials Group Protocol 05 (AHCC05). *ASCO Annual Meeting, Journal of Clinical Oncology* 2010; **28** (Suppl 7s): Abs. 4072.

Chow PK, Poon D, Choo S *et al.* Phase I study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma: The Asia-Pacific Hepatocellular Carcinoma Trials Group protocol 05 (AHCC05). *ASCO Annual Meeting, Journal of Clinical Oncology* 2009; **27** (Suppl 7s): Abs. 15538.

Retrospective Studies in Hepatocellular Carcinoma

Iñarrairaegui M, Pardo F, Sangro B. Reply to: Downstaging to liver resection by radioembolization: A difficult to reach strategy? *European Journal of Surgical Oncology* 2013 May 23; ePub doi: 10.1016/j.ejso.2013.05.006. [Reply to Tabone *et al.* *European Journal of Surgical Oncology* 2013; ePub.]

Tabone M, Calvo A, Viganò L, Ferrero A. Downstaging to liver resection by radioembolization: A difficult to reach strategy? *European Journal of Surgical Oncology* 2013 Jun 3; ePub doi: 10.1016/j.ejso.2013.05.010. [Comment on Iñarrairaegui *et al.* *European Journal of Surgical Oncology* 2012; **38**: 594–601.]

Golfieri R, Bilbao JI, Carpanese L *et al*; on behalf of the European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators. Comparison of the survival and tolerability of radioembolization in elderly versus younger patients with unresectable hepatocellular carcinoma. *Journal of Hepatology* 2013 May 23; ePub doi: S0168-8278(13)00356-5. 10.1016/j.jhep.2013.05.025.

- Edeline J, Lenoir L, Boudjema K *et al.* Volumetric changes after ⁹⁰Y radioembolization for hepatocellular carcinoma in cirrhosis: An option to portal vein embolization in a preoperative setting? *Annals of Surgical Oncology* 2013 Mar 15; ePub doi: 10.1245/s10434-013-2906-2909.
- Hawkins CM, Kukreja K, Geller JI *et al.* Radioembolisation for treatment of pediatric hepatocellular carcinoma. *Pediatric Radiology* 2012 Dec 5; ePub doi: 10.1007/s00247-012-2568-y.
- Ettorre G, Vennarecci, R, Santoro, P *et al.* Bridging and downstaging to transplantation in HCC. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 41–43.
- Xie F, Zang J, Guo X *et al.* Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. *Journal of Cancer Research and Clinical Oncology* 2012; **138**: 455–462.
- Burgmans MC, Irani FG, Chan WY *et al.* Radioembolization after portal vein embolization in a patient with multifocal hepatocellular carcinoma. *Cardiovascular and Interventional Radiology* 2012; **35**: 1519–1523.
- Iñarrairaegui M, Pardo F, Bilbao JI *et al.* Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. *European Journal of Surgical Oncology* 2012; **38**: 594–601.
- Ray CE Jr, Battaglia C, Libby AM *et al.* Interventional radiologic treatment of hepatocellular carcinoma - a cost analysis from the payer perspective. *Journal of Vascular and Interventional Radiology* 2012; **23**: 306–314.
- Sangro B. Reply to Dr. Wigg. *Hepatology* 2012; **55**: 981–982.[Reply to: Wigg A. Yttrium 90 therapy for HCC; is it any better than conventional external beam radiotherapy? *Hepatology* 2012; **55**: 981.]
- Wigg A. Yttrium 90 therapy for HCC; is it any better than conventional external beam radiotherapy? *Hepatology* 2012; **55**: 981.
- Lance C, McLennan G, Obuchowski N *et al.* Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. *Journal of Vascular and Interventional Radiology* 2011; **22**: 1697–1705.
- Sangro B, Carpanese L, Cianni R *et al on behalf of European Network on Radioembolization with yttrium-90 resin microspheres (ENRY)*. Survival after ⁹⁰Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A European evaluation. *Hepatology* 2011; **54**: 868–878.
- D'Avola D, Iñarrairaegui M, Pardo F *et al.* Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. *Annals of Surgical Oncology* 2011; **18**: 1964–1971.
- Ettorre GM, Santoro R, Claudio P *et al.* Short-term follow-up of radioembolization with yttrium-90 microspheres before liver transplantation: new perspectives in advanced hepatocellular carcinoma. *Transplantation* 2010; **90**: 930–931.
- Strigari L, Sciuto R, Rea S *et al.* Efficacy and toxicity related to treatment of hepatocellular carcinoma with ⁹⁰Y-SIR spheres: radiobiologic considerations. *Journal of Nuclear Medicine* 2010; **51**: 1377–1385.
- Tsai AL, Burke CT, Kennedy AS *et al.* Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. *Journal of Vascular and Interventional Radiology* 2010; **21**:1377–1384.
- Iñarrairaegui M, Thurston KG, Bilbao JI *et al.* Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. *Journal of Vascular and Interventional Radiology* 2010; **21**: 1205–1212.
- Iñarrairaegui M, Martínez-Cuesta A, Rodríguez M *et al.* Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. *International Journal of Radiation Oncology, Biology and Physics* 2010; **77**: 1441–1448.
- Kooby DA, Egnatashvili V, Srinivasan S *et al.* Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. *Journal of Vascular and Interventional Radiology* 2010; **21**: 224–230.
- D'Avola D, Iñarrairaegui M, Bilbao JI *et al.* A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. *Hepato-gastroenterology* 2009; **56**: 1683–1688.

Barakat O, Skolkin MD, Toombs BD *et al.* Major liver resection for hepatocellular carcinoma in the morbidly obese: a proposed strategy to improve outcome. *World Journal of Surgical Oncology* 2008; **6**: 100.

Rivera L, Giap H, Miller W *et al.* Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. *World Journal of Gastroenterology* 2006; **12**: 5729–5732.

Chui A, Rao A, Island E *et al.* Multimodality tumor control and living donor transplantation for unresectable hepatocellular carcinoma. *Transplantation Proceedings* 2004; **36**: 2287–2288.

Lau W, Ho S, Yu S *et al.* Salvage surgery following downstaging of unresectable hepatocellular carcinoma. *Annals of Surgery* 2004; **240**: 299–305.

Szeto C, Wong T, Leung C *et al.* Selective internal radiation therapy by yttrium-90 microspheres for hepatocellular carcinoma after renal transplantation. *Clinical Transplantation* 2001; **15**: 284–288.

Lau W, Ho S, Leung T *et al.* What determines survival duration in hepatocellular carcinoma treated with intraarterial yttrium-90 microspheres? *Hepato-Gastroenterology* 2001; **48**: 338–340.

Abstracts on Retrospective Studies in Hepatocellular Carcinoma

Chow P, Teo JY, Allen JC *et al.* Treatment of right-sided hepatocellular carcinoma with uni-lobar Y-90 radioembolisation and induction of hypertrophy in the contralateral left lobe. *ASCO Annual Meeting 2013, Journal of Clinical Oncology* **31** (Suppl): Abs. e15102.

Khor AYK, Toh Y, Allen JC *et al.* Clinical outcomes with yttrium-90 resin microsphere radioembolization for hepatocellular carcinoma in a multiethnic southeast Asian population. *ASCO Annual Meeting 2013, Journal of Clinical Oncology* **31** (Suppl): Abs. e15137.

Gadani S, Mahvash A, Avritscher R *et al.* Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable HCC: A retrospective study for evaluation of survival benefit and adverse events. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S35 Abs. 62.

Lam MG, Seinstra BA, M. van den Bosch M *et al.* Comparison between resin and glass microspheres for yttrium-90 radioembolization treatment of hepatocellular carcinoma. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S149 Abs. 345.

Rajan P, Dang PR, Fischman AM *et al.* Role of yttrium-90 radioembolization after failure of chemoembolization with drug eluting beads for hepatocellular carcinoma: Single center evaluation of safety and efficacy. *15th Annual Symposium on Clinical Interventional Oncology (CIO) 2013*; Abs 10.

Rana N, Ju AW, Bazylewicz M *et al.* Yttrium-90 radioembolization is safe in patients with hepatocellular carcinoma who have received sorafenib. *15th Annual Symposium on Clinical Interventional Oncology (CIO) 2013*; Abs 11.

Sciuto R, Annovazzi A, Rea S *et al.* ¹⁸F-FDG PET/CT role in predicting clinical outcome after ⁹⁰Y-labeled resin microspheres treatment (⁹⁰Y-RE) in advanced hepatocellular carcinoma (HCC). *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. OP471.

De Palma D, Boni L, Carrafiello G *et al.* Promising preliminary data about treatment of multifocal hepatocellular carcinoma with ⁹⁰Y microspheres. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0130.

Lin K, Lee R, Liu C *et al.* The value of whole-body FDG-PET/CT in detection of extrahepatic metastases in hepatocellular carcinoma patients treated with Yttrium-90 radioembolization. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0508.

Vennarecci G, Santoro R, Lepiane P *et al.* Use of hepatic intra-arterial infusion of yttrium-90 microsphere as downstaging and bridge to liver transplantation in patients with hepatocellular carcinoma. *International Hepato-Pancreato-Biliary Association Congress 2012*; Abs. FOS28.16.

Ettore G, Sangro B, Cianni R *et al.* European multicentre evaluation of the impact of prior procedures on survival and safety following radioembolization in patients with unresectable hepatocellular carcinoma. *International Hepato-Pancreato-Biliary Association Congress 2012*; Abs. H471.

- Fiore F, Bilbao JI, Carpanese L *et al.* The efficacy, safety, and tolerability of radioembolization in unresectable hepatocellular carcinoma with whole-liver, lobar, or segmental treatment. *World Conference on Interventional Oncology (WCIO) meeting 2012*; Poster 18.
- Kucuk O, Soydal C, Araz M *et al.* Evaluation of the response to SIRT in patients with HCC according to pretreatment MAA uptake. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine 2012*; **53** (Suppl 1): Abs. 1151.
- Rodriguez M, Maini C, Salvatori R *et al.* Impact of target area (whole-liver, lobar or segmental) in unresectable hepatocellular carcinoma (HCC) patients treated by radioembolization. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging 2011*; **38** (Suppl 2): Abs. OP021.
- Sciuto R, Carpanese L, Ettore GM *et al.* Efficacy and safety of ⁹⁰Y-labelled resin microspheres treatment (⁹⁰Y-RE) in hepatocellular carcinoma (HCC): Results of a phase II study. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging 2011*; **38** (Suppl 2): Abs. OP130.
- Sangro B, Carpanese L, Salvatori R *et al.* Safety and efficacy of radioembolization amongst patients who met the inclusion criteria for the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial. *5th International Liver Cancer Association (ILCA) meeting September 2011*; Abs. P-141.
- Sangro B, Maini CL, Notarianni E *et al.* Radioembolization for unresectable hepatocellular carcinoma (HCC) in the elderly. *5th International Liver Cancer Association (ILCA) meeting September 2011*; Abs. P-142.
- Sangro B, Ettore G, Cianni R *et al.* A European multicentre evaluation of survival, safety and liver function after radioembolisation with ⁹⁰Y-resin microspheres (ENRY) for unresectable hepatocellular carcinoma. *13th World Congress on Gastrointestinal Cancer, Annals of Oncology 2011*; **22** (Suppl 5): v17 Abs. O-0023.
- Ettore GM, Sangro B, Cianni R *et al.* Impact of prior procedures on overall survival following radioembolization in patients with unresectable hepatocellular carcinoma. *ASCO Annual Meeting, Journal of Clinical Oncology 2011*; **29** (Suppl): Abs. 4099.
- Sangro B, Ettore G, Cianni R *et al.* Survival and tolerability following ⁹⁰Y-resin microsphere radioembolisation in patients with unresectable BCLC stage C hepatocellular carcinoma (HCC). *European Association for the Study of the Liver (EASL) Congress, Journal of Hepatology 2011*; **54** (Suppl 1):S36 Abs. 650.
- Higgins L, Rose S, Lorenzetti D *et al.* A systematic review and meta-analysis of transarterial radioembolization (TARE) for hepatocellular carcinoma (HCC). *European Association for the Study of the Liver (EASL) Congress, Journal of Hepatology 2011*; **54** (Suppl 1):S253–254 Abs. 625.
- Mahvash A, Murthy R, Avritscher R *et al.* Yttrium-90 resin hepatic arterial radioembolotherapy as a therapeutic adjunct to sorafenib for advanced non-transplantable, non-resectable hepatocellular cancer. *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology 2011*; **22** (Suppl): S90–91 Abs. 210.
- Lance C, McLennan G, Cheah G *et al.* Comparative analysis of the safety and efficacy of chemoembolization and Y90 radioembolization in patients with unresectable hepatocellular carcinoma. *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology 2011*; **22** (Suppl): S121–122 Abs. 288.
- Presidente A, Lombardi G, D'angelo R *et al.* Radioembolization with Y90 microspheres in HCC associated to portal vein thrombosis: personal experience. *European Congress of Radiology 2011*; Abs. C-1209.
- Miglioresi L, Vennarecci G, Santoro R *et al.* Hepatic intra-arterial infusion of yttrium-90 microspheres for hepatocellular carcinoma before liver transplantation. *7th Meeting of the HCC Eastern & Western Experiences (HCC2011) 2011*; Abs. 42.
- Vennarecci G, Sciuto R, Carpanese L *et al.* Hepatocellular carcinoma with portal vein thrombosis down-staged by hepatic intra-arterial infusion of yttrium-90 microspheres before liver transplantation: a case report. *7th Meeting of the HCC Eastern & Western Experiences (HCC2011) 2011*; Abs. 56.
- Vennarecci G, Sciuto R, Carpanese L *et al.* Use of hepatic intra-arterial infusion of yttrium-90 microspheres as down-staging and bridge to liver transplantation in patients with hepatocellular carcinoma. *7th Meeting of the HCC Eastern & Western Experiences (HCC2011) 2011*; Abs. 57.

Ettorre G, Sangro B, Cianni R *et al.* Applicability of the Barcelona clinic liver cancer staging system for patients with unresectable hepatocellular carcinoma treated by radioembolisation. *15th Congress of the European Society of Surgical Oncology (ESSO), European Journal of Surgical Oncology* 2010; **36**: 899 Abs. 444.

D'Avola D, Iñarrairaegui M, Alegre F *et al.* Baseline alfa-fetoprotein (AFP) as a prognostic marker of survival in unresectable hepatocellular carcinoma (HCC). *4th International Liver Cancer Association (ILCA) meeting* September 2010; Abs. P-147.

Farris AB, Dhanasekaran R, Dursun N *et al.* Tumorigenesis and angiogenesis factors in hepatocellular carcinoma after locoregional therapy. *Society of Interventional Radiology (SIR) 35th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2010; **21** (Suppl): S14 Abs. 77.

Carpanese L, Pizzi G, Vallati GE *et al.* Radioembolization of advanced hepatocellular carcinoma using ⁹⁰Y-resin microspheres: mid-term results in a single institute experience. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2009; Abs. 1905.4.

Khanna V, Dhanasekaran R, Kooby DA *et al.* Comparison of survival benefits of conventional TACE, Precision TACE (drug eluting beads with doxorubicin) and Yttrium-90 radioembolization (SIR-Spheres) for unresectable HCC. *Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2009; **26** (2S): S84 Abs 217.

Carpanese L, Pizzi G, Vallati GE *et al.* Role of the hepatic intra-arterial injection of Yttrium-90 microspheres in unresectable hepatocellular carcinoma: preliminary experience and clinical results. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2008; Abs. 3009.2.

Iñarrairaegui M, Bilbao JI, Martinez-Cuesta A *et al.* Liver radioembolization for the treatment of hepatocellular carcinoma: feasibility and antitumor effect. *European Association for the Study of the Liver (EASL) Congress* 2008; Abs.

Cabrera R, George T, Soldevila-Pico C *et al.* Safety of sorafenib alone or in combination with locoregional therapy in patients with advanced hepatocellular carcinoma (HCC) and decompensated cirrhosis. *ASCO Gastrointestinal Cancers Symposium* 2008; Abstract 147.

Neuroendocrine Tumour Liver Metastases

Prospective Clinical Studies in Neuroendocrine Tumours Liver Metastases

Saxena A, Chua TC, Bester L *et al.* Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. *Annals of Surgery* 2010; **251**: 910–916.

Kalinowski M, Dressler M, König A *et al.* Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: A prospective single center study. *Digestion* 2009; **79**: 137–142.

King J, Quinn R, Glenn D *et al.* Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. *Cancer* 2008; **113**: 921–929.

Abstracts on Prospective Clinical Studies in Neuroendocrine Tumour Liver Metastases

McElmurray JH, Bream PR, Grzeszczak E *et al.* Phase II clinical trial of Yttrium-90 resin microspheres for the treatment of metastatic neuroendocrine tumor. *World Conference on Interventional Oncology (WCIO) meeting* 2012; Abs. 47.

Retrospective Studies in Neuroendocrine Tumour Liver Metastases

Sommer WH, Ceelen F, García-Albéniz X *et al.* Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. *European Radiology* 2013 Jun 28; ePub doi: 10.1007/s00330-013-2925-8.

Neperud J, Mahvash A, Garg N *et al.* Can imaging patterns of neuroendocrine hepatic metastases predict response yttrium-90 radioembolotherapy? *World Journal of Radiology* 2013; **5**: 241–247.

Ozao-Choy J, Friedman ML, Kim AS *et al.* Radioembolization for treatment of liver metastases from neuroendocrine tumors: Correlation with imaging and biomarkers. *Pancreas* 2013; **42**: 358–360.

Ezziddin S, Meyer C, Kohancova S *et al.* ⁹⁰Y radioembolization after radiation exposure from peptide receptor radionuclide therapy. *Journal of Nuclear Medicine* 2012; **53**: 1663–1669.

Saxena A, Chua TC, Zhao J *et al.* Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery. *Journal of Surgical Oncology* 2012; **105**: 342–350.

Paprottka PM, Hoffmann RT, Haug A *et al.* Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. *Cardiovascular and Interventional Radiology* 2012; **35**: 334–342.

Lacin S, Oz I, Ozkan E *et al.* Intra-arterial treatment with ⁹⁰Yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of ¹¹¹In-octreotide scintigraphy in the evaluation of treatment response. *Cancer Biotherapy & Radiopharmaceuticals* 2011; **26**: 631–637.

Rajekar H, Bogammana K, Stubbs RS. Selective internal radiation therapy (SIRT) for gastrointestinal neuroendocrine tumour (NET) liver metastases: A new and effective modality for treatment. *International Journal of Hepatology* 2011; **2011**: 404916.

Arslan N, Emi M, Alagöz E *et al.* Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center. *Vojnosanitetski Pregled* 2011; **68**: 341–348.

Whitney R, Válek V, Fages JF *et al.* Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. *The Oncologist* 2011; **16**: 594–601.

Chandra P, Yarandi SS, Khazai N *et al.* Management of intractable hypoglycemia with yttrium-90 radioembolization in a patient with malignant insulinoma, *American Journal of the Medical Sciences* 2010; **340**: 414–417.

Cao CQ, Yan TD, Bester L *et al.* Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. *British Journal of Surgery* 2010; **97**: 537–543.

Vasamillette J, Hohenberger P, Schoenberg S *et al.* Treatment monitoring with ¹⁸F-FDG PET in metastatic thymoma after ⁹⁰Y-Dotatoc and selective internal radiation treatment (SIRT). *Hellenic Journal of Nuclear Medicine* 2009; **12**: 271–273.

Granberg D, Garske U, Welin S *et al.* Selective internal radiation therapy in patients with carcinoid liver metastases. *Acta Oncologica* 2008; **47**: 1169–1171.

Rhee TK, Lewandowski RJ, Liu DM *et al.* ⁹⁰Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. *Annals of Surgery* 2008; **247**: 1029–1035.

Kennedy AS, Dezarn W, McNeillie P *et al.* Radioembolization for unresectable neuroendocrine hepatic metastases using resin ⁹⁰Y-microspheres: Early results in 148 patients. *American Journal of Clinical Oncology* 2008; **31**: 271–279.

Murthy R, Kamat P, Nunez R *et al.* Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. *Journal of Vascular and Interventional Radiology* 2008; **19**: 145–151.

Ho K. Malignant insulinomas with hepatic metastases successfully treated with selective internal radiation therapy. *Clinical Endocrinology (Oxford)* 2006; **65**: 410–411.

Madoff D, Gupta S, Ahrar K *et al.* Update on the management of neuroendocrine hepatic metastases. *Journal of Vascular and Interventional Radiology* 2006; **17**: 1235–1250.

Abstracts on Retrospective Studies in Neuroendocrine Tumour Liver Metastases

Gebhard TA, Suhocki P, Engstrom BI *et al.* Metastatic neuroendocrine tumors to the liver: treatment with bland embolization versus radioembolization. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S13 Abs. 9.

McIntosh EB, El-Rayes B, Kauh J *et al.* Resin-based yttrium-90 radioembolization for metastatic neuroendocrine tumors in a single-center cancer registry. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S36 Abs. 65.

Kharoti Y, Ahuja C, Farsad K *et al.* Clinical and imaging response in neuroendocrine hepatic metastasis treated with Y-90 radioembolization. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S151 Abs. 350.

Ahmed F, Kaufman C, Ray, Jr CE. Yttrium-90 radioembolization for metastatic liver pheochromocytoma. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2012; Abs. P-250.

McIntosh EB, Prajapati HJ, Lawal TO *et al.* Prognostic factors of resin-based Yttrium-90 radioembolization for unresectable metastatic neuroendocrine tumors. *World Conference on Interventional Oncology (WCIO) meeting* 2012; Abs. 49.

Wu YV, Tomaszewski G, Groman AE *et al.* Yttrium-90 microspheres (SIR) verses transarterial chemoembolization (TACE) in the treatment of inoperable metastatic neuroendocrine tumors (NETS). *ASCO Gastrointestinal Cancers Symposium* 2012; Abs. 300.

Engelman ES, Leon-Ferre R, Naraev B *et al.* Comparison of hepatic artery embolization and selective internal radiation therapy for metastatic neuroendocrine tumors. *ASCO Gastrointestinal Cancers Symposium* 2012; Abs. 332.

Kennedy A, Elkordy M, Campbell EE *et al.* ⁹⁰Y radioembolization for neuroendocrine cancers liver metastases provides sustained therapeutic effect with minimal toxicity. *ASCO Gastrointestinal Cancers Symposium* 2012; Abs. 343.

Neperud J, Mahvash A, Garg N *et al.* Imaging patterns of neuroendocrine tumor hepatic metastases as a predictor of response to yttrium-90 radioembolotherapy. *World Conference on Interventional Oncology (WCIO) meeting* 2011; Abs. 45.

Paprottka PM, Hoffmann RT, Trumm CG *et al.* ⁹⁰Yttrium-radioembolization of symptomatic, nonresectable neuroendocrine hepatic metastases. *World Conference on Interventional Oncology (WCIO) meeting* 2011; Abs. 51.

Faust H, Metz D, Soulen MC. Y-90 radioembolization is effective initial and salvage therapy for metastatic neuroendocrine tumors. *World Conference on Interventional Oncology (WCIO) meeting* 2011; Abs. P13.

Murthy R, Mahvash A, Avritscher R *et al.* Y90 resin microsphere arterial radioembolotherapy as a therapeutic adjunct to systemic biologic therapy for advanced hepatic metastatic neuroendocrine tumor progression. *World Conference on Interventional Oncology (WCIO) meeting* 2011; Abs. P36.

Jahangir KS, Majoria R, Hagan J *et al.* Hepatic artery radioembolization (HARE) in the management of progressive metastatic neuroendocrine tumors (NETs): A survival and biochemical response analysis in geriatric (G) and young (Y) populations. *ASCO Annual Meeting, Journal of Clinical Oncology* 2011; **29** (Suppl): Abs. e19727.

Mayo SC, De Jong MC, Pulitano C *et al.* Surgery vs intra-arterial therapy for neuroendocrine liver metastasis: a multi-center international analysis. *Society of Surgical Oncology (SSO) Annual Cancer Symposium; Annals of Surgical Oncology* 2011; **18** (Suppl 1): S24–25 Abs. 57.

Jakobs TF, Paprottka P, Hoffmann R *et al.* ⁹⁰Yttrium-radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases *Society of Interventional Radiology (SIR) 35th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2010; **21** (Suppl): S14 Abs. 30.

Küçük Ö, Laçın S, Yagcı S *et al.* Treatment of unresectable neuroendocrine liver tumors with Y-90 microsphere: Ankara University experience. *European Association of Nuclear Medicine (EANM) Conference* 2009; Abs. P207.

Slater JWA, Dhanasekaran R, Kauh J *et al.* Transcatheter therapy for symptomatic, unresectable hepatic metastases of neuroendocrine tumors. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2009; Abs. P-154.

Granberg D, Garske U, Sundin A *et al.* Leverembolisering med SIR-spheres[®] hos patienter med neuroendokrina tumörer. *Svenska Läkarsällskapets Riksstämman* (Swedish Society of Medicine meeting) 2007; Abs. EN 24P. [in Swedish]

McGrath S, Kennedy A, Dezarn W *et al.* Resin ⁹⁰Y-microsphere radioembolisation is effective in controlling hepatic metastases from neuroendocrine primary cancers. *Emerging Trends in Radioembolization using Microspheres: Third Annual Clinical Symposium*; 4–5 May 2007.

Kennedy A, Dezarn W, McNeillie P *et al.* Fractionation, dose selection, and response of hepatic metastases of neuroendocrine tumors after ⁹⁰Y-microsphere brachytherapy. *Annual American Brachytherapy Society Meeting Brachytherapy* 2006; **5** (2): 103 Abs. P-75.

Breast Cancer Liver Metastases

Prospective Clinical Studies in Breast Cancer Liver Metastases

Jakobs TF, Hoffmann RT, Fischer T *et al.* Radioembolization in patients with hepatic metastases from breast cancer. *Journal of Vascular and Interventional Radiology* 2008; **19**: 683–690.

Retrospective Studies in Breast Cancer Liver Metastases

Cianni R, Pelle G, Notarianni E *et al.* Radioembolisation with ⁹⁰Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. *European Radiology* 2013; **23**: 182–189.

Haug AR, Tiega Donfack BP, Trumm C *et al.* ¹⁸F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. *Journal of Nuclear Medicine* 2012; **53**: 371–377.

Paprottka PM, Schmidt GP, Trumm CG *et al.* Changes in normal liver and spleen volume after radioembolization with ⁹⁰Y-resin microspheres in metastatic breast cancer patients: findings and clinical significance. *Cardiovascular and Interventional Radiology* 2011; **34**: 964–972.

Coldwell D, Kennedy A, Nutting C. The use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. *International Journal of Radiation Oncology, Biology and Physics* 2007; **69**: 800–804.

Rubin D, Nutting C, Jones B. Metastatic breast cancer in a 54-year-old woman: Integrative treatment with yttrium-90 radioembolization. *Integrative Cancer Therapies* 2004; **3**: 262–267.

Abstracts on Retrospective Studies in Breast Cancer Liver Metastases

Michl M, Hoffmann RT, Laubender R *et al.* Selective internal radiation therapy (SIRT) for treatment of patients with breast cancer with metastatic liver disease. *ASCO Annual Meeting, Journal of Clinical Oncology* 2010; **28** (Suppl 7s): Abs. 1135.

Coldwell D. Treatment of hepatic metastases from breast cancer with resin Yttrium-90 radioembolization. *2nd European Symposium on Liver-Directed Cancer Therapies using Microspheres* February 2008.

Pancreatic Cancer Liver Metastases

Prospective Clinical Studies in Pancreatic Cancer Liver Metastases

Gulec SA, Wheeler J, Pennington K *et al.* Chemotherapy with Yttrium-90 microsphere selective internal radiation treatment and selective external radiation treatment in patients with metastatic pancreatic cancer. *Journal of Interventional Oncology* 2009; **2**: 84–92.

Abstracts on Prospective Studies in Pancreatic Cancer Liver Metastases

Gibbs P, Lipton L, Price D *et al.* A phase II trial of radioembolization and systemic chemotherapy in patients with liver metastases from primary cancer of the pancreas. *European Society of Medical Oncology – ESMO, Annals of Oncology* 2010; **21** (Suppl 8): Abs 845.

Retrospective Studies in Pancreatic Cancer Liver Metastases

Krug S, Bartsch DK, Schober M *et al.* Successful selective internal radiotherapy (SIRT) in a patient with a malignant solid pseudopapillary pancreatic neoplasm (SPN). *Pancreatology* 2012; **12**: 423–427.

Cao C, Yan TD, Morris DL, Bester L. Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study. *Tumori* 2010; **96**: 955–958.

Abstracts on Retrospective Studies in Pancreatic Cancer Liver Metastases

Michl M, Jakobs TF, Paprottka P *et al.* Prognostic factors for response to radioembolisation (SIRT) of pretreated pancreatic cancer patients with metastatic liver disease. *13th World Congress on Gastrointestinal Cancer, Annals of Oncology* 2011; **22** (Suppl 5): v57 Abs. P-0124.

Michl M, Paprottka P, Hoffmann RT *et al.* Radioembolisation (SIRT) of pretreated pancreatic cancer patients with metastatic liver disease. *12th World Congress on Gastrointestinal Cancer, Annals of Oncology* 2010; **21** (Suppl 7): Abs. P-0105.

Cholangiocarcinoma

Prospective Clinical Studies in Cholangiocarcinoma

Saxena A, Bester L, Chua TC *et al.* Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: A preliminary assessment of this novel treatment option. *Annals of Surgical Oncology* 2010; **17**: 484–491.

Abstracts on Prospective Studies in Cholangiocarcinoma

Camacho JC, Kokabi N, Schuster DM *et al.* PERCIST criteria to predict survival at 3 months following intra-arterial resin-based yttrium-90 (Y-90) radioembolization therapy of unresectable intrahepatic cholangiocarcinoma refractory to standard chemotherapy: A proof of concept study. *ASCO Annual Meeting 2013, Journal of Clinical Oncology* **31** (Suppl): Abs. e15141.

Retrospective Studies in Cholangiocarcinoma

Hyder O, Marsh JW, Salem R *et al.* Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: A multi-institutional analysis. *Annals of Surgical Oncology* 2013 Jul 12; ePub doi: 10.1245/s10434-013-3127-y.

Höberg J, Rizell M, Hultborn R *et al.* Radiation exposure during liver surgery after treatment with ⁹⁰Y microspheres, evaluated with computer simulations and dosimeter measurements. *Journal of Radiological Protection* 2012; **32**: 439–446.

Rafi S, Piduru SM, El-Rayes B *et al.* Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: Survival, efficacy, and safety study. *Cardiovascular and Interventional Radiology* 2013; **36**: 440–448.

Hoffmann RT, Paprottka PM, Schön A *et al.* Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. *Cardiovascular and Interventional Radiology* 2012; **35**: 105–116.

Wijlemans JW, Van Erpecum KJ, Lam MG *et al.* Trans-arterial ⁹⁰yttrium radioembolization for patients with unresectable tumors originating from the biliary tree. *Annals of Hepatology* 2011; **10**: 349–354.

Haug AR, Heinemann V, Bruns CJ *et al.* ¹⁸F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with ⁹⁰Y microspheres. *European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38**: 1037–1045.

Gaba RC, Bui JT, Knuttinen MG, Owens CA. Re: radiation lobectomy--a minimally invasive treatment model for liver cancer. *Journal of Vascular and Interventional Radiology* 2009; **20**: 1394–1396.

Abstracts on Retrospective Studies in Cholangiocarcinoma

Prajapati HJ, Lawal TO, McIntosh EB *et al.* Yttrium-90 radioembolization for chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC): Survivals and prognostic factors. *World Conference on Interventional Oncology (WCIO) meeting* 2012; Abs. 53.

Green G, Nguyen T, Imagawa D *et al.* Possible dose-survival relationship in the treatment of unresectable cholangiocarcinoma with yttrium-90 microspheres. *World Conference on Interventional Oncology (WCIO) meeting* 2011; Abs. 50.

Paprottka PM, Bamberg F, Haug A *et al.* Transarterial hepatic Yttrium-90 radioembolization (RE) in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with improvement of survival. *European Congress of Radiology* 2011; Abs.C-0577.

Khanna V, Dhanasekaran R, Barron BJ. *et al.* Yttrium-90 radioembolization (SIR-Spheres) for cholangiocarcinoma: Preliminary study. *Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2009; **26** (2S): S116–S117 Abs. 309.

Coldwell D. Treatment of unresectable nodular cholangiocarcinoma with yttrium-90 microspheres. *World Congress on Gastrointestinal Cancer Annals of Oncology* 2006; **17** (Sup 6): vi56 Abs. P-102.

Melanoma Liver Metastases

Retrospective Studies in Melanoma Liver Metastases

Piduru SM, Schuster DM, Barron BJ *et al.* Prognostic value of ^{18}F -Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing Yttrium-90 radioembolization. *Journal of Vascular and Interventional Radiology* 2012; **23**: 943–948.

Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. *Cardiovascular and Interventional Radiology* 2013; **36**: 158–165.

Gonsalves CF, Eschelmann DJ, Sullivan KL *et al.* Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. *AJR – American Journal of Roentgenology* 2011; **196**: 468–473.

Murthy R, Mutha P, Madoff DC *et al.* Establishment of the radiation effect of yttrium-90 microspheres: Role of C-arm CT. *Journal of Vascular and Interventional Radiology* 2009; **20**: 422–424.

Kennedy A, Nutting C, Jakobs T *et al.* A first report of radioembolization for hepatic metastases from ocular melanoma. *Cancer Investigation* 2009; **27**: 682–690.

Abstracts on Retrospective Studies in Melanoma Liver Metastases

Prajapati HJ, Lawson DH, Kim HS *et al.* Selective internal Yttrium-90 radioembolization therapy (90-Y SIRT) in patients with unresectable metastatic melanoma (MM) to liver, refractory to systemic therapy: Analysis of imaging findings, survival and factors associated with prolonged survival. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S36 Abs. 64.

Prajapati H, Lawal T, Lawson D *et al.* Selective internal Yttrium-90 radioembolization therapy (^{90}Y SIRT) in patients with unresectable metastatic melanoma (MM) to liver, refractory to systemic therapy: Analysis of safety, survival and factors associated with prolonged survival. *American Association for the Study of Liver Diseases (AASLD) Congress, Hepatology* 2012; **56** (Suppl 1): Abs. 1367.

Purohit NB, Sheikh FT, Bryant N *et al.* Selective internal radiation therapy (SIRT) in the management of ocular melanoma liver metastases: Largest single centre case series in the UK. *British Nuclear Medicine Society 40th Annual Meeting, Nuclear Medicine Communications* 2012; **33**: 526–561 Abs. P13.

Dhanasekaran R, Khanna V, Lawson D *et al.* Survival benefits of Yttrium-90 radioembolization (SIR-Spheres) for hepatic metastasis from melanoma: Preliminary study. *Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2009; **26** (2S): S65 Abs. 167.

Lung Cancer Liver Metastases

Retrospective Studies in Lung Cancer Liver Metastases

Murthy R, Mutha P, Lee JH, Oh Y. Yttrium-90-labeled microsphere radioembolotherapy of liver-dominant metastases from thoracic malignancies. *Journal of Vascular and Interventional Radiology* 2008; **19**: 299–300.

Cervical Cancer Liver Metastases

Retrospective Studies in Cervical Cancer Liver Metastases

Gulec SA, Pennington K, Hall M, Fong Y. Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. *World Journal of Surgical Oncology* 2009; **7**: 6.

Desmoplastic Small Round Cell Tumour Liver Metastases

Retrospective Studies in Desmoplastic Small Round Cell Tumour Liver Metastases

Subbiah V, Murthy R, Anderson PM. [⁹⁰Y]Yttrium microspheres radioembolotherapy in desmoplastic small round cell tumor hepatic metastases. *Journal of Clinical Oncology* 2011; **29**: e292–e294.

Renal Cell Carcinoma Liver Metastases

Retrospective Studies in Renal Cell Carcinoma Liver Metastases

Abdelmaksoud MH, Louie JD, Hwang GL *et al.* Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver. *Journal of Vascular and Interventional Radiology* 2012; **23**: 323–330.

Hemangioendothelioma Liver Metastases

Retrospective Studies in Hemangioendothelioma Liver Metastases

Karaman B, Battal B, Alagoz E *et al.* Complete disappearance of uptake of FDG in the multifocal liver hemangioendothelioma after radioembolization therapy using yttrium-90 microspheres. *Annals of Nuclear Medicine* 2012 Mar 22; ePub doi: 10.1007/s12149-012-0592-5.

Laçın S, Küçük O, Oz I, Bilgiç S. Selective intra-arterial Y-90 microsphere therapy in hemangioendothelioma. *Turkish Journal of Gastroenterology* 2011; **22**: 89–92.

Testicular Cancer Liver Metastases

Retrospective Studies in Testicular Cancer Liver Metastases

Sideras PA, Sofocleous CT, Brody LA *et al.* Superselective internal radiation with yttrium-90 microspheres in the management of a chemorefractory testicular liver metastasis. *Cardiovascular and Interventional Radiology* 2012; **35**: 426–429.

Primary or Metastatic Soft Tissue Sarcomas of the Liver

Abstracts on Retrospective Studies in Primary or Metastatic Soft Tissue Sarcomas of the Liver

Oh JC, Lam MG, Ganjoo KN *et al.* Y-90 radioembolization of primary and metastatic soft tissue sarcomas of the liver. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S148 Abs. 342.

Thyroid Cancer Liver Metastases

Retrospective Studies in Thyroid Cancer Liver Metastases

Arslan N, Üstünsöz B, Alagoz E *et al.* Medüller tiroid kanserli bir olguda inoperabl karaciğer metastazlarının yttrium-90 (Y-90) işaretli mikroküreler ile selektif intraarteriyel radyonüklid tedavisi: ilk ulusal uygulama [Selective intraarterial radionuclide radiotherapy of inoperable liver metastases with yttrium-90 (Y-90) labeled microspheres in a patient with medullary thyroid carcinoma metastasis in the liver: first national administration]. *Gülhane Tıp Dergisi / Gulhane Medical Journal* 2012; **54**: 57–61. [in Turkish]

Liver Metastases from Cancer of Unknown Primary

Retrospective Studies in Liver Metastases from Cancer of Unknown Primary

Kubisch CH, Beigel F, Ihrler S *et al.* Oesophageal ulceration after selective internal radiation therapy in a patient with carcinoma of unknown primary. *Zeitschrift für Gastroenterologie / German Journal of Gastroenterology* 2010; **48**: 546–550.

Tehrani-pour N, Al-Nahhas A, Canelo R *et al.* Concordant F-18 FDG PET and Y-90 Bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: Confirmation with histopathology. *Clinical Nuclear Medicine* 2007; **32**: 371–374.

Liver Tumours from Various Cancer Sources

Prospective Clinical Studies in Liver Tumours from Various Cancer Sources

Morsbach F, Pfammatter T, Reiner CS *et al.* Computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases. *Investigative Radiology* 2013 Jun 6; ePub doi: 10.1097/RLI.0b013e31829810f7.

Wong CO, Savin M, Sherpa KM *et al.* Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma. *Cancer Biotherapy & Radiopharmaceuticals* 2006; **21**: 305–313.

Wong C, Qing F, Savin M *et al.* Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [¹⁸F]Fluorodeoxyglucose positron emission tomographic imaging. *Journal of Vascular and Interventional Radiology* 2005; **16**: 1101–1106.

Lim L, Gibbs P, Yip D *et al.* Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. *Internal Medicine Journal* 2005; **35**: 222–227.

Abstracts on Prospective Clinical Studies in Liver Tumours from Various Cancer Sources

Cohen SJ, Konski AA, Putnam S *et al.* A phase I study of capecitabine in combination with yttrium-90 labeled resin microspheres (SIR-Spheres) in patients (pts) with advanced cancer. *ASCO Annual Meeting, Journal of Clinical Oncology* 2011; **29** (Suppl): Abs. e14612.

Retrospective Studies in Liver Tumours from Various Cancer Sources

Peterson JL, Vallow LA, Johnson DW *et al.* Complications after ⁹⁰Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients. *Brachytherapy* 2013 Aug 14; ePub doi: 10.1016/j.brachy.2013.05.008.

Smits ML, van den Hoven AF, Rosenbaum CE *et al.* Clinical and laboratory toxicity after intra-arterial radioembolization with ⁹⁰Y-microspheres for unresectable liver metastases. *PLoS One* 2013; **24**; 8: e69448.

Bester L, Meteling B, Pocock N *et al.* Radioembolisation with Yttrium-90 microspheres: An effective treatment modality for unresectable liver metastases. *Journal of Medical Imaging and Radiation Oncology* 2013; **57**: 72–80.

Ahmadzadehfar H, Meyer C, Ezziddin S *et al.* Hepatic volume changes induced by radioembolization with ⁹⁰Y resin microspheres. A single-centre study. *European Journal of Nuclear Medicine and Molecular Imaging* 2013; **40**: 80–90.

Lam MG, Abdelmaksoud MH, Chang DT *et al.* Safety of ⁹⁰Y radioembolization in patients who have undergone previous external beam radiation therapy. *International Journal of Radiation Oncology, Biology and Physics* 2013 Jul 9; ePub doi: 10.1016/j.ijrobp.2013.05.041.

Turkmen C, Ucar A, Poyanli A *et al.* Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease. *Cancer Biotherapy & Radiopharmaceuticals* 2013 May 6; ePub doi: 10.1089/cbr.2012.1455.

Fernández-Ros N, Silva N, Bilbao JI *et al.* Partial liver volume radioembolization induces hypertrophy in the spared hemi liver and no major signs of portal hypertension. *HPB (Oxford)* 2013 Mar 27; ePub doi: 10.1111/hpb.12095.

- Bester L, Feitelson S, Milner B *et al.* Impact of prior hepatectomy on the safety and efficacy of radioembolization with yttrium-90 microspheres for patients with unresectable liver tumors. *American Journal of Clinical Oncology* 2013 Feb 5; ePub doi: 10.1097/COC.0b013e31827deea1.
- Lam MG, Louie JD, Iagaru AH *et al.* Safety of repeated Yttrium-90 radioembolization. *Cardiovascular and Interventional Radiology* 2013 Jan 26; ePub doi: 10.1007/s00270-013-0547-9.
- Seidensticker R, Seidensticker M, Damm R *et al.* Hepatic toxicity after radioembolization of the liver using ⁹⁰Y-microspheres: Sequential lobar versus whole liver approach. *Cardiovascular and Interventional Radiology* 2012; **35**:1109–1118.
- Ahmadzadehfar H, Meyer C, Ezziddin S *et al.* Hypertrophy of the contralateral hepatic lobe after selective internal radiation therapy. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 44–45.
- Zalom M, Yu R, Friedman M *et al.* FDG PET/CT as a prognostic test after ⁹⁰Y radioembolization in patients with metastatic hepatic disease. *Clinical Nuclear Medicine* 2012; **37**: 862–865.
- Gensure RH, Foran DJ, Lee VM *et al.* Evaluation of hepatic tumor response to Yttrium-90 radioembolization therapy using texture signatures generated from contrast-enhanced CT images. *Academic Radiology* 2012 Jul 26; ePub doi: 10.1016/j.acra.2012.04.015.
- Walrand S, Lhomme R, Goffette P *et al.* Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy. *European Journal of Nuclear Medicine and Molecular Imaging Research* 2012 May 19; **2**: 20. ePub doi 0.1186/2191-219X-2-20.
- Bester L, Meteling B, Pocock N *et al.* Radioembolization versus standard care of hepatic metastases: Comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. *Journal of Vascular and Interventional Radiology* 2012; **23**: 96–105.
- Nosher JL, Ohman-Strickland PA, Jabbour S *et al.* Changes in liver and spleen volumes and liver function after radioembolization with yttrium-90 resin microspheres. *Journal of Vascular and Interventional Radiology* 2011; **22**: 706–716.
- Kucuk ON, Soydal C, Lacin S *et al.* Correction: Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors. *World Journal of Surgical Oncology* 2011; **9**: 120.
- Kucuk ON, Soydal C, Lacin S *et al.* Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors. *World Journal of Surgical Oncology* 2011; **9**: 86.
- Whitney R, Tatum C, Hahl M *et al.* Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. *Journal of Surgical Research* 2011; **166**: 236–240.
- Brown RE, Bower MR, Metzger TL *et al.* Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: is it safe? *HPB (Oxford)* 2011; **13**: 91–95.
- Gayed IW, Wahba H, Wan D *et al.* Effect of Y-90 SIR-Spheres therapy for multiple liver metastases in a variety of tumors. *Journal of Cancer Science & Therapy* 2010; **2**: 43-46.
- Iñarrairaegui M, Bilbao JI, Rodríguez M *et al.* Liver radioembolization using ⁹⁰Y resin microspheres in elderly patients: tolerance and outcome. *Hospital Practice (Minneapolis)* 2010; **38**: 103–109.
- Omed A, Lawrance JA, Murphy G *et al.* A retrospective analysis of selective internal radiation therapy (SIRT) with yttrium-90 microspheres in patients with unresectable hepatic malignancies. *Clinical Radiology* 2010; **65**: 720–728.
- Evans KA, Richardson MG, Pavlakis N *et al.* Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres. *Journal of Vascular and Interventional Radiology* 2010; **21**: 1521–1526.
- Peynircioglu B, Cil B, Bozkurt F *et al.* Radioembolization for the treatment of unresectable liver cancer: initial experience at a single center. *Diagnostic and Interventional Radiology* 2010; **16**: 70–78.
- Cianni R, Urigo C, Notarianni E *et al.* Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. *La Radiologia Medica* 2010; **115**: 619–633.
- Hoffmann RT, Jakobs TF, Kubisch C *et al.* Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease – is it feasible? *European Journal of Radiology* 2010; **74**: 199–205.
- Johnson DW, Mori, KH, O’Laughlin SR *et al.* Safety and efficacy of Yttrium-90 labeled microsphere radiation treatment for hepatic metastases. *Northeast Florida Medicine* 2009; **60**: 37–41.

- Stuart JE, Tan B, Myerson RJ *et al.* Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: Initial outcomes. *Journal of Vascular and Interventional Radiology* 2008; **19**: 1427–1433.
- Khodjibekova M, Szyszko T, Singh A *et al.* Treatment of primary and secondary liver tumours with selective internal radiation therapy. *Journal of Experimental Clinical Cancer Research* 2007; **26**: 561–570.
- Rowe B, Weiner R, Foster J *et al.* ⁹⁰Yttrium microspheres for nonresectable liver cancer: the University of Connecticut Health Center experience. *Connecticut Medicine* 2007; **71**: 523–528.
- Jiao LR, Szyszko T, Al-Nahhas *et al.* Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. *European Journal of Surgical Oncology* 2007; **33**: 597–602.
- Gulec SA, Mesoloras G, Dezarn WA *et al.* Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratio. *Journal of Translational Medicine* 2007; **5**: 15.
- Szyszko T, AL-Nahhas A, Canelo R *et al.* Assessment of response to treatment of unresectable liver tumours with ⁹⁰Y microspheres: Value of FDG PET versus computed tomography. *Nuclear Medicine Communications* 2007; **28**: 15–20.
- Jakobs TF, Hoffmann RT, Poepperl G *et al.* Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using ⁹⁰yttrium resin-microspheres. *European Radiology* 2007; **17**: 1320–1330.
- Brock H; Günther RW; Haage P. Leberzirrhose als folge selektiver hepatischer radioembolisation mit ⁹⁰Yttrium-mikrosphären. *Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren* 2006; **178**: 538–549. [in German]
- Poepperl G, Helmberger T, Munzing W *et al.* Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. *Cancer Biotherapy & Radiopharmaceuticals* 2005; **20**: 200–208.

Abstracts on Retrospective Studies in Liver Tumours from Various Cancer Sources

- Martinez BK, Gupta NK, Flanders V *et al.* Safety and feasibility of yttrium-90 (Y-90) treatment for primary and metastatic liver tumors at a community hospital. *ASCO Annual Meeting 2013, Journal of Clinical Oncology* **31** (Suppl): Abs. e14698.
- Uslu L, Gulsen F, Sager S *et al.* Radioembolization with Yttrium-90 microspheres in unresectable primary and metastatic liver tumors. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0510.
- De Cicco C, Cremonesi M, Colandrea M *et al.* Response assessment after radioembolization with ⁹⁰Y-microspheres for liver metastases: Comparing outcomes with FDG-PET imaging. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0132.
- Seidensticker M, Garlipp B, Seidensticker R *et al.* Induction of hypertrophy of the left hepatic lobe by unilateral right-sided radioembolization using ⁹⁰Y-labelled resin microspheres in patients with right-sided secondary malignant liver tumors. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2012; Abs. P–238.
- Dang RP, Fischman AM, Kim E *et al.* Safety and feasibility of whole-liver Yttrium-90 (Y90) radioembolization. *World Conference on Interventional Oncology (WCIO) meeting* 2012; Poster 40.
- Cholapranee A, Dagli M, Mondschein JI *et al.* Y-90 Radioembolization as second-line therapy for hepatic metastases. *World Conference on Interventional Oncology (WCIO) meeting* 2012; Poster 41.
- Cholapranee A, Soulen MC. Risk of liver abscess following Y-90 radioembolization in patients with prior biliary intervention. *World Conference on Interventional Oncology (WCIO) meeting* 2012; Poster 43.
- Sharma A, Kolar B, Katz A *et al.* Y90 radioembolization: Comparison of effects on clinical performance status and liver toxicity in patients with HCC and hepatic metastases from other primary tumors - a single institutional experience. *World Conference on Interventional Oncology (WCIO) meeting* 2012; Poster 44.
- Withrow RC, Pohl C. Treatment of Stage 4 gynecologic malignancies by hepatic radioembolization. *World Conference on Interventional Oncology (WCIO) meeting* 2012; Poster 45.

- Bozkurt M, Volkan-Salanci B, Peynircioglu B *et al.* Accelerated progression of metastatic disease shortly after Y90-microsphere treatment: Is there a causative relation? *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2012; **53** (Suppl 1): Abs. 441.
- Wilhelm K, Logvinski T, Meyer C *et al.* Lobar Yttrium-90 (⁹⁰Y) radioembolization for induction of contralateral lobar hypertrophy in patients with liver metastases. *GEST meeting abstracts, Journal of Vascular and Interventional Radiology* 2012; **23**: 577.e4 Abs.
- Mahvash A, Moayyad J, Shreyaah S *et al.* Y90 radioembolization in patients with compromise of the Ampulla of Vater. *GEST meeting abstracts, Journal of Vascular and Interventional Radiology* 2012; **23**: 577.e12 Abs.
- Lam MG, Shah RP, Goris ML *et al.* Safety of repeated treatment with Yttrium-90 radioembolization. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S71 Abs. 171.
- Nitz MD, Anderson CL, Saad WE *et al.* Preliminary analysis of angiographic contrast density as a predictor of liver perfusion change in radioembolization. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S148–S149 Abs. 371.
- Saxena A, Chua TC, Meteling B *et al.* Radioembolization with yttrium-90 microspheres is associated with a significantly improved survival compared to conservative therapy after treatment of unresectable hepatic tumors: A large single center experience of 537 patients. *65th Annual Cancer Symposium of the Society of Surgical Oncology, Asia-Pacific Journal of Clinical Oncology* 2012; **7** (Suppl S4): Abs. 212.
- Ros NF, Silva N, Iñarrairaegui M *et al.* La radioembolización hepática lobar induce hipertrofia del lóbulo contralateral. *Spanish Association for the Study of the Liver* 2012; Abs.
- Nichols EM, Grabowski S, Hanlon A *et al.* Performance status (PS), number of lesions and interval from metastatic diagnosis to treatment (IMDTT) predict for overall survival (OS) in patients treated with hepatic transarterial radioembolization (TARE) with yttrium-90 (Y90) microspheres. *53rd Annual Meeting of American Society for Radiation Oncology (ASTRO), International Journal of Radiation Oncology, Biology and Physics* 2011; **81** (2 Suppl): S346–S347 Abs. 2281.
- Bagni O, D'Arienzo M, Salvatori R *et al.* Can ⁹⁰Y-PET predict the outcome of lesions after SIRT? Biodistribution assessment and preliminary data of Voxel Based Dosimetry. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. OP023.
- Kucuk ON, Soydal C, Lacin S *et al.* Intra-arterial radioembolization with Y-90 for unresectable primary and metastatic liver tumors and evaluation of treatment response by FDG PET/CT. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. P470.
- Uslu L, Arslan E, Ozhan M *et al.* Radioembolization using yttrium-90 microspheres for advanced primary and metastatic liver malignancies. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. P474.
- Kaplan GH, Yıldız A, Yılmaz S *et al.* The role radioembolization for treatment of liver malignancies. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. P476.
- Cove-Smith L, Wilson G. Efficacy and toxicity of selective internal radiation therapy (SIRT) with yttrium 90 microspheres for the treatment of unresectable hepatic tumours: a retrospective analysis of 58 patients. *13th World Congress on Gastrointestinal Cancer, Annals of Oncology* 2011; **22** (Suppl 5): v64 Abs. P-0150.
- Sella D, Rilling WS. Cost considerations in interventional oncology: Are IO treatments expensive relative to the alternatives? *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2011; **22** (Suppl): S108–109 Abs. 253.
- Presidente A, Lombardi G, D'angelo R *et al.* Selective internal radiation therapy with ⁹⁰Y microspheres for liver metastases: single-centre experience. *European Congress of Radiology* 2011; Abs. C-0718.
- Subbiah IM, CenP, Tanikella R *et al.* Radioembolization of unresectable primary and secondary hepatic malignancies using yttrium-90: The University of Texas at Houston experience. *ASCO Gastrointestinal Cancers Symposium, Journal of Clinical Oncology* 2011; **29** (Suppl 4): Abs. 311.

- Nutting C, Kennedy A, Kortz E. Radioembolization of liver metastases in the setting of a violated Ampulla. *GEST meeting 2010*; Abs.
- Arslan N, Emi M, Alagoz E *et al.* Selective internal radiation therapy (SIRT) with ⁹⁰Y-microspheres for unresectable malignant liver tumors. *European Association of Nuclear Medicine (EANM) Conference 2009*; Abs. PW060.
- Küçük Ö, Laçın S, Yagcı S *et al.* Evaluation of Y-90 microsphere therapy response of metastatic or primary liver tumor with PDG-PET/CT: Ankara University preliminary results. *European Association of Nuclear Medicine (EANM) Conference 2009*; Abs. P208.
- Seaton T, Naji M, Tait P *et al.* Selective internal radiotherapy for unresectable liver tumours: Follow up of 74 cases. *European Association of Nuclear Medicine (EANM) Conference 2009*; Abs. OP374.
- Pitton MB, Eichhorn W, Schreckenberger M *et al.* Selective internal radiation therapy (SIRT): technical remarks and first clinical results. *Cardiovascular and Interventional Radiology in Europe (CIRSE) 2009*; Abs. P-280.
- Alonso-Burgos A, Iñárraiegui M, Sangro B *et al.* Radioembolisation of liver tumors: determinants of antitumor effect using Y90-labeled resin microspheres *Cardiovascular and Interventional Radiology in Europe (CIRSE) 2008*; Abs. P-74.
- Szyszko T, Brooks A, Khan S *et al.* SIR sphere therapy: update of clinical experience over the last 40 months. *36th Annual Meeting of the British Nuclear Medicine Society 2008*; Abs. 172.
- Zhang Z, Machac, J, Heiba S *et al.* ⁹⁰Y SIR-Spheres treatment of unresectable primary or metastatic hepatic tumors. Radiomicrosphere Therapy: 4th Annual Symposium May 2008 *Journal of Interventional Oncology 2009*; **2**: 94.
- Ruehl R, Seidensticker M, Denecke T *et al.* Selektive interne radioembolisation (SIRT) mit mikrosphären bei extensiven, therapierefraktären, progredienten Lebermalignomen. *Deutsche Gesellschaft für Nuklearmedizin (DGN) 2008*; Abs. [in German]
- Vallow L, Kim S, Hayostek C *et al.* An Initial experience of Yttrium-90 microsphere radio-embolization in liver metastasis. *49th Annual Meeting of the American Society for Therapeutic Radiology & Oncology (ASTRO) 2007*; Abs. 2164.
- Szyszko T, Tait P, Khan S *et al.* Yttrium-90 microspheres in liver tumours: effects of extrahepatic disease. *European Association of Nuclear Medicine (EANM) Conference 2007*; Abs. 79.
- Palmedo H, Ezziddin S, Bucerius J *et al.* Selective internal radiotherapy (SIRT) in malignant liver tumors: first clinical results. *European Association of Nuclear Medicine (EANM) Conference 2007*; Abs. 78.
- Bilbao I, Martínez-Cuesta A, Alonso-Burgos A *et al.* Liver radioembolization (RE) with Y⁹⁰ loaded resin microspheres: results in 93 patients in a single institution. *Cardiovascular and Interventional Radiology 2007*; Abs. 1303.3.
- Bilbao JI, Martínez-Cuesta A, Alonso A, Rodríguez J, Arbizu J, Sangro B. Radioembolization with Yttrium-90. *Cardiovascular and Interventional Radiology 2007*; Abstract 1503.2.
- Alonso-Burgos A, Martínez-Cuesta A, Valero M, Arbizu J, Sangro B, Bilbao JI. Radioembolization (RE) with ⁹⁰Yttrium for liver metastases: influence of previous treatments with an antiangiogenic drug (Bevacizumab-Avastin). *Cardiovascular and Interventional Radiology 2007*; Abs. 3003.2.
- Gulec SA, Mesoloras G, Wiarda H *et al.* Y-90 resin microsphere selective internal radiation treatment in primary and metastatic liver cancer: Objective response and therapeutic ratio analysis. *American Hepato-Pancreato-Biliary Association (AHPBA) meeting 2007*; Abs. 62.
- Kennedy A, McNeillie P, Dezarn W *et al.* Factors related to toxicity and response in 680 treatments of resin ⁹⁰Y-microsphere radioembolization in hepatic malignancies. *18th International Congress on Anti-Cancer Treatment 2007*; Abs. 298.
- Cianni R, Satarelli A, Notarianni E *et al.* Radioembolism (Yttrium-90) of hepatic liver metastases. A preliminary experience. *Cardiovascular and Interventional Radiology 2006*. Abs. 49.1.9.
- Jakobs T, Hoffmann R, Yu M *et al.* Yttrium-90 (SIR-Spheres[®]) treatment for metastatic cancer to the liver: midterm result. *World Conference on Interventional Oncology (WCIO) meeting 2006*; Session L1.
- Wang S, Ho Y, Leung F *et al.* Outcomes following selective internal radiation therapy with SIR-Spheres in non-resectable hepatic malignancy. *World Conference on Interventional Oncology (WCIO) meeting 2006*; Abs. 8145.

Janssen J, Quinn R, Morris D *et al.* Clinical side effects associated with the administration of Y⁹⁰ SIR-Spheres. *36th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine* April 2006; Abs. 53.

Yu M, Lewandowski RJ, Wong CO *et al.* Yttrium-90 (SIR-Spheres[®]) treatment for metastatic cancer to the liver: midterm results. *Society of Interventional Radiology (SIR) Conference* March 2006; Abs. 17.

Boán J, Martí-Climent J, Martínez-Cuesta A *et al.* Selective internal radiation therapy of primary or metastatic hepatic tumors with Yttrium-90 microspheres. *European Association of Nuclear Medicine (EANM) Conference* 2005; Abs. 295.

Bailey W, Little A, Lim L *et al.* Yttrium-90 microsphere hepatic artery embolization in the treatment of non-resectable hepatic malignancy. *Australasian Radiology* 2004; **48** (2): Abs. A4.

Bester L, Driver N, Hodges C. Targeted arterial chemo-embolisation using yttrium-90 SIR-Spheres - Clinical experience. *Clinical Oncology Society of Australia (COSA) meeting* 2004; Abs. O113.

Nutting C, Jones B. Techniques for minimizing complications during yttrium-90 radioembolization of unresectable hepatic malignancies. *Cardiovascular and Interventional Radiology* 2004; **27** (Sup.1): Abs. 9.4.3.

SIR-Spheres microspheres are approved in Australia, the European Union (CE Mark) and several other countries for the treatment of patients with non-operable liver tumours. The papers and abstracts on this page report pre-clinical and clinical experience using SIR-Spheres microspheres in the treatment of malignancy outside of the liver, which are currently investigational in nature and that have not been approved or cleared by regulatory authorities.

Lung Malignancies

Retrospective Studies in Lung Metastases

Ricke J, Großer O, Amthauer H. Y90-radioembolization of lung metastases via the bronchial artery: A report of 2 cases. *Cardiovascular and Interventional Radiology* 2013 Jul 10; ePub doi: 10.1007/s00270-013-0690-3.

Haematological Malignancies

Retrospective Studies in Malignant Lymphomatous Splenomegaly

Muylle K, Nguyen J, de Wind A *et al.* Radioembolization of the spleen: A revisited approach for the treatment of malignant lymphomatous splenomegaly. *Cardiovascular and Interventional Radiology* 2012 Sep 25; ePub doi: 10.1007/s00270-012-0484-z.

Primary Renal Cancer

Preclinical Studies in Primary Renal Cancer

Mackie S, de Silva S, Aslan P *et al.* Super selective radio embolization of the porcine kidney with ⁹⁰yttrium resin microspheres: a feasibility, safety and dose ranging study. *Journal of Urology* 2011; **185**: 285–290.

Consensus Statements / Guidelines

Colorectal Cancer Guidelines

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Colon Cancer. Version 1.2014. www.nccn.org/professionals/physician_gls/PDF/colon.pdf

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Rectal Cancer. Version 1.2014. www.nccn.org/professionals/physician_gls/PDF/rectal.pdf

d'Othée BJ, Sofocleous CT, Hanna N *et al.* Development of a research agenda for the management of metastatic colorectal cancer: Proceedings from a multidisciplinary research consensus panel. *Journal of Vascular and Interventional Radiology* 2012; **23**: 153–163.

National Institute for Health and Clinical Excellence (NICE). Selective internal radiation therapy for non-resectable colorectal metastases in the liver. 2011 Jul 27; IPG 401.

Hepatocellular Carcinoma Guidelines

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Hepatobiliary guidelines. Version 2.2013. www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf

Verslype C, Rosmorduc O, Rougier P *et al.* Hepatocellular carcinoma: ESMO–ESDO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 2012; **23** (Suppl 7): vii41–vii48, European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL–EORTC clinical practice guidelines: Management of hepatocellular carcinoma”. *Journal of Hepatology* 2012; **56**:908–943.

European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. *Journal of Hepatology* 2012; ePub doi: <http://dx.doi.org/10.1016/j.jhep.2012.03.006>.

[Erratum to “EASL–EORTC clinical practice guidelines: Management of hepatocellular carcinoma”. *Journal of Hepatology* 2012; **56**: 908–943].

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020–1022.

Ferenci P, Fried M, Labrecque D *et al.* World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. *Journal of Gastrointestinal and Liver Diseases* 2010; **19**: 311–317 and *Journal of Clinical Gastroenterology* 2010; **44**: 239–245.

Thomas MB, Jaffe D, Choti MM *et al.* Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting. *Journal of Clinical Oncology* 2010; **28**: 3994–4005.

Jelic S, Sotiropoulos GC on behalf of the ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Annals of Oncology* 2010; **21** (Suppl 5): v59–64.

Dixon E, Abdalla E, Schwarz RE, Vauthey JN. AHPBA/SSO/SSAT Sponsored Consensus Conference on Multidisciplinary Treatment of Hepatocellular Carcinoma. *HPB* 2010; **12**: 287–288.

Schwarz RE, Abou-Alfa GK, Geschwind JF *et al.* Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. *HPB* 2010; **12**: 313–320.

Burak KW, Thomas MB, Zhu AX. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. *HPB* 2010; **12**: 321–322.

Neuroendocrine Tumour Guidelines

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Neuroendocrine tumors. Version 2.2013. http://www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf

Öberg K, Knigge U, Kwekkeboom D *et al.* Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 2012; **23** (Suppl 7): vii124–vii130.

Kulke MH, Siu LL, Tepper JE, Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. *Journal of Clinical Oncology* 2011; **29**: 934–943.

Kulke MH, Anthony L, Bushnell DL *et al.* NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. *Pancreas* 2010; **39**: 735–752.

Boudreaux JP, Klimstra DS, Hassan MM *et al.* The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. *Pancreas* 2010; **39**: 753–766.

Phan AT, Öberg K, Choi J *et al.* NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). *Pancreas* 2010; **39**: 784–798.

Vinik AI, Anthony L, Boudreaux JP *et al.* Neuroendocrine tumors: a critical appraisal of management strategies. *Pancreas* 2010; **39**: 801–818.

General Consensus Statements / Guidelines

Dezarn WA, Cessna JT, DeWerd LA *et al.* Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for ⁹⁰Y microsphere brachytherapy in the treatment of hepatic malignancies. *Medical Physics* 2011; **38**: 4824–4845.

Giammarile F, Bodei L, Chiesa C *et al.* EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. *European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38**: 1393–1406.

Canadian Agency for Drugs and Technologies in Health (CADTH). Yttrium-90 microspheres for cancer patients with primary or secondary liver tumors: clinical and cost-effectiveness. CADTH 13 June 2011: http://www.cadth.ca/media/pdf/htis/june-2011/RB0369_Yttrium-90_Microspheres_Final.pdf

Salem R, Lewandowski RJ, Gates VL *et al.* Research reporting standards for radioembolization of hepatic malignancies. *Journal of Vascular and Interventional Radiology* 2011; **22**: 265–278.

Fong Y, Wasan H, Leung TWT *et al.* Integration of radiomicrosphere therapy into the contemporary management strategies for primary and metastatic liver cancer: Oncology expert opinions and recommendations. *Journal of Interventional Oncology* 2009; **2**: 46–58.

American College of Radiology (ACR), American Society for Therapeutic Radiology and Oncology (ASTRO), and the Society of Interventional Radiology (SIR). Practice guideline for radioembolization with microsphere brachytherapy device (RMBD) for treatment of liver malignancies. 2008; Res. 2: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/iv/RMBD.aspx

Kennedy A, Nag S, Salem R *et al.* Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the Radioembolization Brachytherapy Oncology Consortium (REBOC). *International Journal of Radiation Oncology, Biology and Physics* 2007; **68**: 13–23.

Kennedy A. ⁹⁰Y-microsphere liver brachytherapy for primary or metastatic tumors. In: 2006 ACRO Practice Management Guide: *American College of Radiation Oncology* 2006; 349–359.

Review Articles

Colorectal Cancer

- Foubert F, Matysiak-Budnik T, Touchefeu Y. Options for metastatic colorectal cancer beyond the second line of treatment. *Digestive and Liver Disease* 2013 Aug 14; ePub doi: 10.1016/j.dld.2013.07.002.
- Damm R, Seidensticker R, Ricke J, Seidensticker M. [Interventional radiological procedures in the therapy for colorectal liver metastases]. *Zentralblatt für Chirurgie* 2013; **138**: 76–83. [in German]
- Seront E, Van den Eynde M. Liver-directed therapies: Does it make sense in the current therapeutic strategy for patients with confined liver colorectal metastases? *Clinical Colorectal Cancer* 2012; **11**: 177–184.
- Sharma R. Synergy of yttrium-90 microspheres therapy with radiosensitising chemotherapy. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres, European Journal of Cancer Supplements* 2012; **10** (3): 4–6.
- Van Cutsem E. Progress in the management of chemorefractory colorectal cancer. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres, European Journal of Cancer Supplements* 2012; **10** (3): 7–9.
- Wasan H. Selective internal radiation therapy first-line therapy – SIRFLOX and FOXFIRE. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres, European Journal of Cancer Supplements* 2012; **10** (3): 12–14.
- Peeters M. Future directions for selective internal radiation therapy in colorectal cancer. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres, European Journal of Cancer Supplements* 2012; **10** (3): 15–17.
- Alberts SR. Update on the optimal management of patients with colorectal liver metastases. *Critical Reviews in Oncology Hematology* 2012 Mar 16; ePub doi: 10.1016/critrevonc.2012.02.007.
- Wasan H, Kennedy A, Coldwell D *et al.* Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases. *American Journal of Clinical Oncology* 2012; **35**: 293–301.
- Cosimelli M, Mancini R, Carpanese L *et al.* Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer. *Expert Opinion on Therapeutic Targets* 2012; **16**: S11–S16.
- Haddad AJ, Bani Hani M *et al.* Colorectal liver metastases. *International Journal of Surgical Oncology* 2011; **2011**: 285840.
- Meyer JE, Cohen SJ. Beyond first-line therapy: combining chemotherapy and radioembolization for hepatic colorectal metastases. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 103 ePub doi: 10.4172/2155-9619.1000103.
- Hill EJ, Sharma RA. Multi-modality therapy of hepatic metastases from colorectal carcinoma: optimal combination of systemic chemotherapy with radio-embolization. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 108 ePub doi: 10.4172/2155-9619.1000108.
- de Baere T, Deschamps F. Arterial therapies of colorectal cancer metastases to the liver. *Abdominal Imaging* 2011; **36**: 661–670.
- Boutros C, Espat NJ. What, how, and when to offer nonresectional therapy for colorectal cancer liver metastases. *Journal of Gastrointestinal Surgery* 2011; **15**: 420–422.
- Eadens MJ, Grothey A. Curable metastatic colorectal cancer. *Current Oncology Reports* 2011; **13**: 168–176.
- Kobayashi A, Miyagawa S. Advances in therapeutics for liver metastasis from colorectal cancer. *World Journal of Gastrointestinal Oncology* 2010; **2**: 380–389.
- Nicolay NH, Berry DP, Sharma RA. Author reply: Radioembolization for colorectal liver metastases. *Nature Reviews Clinical Oncology* 2010; **7**: ePub doi:10.1038/nrclinonc.2009.165-c2. [reply to Vente MA *et al.* *Nature Reviews Clinical Oncology* 2010; **7**: ePub doi: 10.1038/nrclinonc.2009.165-c1.]
- Vente MA, van den Bosch MA, Lam MG, Nijsen JF. Radioembolization for colorectal liver metastases. *Nature Reviews Clinical Oncology* 2010; **7**: ePub doi: 10.1038/nrclinonc.2009.165-c1. [Comment on: Nicolay NH *et al.* *Nature Reviews Clinical Oncology* 2009; **6**: 687–697.]

- Pwint TP, Midgley R, Kerr DJ. Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver. *Seminars in Oncology* 2010; **37**: 149–159.
- Abdel-Misih SR, Schmidt CR, Bloomston PM. Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases. *World Journal of Surgical Oncology* 2009; **7**: 72.
- Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy *Nature Reviews Clinical Oncology* 2009; **6**: 687–697.
- Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer (Review). *Cochrane Database of Systematic Reviews* 2009 Oct 7;(4):CD007045.
- Kuebler JP. Radioembolization of liver metastases in patients with colorectal cancer: A nonsurgical treatment with combined modality potential. *Journal of Clinical Oncology* 2009; **27**: 4041–4042.
- Stuart K. Liver-directed therapies for colorectal metastases. *Seminars in Colon & Rectal Surgery* 2008; **19**: 207–215.
- Paschos KA, Bird NC. Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis. *Hippokratia* 2008; **12**: 132–138.
- Wasan H. The emerging synergy between radioembolisation, systemic chemotherapy and liver surgery in metastatic colorectal cancer. *European Oncological Disease* 2007; **1**: 54–58.
- Gulec SA, Fong Y. Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. *Archives of Surgery* 2007; **142**: 675–682.
- Khatri VP, Cheeb KG, Petrellic NJ. Modern multimodality approach to hepatic colorectal metastases: Solutions and controversies. *Surgical Oncology* 2007; **16**: 71–83.
- Ryan D. Nonsurgical approaches to colorectal cancer. *The Oncologist* 2006; **11**: 999–1002.
- Welsh JS, Kennedy AS, Thomadsen B. Selective internal radiation therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. *International Journal of Radiation Oncology, Biology and Physics* 2006; **66** (2 Suppl. S): S62–S73.
- Morris D. Selective internal radiation therapy with ⁹⁰Y-microspheres for colorectal liver metastases: cart before the horse or otherwise? *ANZ Journal of Surgery* 2006; **76**: 675.
- Hendlisz A, Personeni N, Delaunoit T *et al.* Hepatic intra-arterial injection of yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes. *Acta Gastroenterologica Belgica* 2006; **69**: 55–58.
- Liu L, Zhang W, Jiang H. Current treatment for liver metastases from colorectal cancer. *World Journal of Gastroenterology* 2003; **9**: 193–200.

Hepatocellular Carcinoma

- Reig M, Burrel M, Bruix J. Treatment of hepatocellular carcinoma with radioembolization: Gathering assumptions for trial design. *Journal of Vascular and Interventional Radiology* 2013; **24**: 1197–1199.
- Cohen GS, Black M. Multidisciplinary management of hepatocellular carcinoma: A model for therapy. *Journal of Multidisciplinary Healthcare* 2013; **6**: 189–195.
- Weintraub JL, Salem R. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: State of the science. *Journal of Vascular and Interventional Radiology* 2013; **24**:1123–1134.
- Xing M, Kokabi N, Camacho JC *et al.* ⁹⁰Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: An analysis of comparative effectiveness. *Journal of Comparative Effectiveness Research* 2013; **2**: 435–444.
- Göbel T, Blondin D, Kolligs F *et al.* Aktuelle Therapie des hepatozellulären Karzinoms unter besonderer Berücksichtigung neuer und multimodaler Therapiekonzepte [Current therapy of hepatocellular carcinoma with special consideration of new and multimodal treatment concepts]. *Deutsche Medizinische Wochenschrift* 2013; **138**: 1425–1430. [in German]
- Cohen GS, Black M. Multidisciplinary management of hepatocellular carcinoma: A model for therapy. *Journal of Multidisciplinary Healthcare* 2013; **6**:189–195.
- Bargellini I, Florio F, Golfieri R *et al.* Trends in utilization of transarterial treatments for hepatocellular carcinoma: Results of a survey by the Italian Society of Interventional Radiology. *Cardiovascular and Interventional Radiology* 2013 May 30; ePub doi: 10.1007/s00270-013-0656-5.

- Dufour JF, Bargellini I, De Maria N *et al.* Intermediate hepatocellular carcinoma: Current treatments and future perspectives. *Annals of Oncology* 2013; **24** (Suppl 2): ii24–ii29.
- Pollak JS. Consider the perspectives: Interventional radiology. *Journal of Clinical Gastroenterology* 2013 Apr 29; ePub doi: 10.1097/MCG.0b013e31828be6f0.
- Lau WY, Sangro B, Chen PJ *et al.* Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: The emerging role for radioembolization using yttrium-90. *Oncology* 2013; **84**: 311–318.
- Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges and clinical perspectives. *Hepatology* 2013 Mar 19; ePub doi: 10.1002/hep.26382.
- Raoul JL, Gilibert M, Oziel-Taïeb S, Giovannini M. [Palliative treatment for hepatocellular carcinoma]. *Revue du Praticien* 2013; **63**: 233–236. [Article in French]
- Takayasu K. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: Recent progression and perspective. *Oncology* 2013; **84**: 28–33.
- Kim YH, Kim do Y. Yttrium-90 radioembolization for hepatocellular carcinoma: What we know and what we need to know. *Oncology* 2013; **84** (Suppl 1): 34–39.
- Shrimal A, Prasanth M, Kulkarni AV. Interventional radiological treatment of hepatocellular carcinoma: an update. *Indian Journal of Surgery* 2012; **74**: 91–99.
- Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. *Clinical Gastroenterology and Hepatology* 2013 Jan 25; ePub doi: 10.1016/j.cgh.2012.12.039.
- Sangro B, Bilbao JI, Iñarrairaegui M. Reply to: "Pre-therapeutic dosimetry evaluation and selective internal radiation therapy of hepatocellular carcinoma using yttrium-90-loaded microspheres." *Journal of Hepatology* 2013 Jan 12; ePub doi: 10.1016/j.jhep.2013.01.002.
- Garine E, Rolland Y, Boucher E. Pre-therapeutic dosimetry evaluation and selective internal radiation therapy of hepatocellular carcinoma using yttrium-90-loaded microspheres. *Journal of Hepatology* 2013 Jan 11; ePub doi: 10.1016/j.jhep.2012.11.050. [letter to the editor]
- Kim do Y, Han KH. How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. *Digestive Diseases* 2012; **30**: 598–602.
- Bolondi L, Piscaglia F. Yttrium 90 radioembolization: the horizon is changing for patients with intermediate and advanced hepatocellular carcinoma. [Editorial to Mazzaferro V, Sposito C, Bhoori S *et al.* Yttrium (90) radioembolization for intermediate-advanced hepatocarcinoma: A phase II study. *Hepatology* 2012 Aug 22; ePub doi: 10.1002/hep.26014.] *Hepatology* 2012 Nov 23; ePub doi: 10.1002/hep.26154.
- Rosmorduc O. State of the art – hepatocellular carcinoma. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres, European Journal of Cancer Supplements* 2012; **10** (3): 20–22.
- Sangro B. The ENRY analysis: A 325-patient European multicentre analysis. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres, European Journal of Cancer Supplements* 2012; **10** (3): 23–26.
- Kolligs F. BCLC treatment algorithm and the place of selective internal radiation therapy. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres, European Journal of Cancer Supplements* 2012; **10** (3): 27–29.
- Chow P, Ricke J, Malfertheiner P, Vilgrain V. Evolving clinical evidence for selective internal radiation therapy in hepatocellular carcinoma. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres, European Journal of Cancer Supplements* 2012; **10** (3): 30–33.
- Lau J. Hepatocellular carcinoma resection post-selective internal radiation therapy. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres, European Journal of Cancer Supplements* 2012; **10** (3): 39–40.
- Willatt JM, Francis IR, Novelli PM *et al.* Interventional therapies for hepatocellular carcinoma. *Cancer Imaging* 2012; **12**: 79–88.
- May BJ, Murthy R, Madoff DC. What's new in transarterial therapies for hepatocellular carcinoma? *Gastrointestinal Cancer Research* 2012; **5** (Suppl 1): S14–S19.
- Andreana L, Isgrò G, Marelli L *et al.* Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: Trans-arterial radio-embolisation of HCC. *Cancer Treatment Reviews* 2012; **38**: 641–649.

- Brailion A; Ren W, Qi X, Jia J *et al*; van den Bosch MAAJ, Defreyne L; Oliveri RS, Wetterslev J, Gluud C; Forner A, Bruix J [authors' reply]. Hepatocellular carcinoma. *Lancet* 2012; **380**: 469–471. [Comment on Forner A, Llovet JM, Bruix J. *Lancet* 2012; **379**: 1245–1255.]
- Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; **379**: 1245–1255.
- Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. *Journal of Hepatology* 2012; **56**: 467–473.
- Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: Current progress and perspective. *Japanese Journal of Clinical Oncology* 2012; **42**: 247–255.
- Radeleff BA, Stampfl U, Sommer CM *et al*. Transvaskuläre ablation des hepatozellulären karzinoms ist chemotherapie alles? [Transarterial ablation of hepatocellular carcinoma: Status and developments]. *Radiologe* 2012; **52**: 44–55. [in German]
- Meza-Junco J, Montano-Loza AJ, Liu DM *et al*. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? *Cancer Treatment Reviews* 2012; **38**: 54–62.
- Takayasu K. Superselective transarterial chemoembolization for hepatocellular carcinoma: Recent progression and perspective. *Oncology* 2011; **81**: 105–110.
- Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. *Radiology* 2012; **262**: 43–58.
- Shah RP, Brown KT, Sofocleous CT. Arterially directed therapies for hepatocellular carcinoma. *AJR American Journal of Roentgenology* 2011; **197**: W590–W602.
- Herzer K, Müller S, Antoch G, Hilgard P. Locoregional therapies for hepatocellular: radioembolization with yttrium-90 microspheres. *Minerva Gastroenterologica e Dietologica* 2011; **57**: 287–298.
- Ettorre GM, Vennarecci G, Santoro R *et al*. Experiences in hepatic surgery and transplantation after radioembolization. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 109 doi: ePub 10.4172/2155-9619.1000109.
- Sangro B, Iñarrairaegui M. Radioembolization for hepatocellular carcinoma: evidence-based answers to frequently asked questions. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 110 ePub doi: 10.4172/2155-9519.1000110.
- Guimaraes M, Uflacker R. Locoregional therapy for hepatocellular carcinoma. *Clinics in Liver Disease* 2011; **15**: 395–421.
- Sangro B, D'Avola D, Iñarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. *Expert Opinion on Pharmacotherapy* 2011; **12**: 1057–1073.
- Kim R, Byrne MT, Tan A, Aucejo F. What is the indication for sorafenib in hepatocellular carcinoma? a clinical challenge. *Oncology (Williston Park)* 2011; **25**: 283–291.
- Razumilava N, Gores GJ. Sorafenib for HCC: a pragmatic perspective. The Kim *et al* Article Reviewed *Oncology (Williston Park)* 2011; **25**: 295.
- Bujold A, Dawson LA. Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma. *Cancer/Radiothérapie* 2011; **15**: 54–63.
- Munene G, Vauthey JN, Dixon E. Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. *International Journal of Hepatology* 2011; **2011**: 565060.
- Lau WY, Lai EC, Leung TW. Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review. *International Journal of Radiation Oncology, Biology and Physics* 2011; **81**: 460–467.
- Sangro B, Salem R, Kennedy A *et al*. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. *American Journal of Clinical Oncology* 2011; **34**: 422–431.
- Kolligs FT, Hoffmann RT, op den Winkel M *et al*. Diagnose und multimodale therapie des hepatozellulären karzinoms [Diagnosis and multimodal therapy for hepatocellular carcinoma]. *Zeitschrift für Gastroenterologie* 2010; **48**: 274–288. [in German]
- Davis CR. Interventional radiological treatment of hepatocellular carcinoma. *Cancer Control* 2010; **17**: 87–99.
- Lambert B, Van Vlierberghe H, Troisi R, Defreyne L. Radionuclide therapy for hepatocellular carcinoma. *Acta Gastro-Enterologica Belgica* 2010; **73**: 484–488.
- Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. *Infectious Disease Clinics of North America* 2010; **24**: 899–919.

- Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. *Nature Reviews Gastroenterology and Hepatology* 2010; **7**: 448–458.
- Poon RT. Recent advances in management of hepatocellular carcinoma. *Hong Kong Medical Diary* 2010; **15**: 18–22.
- Kulik L. Is radioembolization ready for the Barcelona Clinic Liver Cancer staging system? *Hepatology* 2010; **52**: 1528–1530.
- Van de Wiele C. Radioembolization of hepatocellular carcinoma. *Current Drug Discovery Technologies* 2010; **7**: 247–252.
- Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? *The Oncologist* 2010; **15** (suppl 4): 42–52.
- Lencioni R. Loco-regional treatment of hepatocellular carcinoma. *Hepatology* 2010; **52**: 762–773.
- Lencioni R. Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. *Oncology* 2010; **78** (Suppl 1): 107–112.
- Lencioni R, Crocetti L, De Simone P, Filippini F. Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects. *Transplant International* 2010; **23**: 698–703.
- Senthil M, Mailey B, Leong L *et al.* Liver-directed regional therapy in the multi-disciplinary management of hepatocellular cancer. *Current Cancer Therapy Reviews* 2010; **6**: 19–25.
- Rossi L, Zoratto F, Papa A *et al.* Current approach in the treatment of hepatocellular carcinoma. *World Journal of Gastrointestinal Oncology* 2010; **2**: 348–359.
- Tsochatzis EA, Germani G, Burroughs AK. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. *Seminars in Oncology* 2010; **37**: 89–93.
- Antoch G, Mueller SP, Hamami M *et al.* [Selektive interne radiotherapie (SIRT) beim hepatozellulären karzinom] / Selective internal radiotherapy (SIRT) for hepatocellular carcinoma. *Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren* 2010; **182**: 660–670. [in German]
- Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? *Annals of Surgical Oncology* 2010; **17**: 1234–1246.
- Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. *Nature Reviews Gastroenterology and Hepatology* 2010; **7**: 41–49.
- Riaz A, Salem R. Yttrium-90 radioembolization in the management of liver tumors: expanding the global experience. *European Journal of Nuclear Medicine and Molecular Imaging* 2010; **37**: 451–452.
- Fornier A, Trinchet JC. Transarterial therapies in HCC: Does embolization increase survival? *Journal of Hepatology* 2009; **51**: 981–983.
- Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. *Nature Clinical Practice Gastroenterology Hepatology* 2009; **6**: 159–169.
- Sangro B, Bilbao JI, Iñarrairaegui M *et al.* Treatment of hepatocellular carcinoma by radioembolization using ⁹⁰Y microspheres. *Digestive Diseases* 2009; **27**: 164–169.
- Hilgard P, Müller S, Hamami M *et al.* Selektive interne Radiotherapie (Radioembolisation) und Strahlentherapie beim HCC – Stand und Perspektiven / Selective internal radiotherapy (radioembolization) and radiation therapy for HCC – current status and perspectives. *Zeitschrift für Gastroenterologie / German Journal of Gastroenterology* 2009; **47**: 37–54. [in German]
- Al-Kalbani A, Kamel Y. Y-90 microspheres in the treatment of unresectable hepatocellular carcinoma. *The Saudi Journal of Gastroenterology* 2008; **14**: 90–92.
- Lau WY, Lai ECH. Hepatocellular carcinoma: current management and recent advances. *Hepatobiliary & Pancreatic Diseases International* 2008; **7**: 237–257.
- Ibrahim SM, Lewandowski RJ, Sato KT *et al.* Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review. *World Journal of Gastroenterology* 2008; **14**: 1664–1669.
- Mojtahedi A, Yang X, Goswami GK. Embolotherapy in the management of hepatocellular carcinoma. *Seminars in Interventional Radiology* 2008; **25**: 234–241.
- Allison C. Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma. *Issues in Emerging Health Technologies* 2007; **102**: 1–6.
- Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. *Oncogene* 2006; **25**: 3866–3884.

Clark H, Carson W, Kavanagh P *et al.* Staging and current treatment of hepatocellular carcinoma. *Radiographics* 2005; **25**: S3–S23.

Lambert B, Van de Wiele C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. *European Journal of Nuclear Medicine and Molecular Imaging* 2005; **32**: 980–989.

Ho S, Johnson P, Leung W *et al.* Combating hepatocellular carcinoma with an integrated approach. *Chinese Medical Journal* 1998; **112**: 80–83.

Ngan H. Imaging and radiological intervention in hepatocellular carcinoma. *Hong Kong Medical Journal* 1997; **3**: 57–68.

Neuroendocrine Tumours

Wang SC, Fidelman N, Nakakuraa EK. Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver. *Seminars in Oncology* 2013; **40**: 69–74.

Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. *International Journal of Hepatology* 2012; **2012**: 973946.

Bester L. Selective internal radiation therapy for neuroendocrine liver metastases. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 67–69.

Alistar A, Sung M, Michelle K. Clinical pathways for pancreatic neuroendocrine tumors. *Journal of Gastrointestinal Cancer* 2012; **43**: 532–540.

Reidy-Lagunes D, Thornton R. Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different? *Current Oncology Reports* 2012; **14**: 249–256.

Yang TX, Chua TC, Morris DL. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases – A systematic review. *Surgical Oncology* 2012; **21**: 299–308.

Rossi RE, Massironi S, Spampatti MP *et al.* Treatment of liver metastases in patients with digestive neuroendocrine tumors. *Journal of Gastrointestinal Surgery* 2012; **16**: 1981–1992.

Kennedy A, Coldwell D, Sangro B *et al.* Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. *American Journal of Clinical Oncology* 2012; **35**: 393–398.

Zappa M, Abdel-Rehim M, Hentic O *et al.* Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. *Targeted Oncology* 2012; **7**: 107–116.

Vyleta M, Coldwell D. Radioembolization in the treatment of neuroendocrine tumor metastases to the liver. *International Journal of Hepatology* 2011; **2011**: 785315.

Lewis MA, Hubbard J. Multimodal liver-directed management of neuroendocrine hepatic metastases. *International Journal of Hepatology* 2011; **2011**: 452343.

Harring T, Nguyen T, Goss J, O'Mahony C. Treatment of liver metastases in patients with neuroendocrine tumors: A comprehensive review. *International Journal of Hepatology* 2011; **2011**: 154541.

Anthony L. Neuroendocrine hepatic tumors: summary of patient selection, response and toxicity of radioembolization in 281 patients. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 104
ePub doi: 10.4172/2155-9619.1000104.

Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. *Cancer Control* 2011; **18**: 127–137.

Auernhammer CJ, Göke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. *Gut* 2011; **60**: 1009–1021.

Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. *CA A Cancer Journal for Clinicians* 2011; **61**: 113–132.

Saxena A, Chua TC, Morris DL. Surgical management and emerging therapies to prolong survival in metastatic neuroendocrine cancer. *Annals of Surgical Oncology* 2011; **18**: S222–S223.

Chandra P, Yarandi SS, Khazai N *et al.* Management of intractable hypoglycemia with yttrium-90 radioembolization in a patient with malignant insulinoma. *American Journal of the Medical Sciences* 2010; **340**: 414–417.

- Frilling A, Sotiropoulos GC, Li J *et al.* Multimodal management of neuroendocrine liver metastases. *HPB (Oxford)* 2010; **12**: 361–379.
- Nazario J, Gupta S. Transarterial liver-directed therapies of neuroendocrine hepatic metastases. *Seminars in Oncology* 2010; **37**: 118–126.
- Arnold R, Kegel T. Aktuelle therapiestrategien gegen neuroendokrine tumoren. *InFo Onkologie* 2010 Feb 18; 3–8. [in German]
- Hendlisz A, Flamen P, Van den Eynde M *et al.* Locoregional and radioisotopic targeted treatment of neuroendocrine tumours. *Acta Gastro-Enterologica Belgica* 2009; **72**: 44–48.
- Ehehalt F, Saeger HD, Schmidt CM, Grützmann R. Neuroendocrine tumors of the pancreas. *Oncologist* 2009; **14**: 456–467.
- Auernhammer CJ, Jauch KW, Hoffmann JN. Lebermetastasierung bei neuroendokrinen Karzinomen des gastro-entero-pankreatischen Systems - Therapiestrategien [Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system--therapeutic strategies] *Zentralblatt für Chirurgie* 2009; **134**: 410–417. [in German]
- Khasraw M, Gill A, Harrington T *et al.* Management of advanced neuroendocrine tumors with hepatic metastasis. *Journal of Clinical Gastroenterology* 2009; **43**: 838–847.
- Liu DM, Kennedy A *et al.* Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. *American Journal of Clinical Oncology* 2009; **32**: 200–215.
- Auernhammer CJ. Aktuelle standards und perspektiven in diagnostik und therapie von neuroendokrinen tumoren des gastroenteropancreatischen systems. *Journal Onkologie* 2008; 04–08. [in German]
- Falconi M, Plockinger U, Kwekkeboom DJ *et al.* Well-differentiated pancreatic nonfunctioning tumors/carcinoma. *Neuroendocrinology* 2006; **84**: 196–211.
- Madoff D, Gupta S, Ahrar K *et al.* Update on the management of neuroendocrine hepatic metastases. *Journal of Vascular and Interventional Radiology* 2006; **17**: 1235–1250.
- Plockinger U, Rindi G, Arnold R *et al.* Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). *Neuroendocrinology* 2004; **80**: 394–424.

Breast Cancer

- Diamond JR, Finlayson CA, Borges VF. Hepatic complications of breast cancer. *Lancet Oncology* 2009; **10**: 615–621.
- Smits ML, Prince JF, Rosenbaum CE *et al.* Intra-arterial radioembolization of breast cancer liver metastases; A structured review. *European Journal of Pharmacology* 2013 Mar 29; ePub doi: 10.1016/j.ejphar.2012.11.067.

Cholangiocarcinoma

- De W Marsh R, Alonzo M, Bajaj S *et al.* Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part II: multidisciplinary management. *Journal of Surgical Oncology* 2012; **106**: 339–345.
- Kolligs F. Selective internal radiation therapy for cholangiocarcinoma. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 70–71.
- Hong K, Geschwind JF. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. *Seminars in Oncology* 2010; **37**:110–117.

Ocular Melanoma

- Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. *Seminars in Oncology* 2010; **37**: 127–138.
- Damato B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. *Eye (London)* 2012 Jun 29; ePub doi: 10.1038/eye.2012.126.

Desmoplastic Small Round Cell Tumours

Dufresne A, Cassier P, Couraud L *et al.* Desmoplastic small round cell tumor: Current management and recent findings. *Sarcoma* 2012; **2012**: 714986. ePub 2012 Mar 29; doi: 10.1155/2012/714986.

Hayes-Jordan A, Anderson PM. The diagnosis and management of desmoplastic small round cell tumor: a review. *Current Opinion in Oncology* 2011; **23**: 385–389.

Pancreatic Cancer

Brown DB, Narayanan G. Interventional radiology and the pancreatic cancer patient. *The Cancer Journal* 2012; **18**: 591–601.

General

Maor Y, Malnick S. Liver injury induced by anticancer chemotherapy and radiation therapy. *International Journal of Hepatology* 2013; **2013**: 815105.

Hickey R, Vouche M, Sze DY *et al.* Cancer concepts and principles: Primer for the interventional oncologist — Part I. *Journal of Vascular and Interventional Radiology* 2013; **24**: 1157–1164.

Hickey R, Vouche M, Sze DY *et al.* Cancer concepts and principles: Primer for the interventional oncologist — Part II. *Journal of Vascular and Interventional Radiology* 2013; **24**: 1167–1188.

Gabriel M. Radionuclide therapy beyond radioiodine. *Wiener Medizinische Wochenschrift* 2012; **162**: 430–439.

Sheth RA, Hesketh R, Kong DS *et al.* Barriers to drug delivery in interventional oncology. *Journal of Vascular and Interventional Radiology* 2013; **24**: 1201–1207.

Kritzinger J, Klass D, Ho S *et al.* Hepatic embolotherapy in interventional oncology: Technology, techniques, and applications. *Clinical Radiology* 2013; **68**: 1–15.

Mahnken AH, Spreafico C, Maleux G *et al.* Standards of practice in transarterial radioembolization. *Cardiovascular and Interventional Radiology* 2013 Mar 20; ePub doi 10.1007/s00270-013-0600-8.

Mahnken AH, Pereira P, de Baère T. Interventional oncologic approaches to liver Metastases. *Radiology* 2013; **266**: 407–430.

Johnston FM, Mavros MN, Herman JM, Pawlik TM. Local therapies for hepatic metastases. *Journal of the National Comprehensive Cancer Network* 2013; **11**: 153–160.

Mahnken AH, Pereira PL, de Baère T *et al.* Interventional oncologic approaches to liver metastases. *Radiology* 2013; **266**: 407–430.

Mäenpää H, Tenhunen M. [Radionuclide therapy for cancer—what's new?]. *Duodecim* 2012; **128**: 2209–2216. [in Finnish]

Smits MLJ, van den Bosch MA, Nijssen JF *et al.* The evolution of radioembolisation. [Correspondence to Cosimelli M. The evolution of radioembolization. *Lancet Oncology* 2012; **13**: 965–966.] *Lancet Oncology* 2012; **13**: E519.

Cosimelli M. The evolution of radioembolisation. *Lancet Oncology* 2012; **13**: 965–966.

Berry D. Liver resection post-selective internal radiation therapy – an overview. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 36–38.

Jakobs T. Selective internal radiation therapy for other liver metastases. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 72–74.

Wasan H. Patient selection criteria for selective internal radiation therapy and integration into treatment guidelines. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 76–80.

Memon K, Lewandowski RJ, Riaz A, Salem R. Chemoembolization and radioembolization for metastatic disease to the liver: Available data and future studies. *Current Treatment Options in Oncology* 2012 Jul 9; ePub doi: 10.1007/s11864-012-0200-x.

Høyer M, Swaminath A, Bydder S *et al.* Radiotherapy for liver metastases: a review of evidence. *International Journal of Radiation Oncology Biology Physics* 2012; **82**: 1047–1457.

Gaba RC. Chemoembolization practice patterns and technical methods among interventional radiologists: Results of an online survey. *AJR American Journal of Roentgenology* 2012; **198**: 692–699.

- Kennedy A, Coldwell D, Sangro B *et al.* Integrating radioembolization (^{90}Y Microspheres) into current treatment options for liver tumors: Introduction to the international working group report. *American Journal of Clinical Oncology* 2012; **35**: 81–90.
- Kennedy A, Coldwell D, Sangro B *et al.* Radioembolization for the treatment of liver tumors: general principles. *American Journal of Clinical Oncology* 2012; **35**: 91–99.
- Lau WY, Kennedy AS, Kim YH *et al.* Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. *International Journal of Radiation Oncology, Biology and Physics* 2012; **82**: 401–407.
- Coldwell D, Sangro B, Salem R *et al.* Radioembolization in the treatment of unresectable liver tumors: Experience across a range of primary cancers. *American Journal of Clinical Oncology* 2012; **35**: 167–177.
- Kao YH, Tan AE, Ng DC, Goh AS. Response to "Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres." *International Journal of Radiation Oncology, Biology and Physics* 2011; **80**: 1280. [Comment on Lau WY *et al.* *International Journal of Radiation Oncology, Biology and Physics* 2010 Oct 13; later published as 2012; **82**: 401–407.]
- Lau WY, Kennedy AS, Kim YH *et al.* In reply to Dr. Kao *et al.* *International Journal of Radiation Oncology, Biology and Physics* 2011; **80**: 1280–1281.
- Lau KN, Swan RZ, Sindram D *et al.* Hepatic tumor ablation: Application in a community hospital setting. *Surgical Oncology Clinics of North America* 2011; **20**: 455–466.
- Schefter TE. Patient selection factors for stereotactic body radiotherapy and radioembolization for hepatic metastases. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 1.
- Prompers L, Bucerius J, Brans B *et al.* Selective internal radiation therapy (SIRT) in primary or secondary liver cancer. *Methods* 2011; **55**: 253–257.
- Memon K, Lewandowski RJ, Kulik L *et al.* Radioembolization for primary and metastatic liver cancer. *Seminars in Radiation Oncology* 2011; **21**: 294–302.
- Nachtnebel A, Sotti G, Vitale A, Perrini MR. Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. *Decision Support Document* 2011 Mar; **47**.
- Vogl TJ, Mack MG, Eichler K *et al.* Chemoperfusion und -embolisation von Lebermetastasen [Chemoperfusion and Embolization in the Treatment of Liver Metastases]. *RoFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin* 2011; **183**: 12–23. [in German]
- Lowe K Jeyarajah DR. Integration of surgery and radioembolization in treatment of hepatic tumors. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 105 ePub doi: 10.4172/2155-9619.1000105.
- Burrill J, Hafeli U, Liu DM. Advances in radioembolization – embolics and isotopes. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 107 ePub doi: 10.4172/2155-9619.1000107.
- Coldwell D, Sangro B, Wasan H *et al.* General selection criteria of patients for radioembolization of liver tumors: an international working group report. *American Journal of Clinical Oncology* 2011; **34**: 337–341.
- Morgan B, Kennedy AS, Lewington V *et al.* Intra-arterial brachytherapy of hepatic malignancies: watch the flow. *Nature Reviews Clinical Oncology* 2011; **8**: 115–120.
- Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. *Radiology* 2011; **259**: 641–657.
- Hoffmann RT, Paprottka P, Jakobs TF *et al.* Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization). *Abdominal Imaging* 2011; **36**: 671–676..
- Goffredo V, Paradiso A, Ranieri G, Gadaleta CD. Yttrium-90 (^{90}Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). *Critical Reviews in Oncology/Hematology* 2011; **80**: 393–410.
- Smith KA, Kim HS. Interventional radiology and image-guided medicine: interventional oncology. *Seminars in Oncology* 2011; **38**: 151–162.
- Uthappa MC, Ravikumar R, Gupta A. Selective internal radiation therapy: ^{90}Y (yttrium) labeled microspheres for liver malignancies (primary and metastatic). *Indian Journal of Cancer* 2011; **48**: 18–23.
- Sato KT. Yttrium-90 radioembolization for the treatment of primary and metastatic liver tumors. *Seminars in Roentgenology* 2011; **46**: 159–165.

- Lindsay R, Kennedy P. Oncology and interventional radiology. *Oncology News* 2010; **5**: 190–193.
- Kennedy AS. The role of radioembolization for treating liver tumors – Treatment review & latest advances. *Hematology & Oncology News & Issues* 2010 Oct; 17–20.
- Vente MA, Zonnenberg BA, Nijsen JF. Microspheres for radioembolization of liver malignancies. *Expert Review of Medical Devices* 2010; **7**: 581–583.
- Carr BI. Regional hepatic therapy for cancer. *Seminars in Oncology* 2010; **37**: 82.
- Riaz A, Kulik LM, Mulcahy MF *et al*. Yttrium-90 radioembolization in the management of liver malignancies. *Seminars in Oncology* 2010; **37**: 94–101.
- Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. *Cancer Journal* 2010; **16**: 163–175.
- Deleporte A, Flamen P, Hendlisz A. State of the art: radiolabeled microspheres treatment for liver malignancies. *Expert Opinion on Pharmacotherapy* 2010; **11**: 579–586.
- Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors With Yttrium-90 microspheres. *Seminars in Nuclear Medicine* 2010; **40**: 105–121.
- Roche A. Le point sur la chimioembolisation hépatique / Liver chemoembolization: an update. *Bulletin du Cancer* 2009; **96**: 1111–1116. [in French]
- Vogl TJ, Lee C, Zangos S *et al*. Aktueller standpunkt zur selektiven internen radiotherapie (SIRT) bei malignen lebertumoren. *Hessisches Ärzteblatt* 2009 Sept; 584–590. [in German]
- Quick AM, Lo SS, Mayr NA, Kim EY. Radiation therapy for intrahepatic malignancies. *Expert Reviews in Anticancer Therapy* 2009; **9**: 1511–1521.
- Fong AJB, Kemeny N, Brown K. Regional transvascular therapies for liver cancer: Theory, history, evolution and current opinions. *Journal of Interventional Oncology* 2009; **2**: 2–13.
- Hall M, Mesoloras G, Fong Y, Gulec SA. Yttrium 90 microsphere selective internal radiation treatment of hepatic malignancies. *Journal of Interventional Oncology* 2009; **2**: 14–25.
- Rose SC, Gulec SA. Yttrium 90 radiomicrosphere therapy: ongoing clinical trials. *Journal of Interventional Oncology* 2009; **2**: 72–83.
- Van De Wiele C, Defreyne L, Peeters M, Lambert B. Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors. *Quarterly Journal of Nuclear Medicine and Molecular Imaging* 2009; **53**: 317–324.
- Bult W, Vente MA, Zonnenberg BA *et al*. Microsphere radioembolization of liver malignancies: current developments. *Quarterly Journal of Nuclear Medicine and Molecular Imaging* 2009; **53**: 325–335.
- Kennedy AS. Intraarterial yttrium-90 microspheres for hepatic malignancies *ASCO Educational Book* 2009; 251–255.
- Kennedy A. Targeted therapies address hard-to-treat liver tumors. *Oncology News International* 2009 March 23; **18**:
- Lambert B, Van De Wiele C. Selective internal radiation therapy of HCC and liver metastases: a locoregional or worldwide therapy? *The Quarterly Journal of Nuclear Medicine and Molecular Imaging* 2009; **53**: 302–304.
- Wasan H. The role of radioembolisation using SIR-Spheres® in secondary liver metastases of non-colorectal cancer origin – Emerging clinical data. *European Oncology* 2009; **4**: 70–74.
- Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. *Radiographics* 2008; **28**: 101–117.
- Jakobs TF, Hoffmann RT, Tatsch K *et al*. Therapieresponse von Lebertumoren nach selektiver interner Radiotherapie / Therapy response of liver tumors after selective internal radiation therapy. *Radiologe* 2008; **48**: 839–849. [in German]
- Vente MA, Wondergem M, van der Tweel I *et al*. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. *European Radiology* 2009; **19**: 951–959.
- Murthy R, Kamat P, Nuñez R *et al*. Radioembolization of yttrium-90 microspheres for hepatic malignancy. *Seminars in Interventional Radiology* 2008; **25**: 48–57.
- Hoffmann RT, Jakobs TF, Tatsch K, Reiser MF. Selektive interne radiotherapie (SIRT) bei fortgeschrittenen lebertumoren und metastasen. *Deutsche Medizinische Wochenschrift* 2008; **133**: 1–4. [in German]

- Tatsch K, Hoffmann RT, Pöpperl G. Selektive interne radiotherapie (SIRT) inoperabler lebertumoren mit radioaktiv markierten mikrosphären / Selective internal radiotherapy (SIRT) with radioactive microspheres in unresectable liver tumors. *Nuklearmedizin* 2008; **31**: 101–113. [in German]
- Dubel GJ, Soares GM. Regional infusion-radioembolization. *Surgical Oncology Clinics of North America* 2008; **17**: 957–985.
- Liu DM, Cade DN, Knight J *et al.* Yttrium-90 radioembolization: Recent advances in hepatic embolotherapy. *Endovascular Today* June 2008; 75–82.
- Khodjibekova M, Szyszko T, Singh A *et al.* Treatment of primary and secondary liver tumours with selective internal radiation therapy. *Journal of Experimental Clinical Cancer Research* 2007; **26**:561–570.
- Khodjibekova M, Szyszko T, Khan S *et al.* Selective internal radiation therapy with Yttrium-90 for unresectable liver tumours. *Reviews on Recent Clinical Trials* 2007; **2**: 212–216.
- Jakobs TF, Hoffmann RT, Tatsch K *et al.* Entwicklungen und perspektiven radioablativer verfahren / developments and perspectives in radioablative techniques. *Radiologe* 2007 Dec; **47**: 1083–1088. [in German]
- Brown DB, Gould JE, Gervais DA *et al.* Transcatheter therapy for hepatic malignancy: Standardization of terminology and reporting criteria. *Journal of Vascular and Interventional Radiology* 2007; **18**: 1469–1478.
- Gates VL, Atassi B, Lewandowski RJ *et al.* Radioembolization with yttrium-90 microspheres: review of an emerging treatment for liver tumors. *Future Oncology* February 2007; **3**: 73–81.
- Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. *Seminars in Interventional Radiology* 2006; **23** (1): 64–72.
- Salem R, Thurston K. Radioembolization with ⁹⁰yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 3: Comprehensive literature review and future direction. *Journal of Vascular and Interventional Radiology* 2006; **17**: 1571–1594.
- Salem R, Thurston K. Radioembolization with ⁹⁰yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: Special topics. *Journal of Vascular and Interventional Radiology* 2006; **17**: 1425–1439.
- Salem R, Thurston K. Radioembolization with ⁹⁰yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. *Journal of Vascular and Interventional Radiology* 2006; **17**: 1251–1278.
- Brans B, Linden O, Giammarile F *et al.* Clinical applications of newer radionuclide therapies. *European Journal of Cancer* 2006; **42**: 994–1003.
- Murthy R, Habbu A, Salem R. Trans-arterial hepatic radioembolisation of yttrium-90 microspheres. *Biomedical Imaging and Intervention Journal* 2006; **2** (3): e43
- Kennedy A, Coldwell D, Liu D *et al.* Liver directed radiotherapy with microspheres: second annual clinical symposium. *American Journal of Oncology Review* 2006; **4**: 1–8.
- Garrean S, Espat N. Yttrium-90 internal radiation therapy for hepatic malignancy. *Surgical Oncology* 2005; **14**: 179–193.
- Coldwell D, Sewell P. The expanding role of interventional radiology in the supportive care of the oncology patient: From diagnosis to therapy. *Seminars in Oncology* 2005; **32**: 169–173.
- Sinha VR, Goyal V, Trehan A. Radioactive microspheres in therapeutics. *Pharmazie* 2004; **59**: 419–426.
- Bronson J. The malignant liver: Community-based state-of-the-art therapy. *Imaging Economics* 2004; **17**: 25–30.
- Moroz P, Gray B. Radiotherapy in the treatment of advanced liver cancer: current status and future directions. *Asian Journal of Surgery* 2000; **23**: 32–41.
- Ho S, Lau W, Leung T *et al.* Internal radiation therapy for patients with primary or metastatic hepatic cancer. *Cancer* 1998; **83**: 1894–1907.

Mechanistic Aspects of Treatment

Papers on Mechanistic Aspects of Treatment

- van den Hoven AF, Prince JF, Samim M *et al.* Erratum to: Posttreatment PET-CT-confirmed intrahepatic radioembolization performed without coil embolization, by using the antireflux Surefire Infusion System. *Cardiovascular and Interventional Radiology* 2013 Aug 17; ePub doi: 10.1007/s00270-013-0720-1.
- Zade AA, Rangarajan V, Purandare NC *et al.* ⁹⁰Y microsphere therapy: Does ⁹⁰Y PET/CT imaging obviate the need for ⁹⁰Y Bremsstrahlung SPECT/CT imaging? *Nuclear Medicine Communications* 2013 Aug 12; ePub doi: 10.1097/MNM.0b013e328364aa4b.
- Palmowski M, Goedicke A, Vogg A *et al.* Simultaneous dual-isotope SPECT/CT with ^{99m}Tc- and ¹¹¹In-labelled albumin microspheres in treatment planning for SIRT. *European Radiology* 2013 Jun 16; ePub doi: 10.1007/s00330-013-2916-9.
- Kao Y-H, Steinberg JD, Tay Y-S *et al.* Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres. *EJNMMI Research* 2013; **3**: 57.
- Lam MG, Abdelmaksoud MH, Chang DT *et al.* Safety of ⁹⁰Y radioembolization in patients who have undergone previous external beam radiation therapy. *International Journal of Radiation Oncology, Biology and Physics* 2013 Jul 9; ePub doi: 10.1016/j.ijrobp.2013.05.041.
- Bulla K, Hubich S, Pech M *et al.* Superiority of proximal embolization of the gastroduodenal artery with the Amplatzer Vascular Plug 4 before yttrium-90 radioembolization: A retrospective comparison with coils in 134 patients. *Cardiovascular and Interventional Radiology* 2013 Jul 11; ePub doi: 10.1007/s00270-013-0684-1.
- Piana PM, Bar V, Doyle L *et al.* Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. *HPB (Oxford)* 2013 Jun 19; ePub doi: 10.1111/hpb.12135.
- van den Hoven AF, Prince JF, Samim M *et al.* Posttreatment PET-CT-confirmed intrahepatic radioembolization performed without coil embolization, by using the antireflux Surefire Infusion System. *Cardiovascular and Interventional Radiology* 2013 Jun 12; ePub doi: 10.1007/s00270-013-0674-3.
- Dieudonné A, Hobbs RF, Lebtahi R *et al.* Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: Comparison between dose kernel convolution and direct Monte Carlo methods. *Journal of Nuclear Medicine* 2013; **54**: 236–243.
- Maleux G, Deroose C, Fieuws S *et al.* Prospective comparison of hydrogel-coated microcoils versus fibered platinum microcoils in the prophylactic embolization of the gastroduodenal artery before Yttrium-90 radioembolization. *Journal of Vascular and Interventional Radiology* 2013 Apr 9; ePub doi: 10.1016/j.jvir.2013.01.503.
- Enriquez J, Javadi S, Murthy R *et al.* Gastroduodenal artery recanalization after transcatheter fibered coil embolization for prevention of hepaticoenteric flow: Incidence and predisposing technical factors in 142 patients. *Acta Radiologica* 2013 Mar 27. ePub doi: 10.1177/0284185113481696.
- Hagspiel KD, Nambiar A, Hagspiel LM *et al.* Temporary arterial balloon occlusion as an adjunct to yttrium-90 radioembolization. *Cardiovascular and Interventional Radiology* 2012 Dec 11; ePub doi: 10.1007/s00270-012-0523-9.
- Rose SC, Kikolski SG, Chomas JE. Downstream hepatic arterial blood pressure changes caused by deployment of the Surefire AntiReflux Expandable Tip. *Cardiovascular and Interventional Radiology* 2012 Dec 19; ePub doi: 10.1007/s00270-012-0538-2.
- Gil-Alzugaray B, Chopitea A, Iñarrairaegui M *et al.* Prognostic factors and prevention of radioembolization-induced liver disease. *Hepatology* 2012 Dec 10. ePub doi: 10.1002/hep.26191.
- Uliel L, Royal HD, Darcy MD *et al.* From the angio suite to the γ-camera: Vascular mapping and ^{99m}Tc-MAA hepatic perfusion imaging before liver radioembolization--A comprehensive pictorial review. *Journal of Nuclear Medicine* 2012; **53**: 1736–1747.
- Roche G, Teo TK, Tan AE *et al.* Intra-arterial CT angiography visualization of arterial supply to inferior vena cava tumor thrombus prior to radioembolization of hepatocellular carcinoma. *Saudi Journal of Gastroenterology* 2012; **18**: 384–387
- Högberg J, Rizell M, Hultborn R *et al.* Radiation exposure during liver surgery after treatment with ⁹⁰Y microspheres, evaluated with computer simulations and dosimeter measurements. *Journal of Radiological Protection* 2012; **32**: 439–446.

- Samuelson SD, Louie JD, Sze DY *et al.* N-butyl Cyanoacrylate glue Embolization of Arterial Networks to Facilitate Hepatic Arterial Skeletonization before Radioembolization. *Cardiovascular and Interventional Radiology* 2012 Oct 16; ePub doi: 10.1007/s00270-012-0490-1.
- Goedicke A, Berker Y, Verburg F *et al.* Study-parameter impact in quantitative ^{90}Y PET imaging for radioembolization treatment monitoring and dosimetry. *IEEE Transactions in Medical Imaging* 2012 Oct 2; ePub doi: 10.1109/TMI.2012.2221135.
- Helmberger T. Overview of selective internal radiation therapy: from work-up to follow-up. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ^{90}Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 48–50.
- Kennedy A. Calculating yttrium-90 activity with clinical considerations. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ^{90}Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 59–61.
- Ahmadzadehfar H, Sabet A, Meyer C *et al.* The importance of Tc-MAA SPECT/CT for therapy planning of radioembolization in a patient treated with bevacizumab. *Clinical and Nuclear Medicine* 2012; **37**: 1129–1130.
- Paxton AB, Davis SD, Dewerd LA. *et al.* Determining the effects of microsphere and surrounding material composition on ^{90}Y dose kernels using egsrc and mcnp5. *Medical Physics* 2012; **39**: 1424–1434.
- Van de Wiele C, Maes A, Brugman E *et al.* SIRT of liver metastases: Physiological and pathophysiological considerations. *European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39**: 1646–1655.
- Tapping CR, Dixon S, Little MW *et al.* Liquid embolization of the gastroduodenal artery before selective internal radiotherapy (SIRT). *Clinical Radiology* 2012; **67**: 789–792.
- Kleinstreuer C, Basciano CA, Childress EM *et al.* A new catheter for tumor targeting with radioactive microspheres in representative hepatic artery systems. Part I: Impact of catheter presence on local blood flow and microsphere delivery. *Journal of Biomechanical and Engineering* 2012; **134**: 051004.
- Powerski MJ, Scheurig-Münkler C, Banzer J *et al.* Clinical practice in radioembolization of hepatic malignancies: A survey among interventional centers in Europe. *European Journal of Radiology* 2012; **81**: e804–811.
- Gaba RC, Vanmiddlesworth KA. Chemoembolic Hepatopulmonary shunt reduction to allow safe Yttrium-90 radioembolization lobectomy of hepatocellular carcinoma. *Cardiovascular and Interventional Radiology* 2012 Apr 19; ePub doi: 10.1007/s00270-012-0371-7.
- Gaba RC, Parvinian A, Trinos EM *et al.* Safety and efficacy of StarClose SE Vascular Closure System in high-risk liver interventional oncology patients. *Journal of Vascular Access* 2012 Mar 22; ePub doi: 10.5301/jva.5000068.
- McCann JW, Larkin AM, Martino LJ *et al.* Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: Are contact restrictions necessary? *Journal of Vascular and Interventional Radiology* 2012; **23**: 661–667.
- Dieudonné A, Gardin I, Reguiga M *et al.* Dosimétrie personnalisée en radiothérapie interne vectorisée: Exemple du traitement des carcinomes hépatocellulaires par microsphères marquées à l'yttrium 90. [Personalized dosimetry in targeted radionuclide therapy: Example in the treatment of hepatocellular carcinoma with yttrium labelled microspheres]. *Médecine Nucléaire* 2012; **36**: 215–221. [in French]
- López-Benítez R, Hallscheidt P, Kratochwil C *et al.* Protective embolization of the gastroduodenal artery with a one-hydrocoil technique in radioembolization procedures. *Cardiovascular and Interventional Radiology* 2012 Mar 14; ePub doi: 10.1007/s00270-012-0361-9.
- D'Arienzo M, Chiamida P, Chiacchiararelli L *et al.* ^{90}Y PET-based dosimetry after selective internal radiotherapy treatments. *Nuclear Medicine Communications* 2012; **33**: 633–640.
- Kao YH, Tan AEH, Burgmans MC *et al.* Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective ^{90}Y radioembolization. *Journal of Nuclear Medicine* 2012; **53**: 1–8.
- Richards AL, Kleinstreuer C, Kennedy AS *et al.* Experimental microsphere targeting in a representative hepatic artery system. *IEEE Transactions on Biomedical Engineering* 2012; **59**: 198–204.

Lau WY, Kennedy AS, Kim YH *et al.* Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. *International Journal of Radiation Oncology, Biology and Physics* 2012; **82**: 401–407.

Yildiz AE, Peynircioglu B, Cil BE. Applications of the Amplatzer Vascular Plug 4. *Diagnostic and Interventional Radiology* 2012; **18**: 225–230.

Kao YH, Tan AE, Ng DC, Goh AS. Response to "Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres." *International Journal of Radiation Oncology, Biology and Physics* 2011; **80**: 1280. [Comment on Lau WY *et al.* *International Journal of Radiation Oncology, Biology and Physics* 2010 Oct 13; later published as 2012; **82**: 401–407.]

Lau WY, Kennedy AS, Kim YH *et al.* In reply to Dr. Kao *et al.* *International Journal of Radiation Oncology, Biology and Physics* 2011; **80**: 1280–1281.

Dezarn WA, Cessna JT, DeWerd LA *et al.* Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for ⁹⁰Y microsphere brachytherapy in the treatment of hepatic malignancies. *Medical Physics* 2011; **38**: 4824–4845.

Dudeck O, Wilhelmssen S, Stübs P *et al.* Prevention of intraprocedural puncture site bleeding during arterial port implantation by use of a suture-mediated arterial closure system: A prospective randomized trial. *Journal of Vascular and Interventional Radiology* 2011; **22**: 1409–1413.

Jiang M, Nowakowski FS, Wang J *et al.* Characterization of extrahepatic distribution of Tc-99m macroaggregated albumin in hepatic perfusion imaging studies prior to yttrium-90 microsphere therapy. *Cancer Biotherapy and Radiopharmaceuticals* 2011; **26**: 511–518.

Liu DM. Interventional oncology – avoiding common pitfalls to reduce toxicity in hepatic radioembolization. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 106 ePub doi: 10.4172/2155-9619.1000106.

Kennedy A, Dezarn W, Weiss A. Patient specific 3D image-based radiation dose estimates for ⁹⁰Y microsphere hepatic radioembolization in metastatic tumors. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 111 ePub doi: 10.4172/2155-9619.1000111.

Basciano CA, Kleinstreuer C, Kennedy AS. Computational fluid dynamics modeling of ⁹⁰Y microspheres in human hepatic tumors. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 112 ePub doi: 10.4172/2155-9619.1000112.

Strigari L, Benassi M, Chiesa C *et al.* Dosimetry in nuclear medicine therapy: radiobiology application and results. *Quarterly Journal of Nuclear Medicine and Molecular Imaging* 2011; **55**: 205–221.

Sabet A, Ahmadzadehfar H, Muckle M *et al.* Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization. *Journal of Nuclear Medicine* 2011; **52**: 1063–1067.

Kao YH, Tan EH, Ng CE, Goh SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. *Annals of Nuclear Medicine* 2011; **25**: 455–461.

Giammarile F, Bodei L, Chiesa C *et al.* EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. *European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38**: 1393–1406.

Bardiès M, Buvat I. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry? *Quarterly Journal of Nuclear Medicine and Molecular Imaging* 2011; **55**: 5–20.

Chiesa C, Maccauro M, Romito R *et al.* Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with ⁹⁰Y microspheres: the experience of the National Tumor Institute of Milan. *Quarterly Journal of Nuclear Medicine and Molecular Imaging* 2011; **55**: 168–197.

Kao YH, Tan AE, Khoo LS *et al.* Hepatic falciform ligament Tc-99m-macroaggregated albumin activity on SPECT/CT prior to Yttrium-90 microsphere radioembolization: prophylactic measures to prevent non-target microsphere localization via patent hepatic falciform arteries. *Annals of Nuclear Medicine* 2011; **25**: 365–369.

Barentsz MW, Vente MA, Lam MG *et al.* Technical solutions to ensure safe Yttrium-90 radioembolization in patients with initial extrahepatic deposition of ^{99m}Tc-technetium-albumin macroaggregates. *Cardiovascular and Interventional Radiology* 2011; **34**: 1074–1079.

- McWilliams JP, Kee ST, Loh CT *et al.* Prophylactic embolization of the cystic artery before radioembolization: feasibility, safety, and outcomes. *Cardiovascular and Interventional Radiology* 2011; **34**: 786–792.
- Liu CS, Lin KH, Lee RC *et al.* Model-based radiation dose correction for yttrium-90 microsphere treatment of liver tumors with central necrosis. *International Journal of Radiation Oncology, Biology and Physics* 2011; **81**: 660–668.
- Maleux G, Heye S, Vaninbrouckx J, Deroose C. Angiographic considerations in patients undergoing liver-directed radioembolization with ⁹⁰Y microspheres. *Acta Gastro-Enterologica Belgica* 2010; **73**: 489–496.
- Lambert B, Mertens J, Sturm EJ *et al.* ^{99m}Tc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with ⁹⁰Y microspheres. *European Journal of Nuclear Medicine and Molecular Imaging* 2010; **37**: 2328–2333.
- Kim YC, Kim YH, Um SH *et al.* Radiation safety issues in Y-90 microsphere selective hepatic radioembolization therapy: possible radiation exposure from the patients. *Nuclear Medicine and Molecular Imaging* 2010; **44**: 252–260.
- Wang SC, Bester L, Burnes JP *et al.* Clinical care and technical recommendations for ⁹⁰yttrium microsphere treatment of liver cancer. *Journal of Medical Imaging and Radiation Oncology* 2010; **54**: 178–187.
- Dudeck O, Bulla K, Wieners G *et al.* Embolization of the gastroduodenal artery before selective internal radiotherapy: A prospectively randomized trial comparing standard pushable coils with fibered interlock detachable coils. *Cardiovascular and Interventional Radiology* 2011; **34**: 74–80.
- Haydar AA, Wasan H, Wilson C, Tait P. ⁹⁰Y radioembolization: embolization of the gastroduodenal artery is not always appropriate. *Cardiovascular and Interventional Radiology* 2010; **33**: 1069–1071.
- Karunanithy N, Gordon F, Hodolic M *et al.* Embolization of hepatic arterial branches to simplify hepatic blood flow before yttrium 90 radioembolization: a useful technique in the presence of challenging anatomy. *Cardiovascular and Interventional Radiology* 2011; **34**: 287–294.
- Basciano CA, Kleinstreuer C, Kennedy AS *et al.* Computer modeling of controlled microsphere release and targeting in a representative hepatic artery system. *Annals of Biomedical Engineering* 2010; **38**: 1862–1867.
- Gulec SA, Szejnberg ML, Siegel JA *et al.* Hepatic structural dosimetry in ⁹⁰Y microsphere treatment: A Monte Carlo modeling approach based on lobular microanatomy. *Journal of Nuclear Medicine* 2010; **51**: 301–310.
- Bilbao JI, Garrastachu P, Herráiz MJ *et al.* Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors. *Cardiovascular and Interventional Radiology* 2010; **33**: 523–531.
- Kennedy AS, Kleinstreuer C, Basciano CA, Dezarn WA. Computer modeling of yttrium-90-microsphere transport in the hepatic arterial tree to improve clinical outcomes. *International Journal of Radiation Oncology, Biology and Physics* 2010; **76**: 631–637.
- Yu M, Lewandowski RJ, Ibrahim S *et al.* Direct hepatic artery puncture for transarterial therapy in liver cancer. *Journal of Vascular and Interventional Radiology* 2010; **21**: 394–399.
- Narayanan G, Hanumanthaiah S, Mohin G *et al.* Safety and efficacy of the Angio-Seal closure device. *Journal of Interventional Oncology* 2009; **2**: 128–132.
- Pech M, Kraetsch A, Wieners G *et al.* Embolization of the gastroduodenal artery before selective internal radiotherapy: a prospectively randomized trial comparing platinum-fibered microcoils with the Amplatzer Vascular Plug II. *Cardiovascular and Interventional Radiology* 2009; **32**: 455–461.
- Gulec SA, Selwyn R, Weiner R *et al.* Radiomicrosphere therapy: nuclear medicine considerations, guidelines, and protocols. *Journal of Interventional Oncology* 2009; **2**: 26–39.
- Salem R, Riaz A, Gulec S *et al.* Technical issues in radioembolization with yttrium 90 microspheres. *Journal of Interventional Oncology* 2009; **2**: 40–45.
- Selwyn R. Radiomicrosphere therapy dosimetry. *Journal of Interventional Oncology* 2009; **2**: 59–66.
- Wagman R, Apollon S, Garelik I *et al.* Starting an yttrium 90 treatment program for metastatic cancer to the liver. *Journal of Interventional Oncology* 2009; **2**: 67–71.
- Bilbao JI, de Martino A, de Luis E *et al.* Biocompatibility, inflammatory response, and recanalization characteristics of nonradioactive resin microspheres: Histological findings. *Cardiovascular and Interventional Radiology* 2009; **32**: 727–736.

- Rose SC. Mechanical devices for arterial occlusion and therapeutic vascular occlusion utilizing steel coil technique: clinical applications. *American Journal of Roentgenology* 2009; **192**: 321–324.
- Schleipman AR, Gallagher PW, Gerbaudo VH. Optimizing safety of selective internal radiation therapy (SIRT) of hepatic tumors with ^{90}Y resin microspheres: a systematic approach to preparation and radiometric procedures. *Health Physics* 2009; **96** (2 Suppl): S16–S21.
- Solomon SB, Thornton R, Deschamps F *et al.* A treatment planning system for transcatheter hepatic therapies: Pilot study. *Journal of Interventional Oncology* 2008; **1**: 12–18.
- Gulec SA. Considerations in Y-90 microsphere administration via hepatic arterial pump. *Journal of Interventional Oncology* 2008; **1**: 38–42.
- Hieb RA, Neisen MJ, Hohenwarter EJ *et al.* Safety and effectiveness of repeat arterial closure using the AngioSeal device in patients with hepatic malignancy. *Journal of Vascular and Interventional Radiology* 2008; **19**: 1704–1708.
- Cremonesi M, Ferrari M, Bartolomei M *et al.* Radioembolisation with ^{90}Y -microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. *European Journal of Nuclear Medicine and Molecular Imaging* 2008; **35**: 2088–2096.
- Selwyn R, Micka J, DeWerd L *et al.* Technical note: the calibration of ^{90}Y -labeled SIR-Spheres using a non-destructive spectroscopic assay. *Medical Physics* 2008; **35**: 1278–1279.
- Avila-Rodriguez M, Selwyn R, Hampel J *et al.* Positron-emitting resin microspheres as surrogates of ^{90}Y SIR-Spheres: a radiolabeling and stability study. *Nuclear Medicine and Biology* 2007; **34**: 585–590.
- Salem R. Radioembolization with ^{90}Y microspheres: technical considerations. *Journal of Vascular and Interventional Radiology* 2007; **18**: 1460–1461.
- Denecke T, Rühl R, Hildebrandt B *et al.* Planning transarterial radioembolization of colorectal liver metastases with Yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques. *European Radiology* 2008; **18**: 892–902.
- Salem R, Lewandowski RJ, Sato KT *et al.* Technical aspects of radioembolization with ^{90}Y microspheres. *Techniques in Vascular and Interventional Radiology* 2007; **10**: 12–29.
- Selwyn RG, Avila-Rodriguez MA, Converse AK *et al.* ^{18}F -labeled resin microspheres as surrogates for ^{90}Y resin microspheres used in the treatment of hepatic tumors: a radiolabeling and PET validation study. *Physics in Medicine and Biology* 2007; **52**: 7397–7408.
- Gulec SA and Siegel JA. Posttherapy radiation safety considerations in radiomicrosphere treatment with ^{90}Y -microspheres. *The Journal of Nuclear Medicine* 2007; **48**: 2080–2086.
- Bester L, Salem R. Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. *Journal of Vascular and Interventional Radiology* 2007; **18**: 1310–1314.
- Dezarn WA, Kennedy AS. Resin ^{90}Y microsphere activity measurements for liver brachytherapy. *Medical Physics* 2007; **34**: 1896–1900.
- Lewandowski RJ, Sato KT, Atassi B *et al.* Radioembolization with ^{90}Y microspheres: angiographic and technical considerations. *Cardiovascular and Interventional Radiology* 2007; **30**: 571–592.
- Cosin O, Bilbao JI, Alvarez S *et al.* Right gastric artery embolization prior to treatment with yttrium-90 microspheres. *Cardiovascular and Interventional Radiology* 2007; **30**: 98–103.
- Gulec S, Mesoloras G, Stabin M. Dosimetric techniques in ^{90}Y -microsphere therapy of liver cancer: The MIRD equations for dose calculations. *Journal of Nuclear Medicine* 2006; **47**: 1209–1211.
- Mo L, Avci B, James D *et al.* Development of activity standard for ^{90}Y microspheres. *Applied Radiation and Isotopes* 2005; **63**: 193–199.
- Dhabuwala A, Lamerton P, Stubbs R. Relationship of $^{99\text{m}}\text{Tc}$ labelled macroaggregated albumin ($^{99\text{m}}\text{TC-MAA}$) uptake by colorectal liver metastases to response following Selective Internal Radiation Therapy (SIRT). *BMC Nuclear Medicine* 2005; **5**: 7.
- Murthy R, Nunez R, Szklaruk J *et al.* Yttrium-90 microsphere therapy for hepatic malignancy: Devices, indications, technical considerations, and potential complications. *Radiographics* 2005; **25**: S41–S55.
- Kennedy A, Nutting C, Coldwell D *et al.* Pathologic response and microdosimetry of ^{90}Y microspheres in man: review of four explanted whole livers. *International Journal of Radiation Oncology, Biology and Physics* 2004; **60**: 1552–1563.

Moroz P, Anderson J, Van Hazel G *et al.* Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. *Journal of Surgical Oncology* 2001; **78**: 248–252.

Campbell A, Bailey I, Burton M. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. *Physics in Medicine and Biology* 2001; **46**: 487–498.

Campbell A, Bailey I, Burton M. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. *Physics in Medicine and Biology* 2000; **45**: 1023–1033.

Halley S, Walker T, Gray B *et al.* Microsphere distribution within a metastatic liver tumour following selective internal radiation therapy. *GI Cancer* 2000; **3**: 193–197.

Ho S, Lau W, Leung T *et al.* Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. *European Journal of Nuclear Medicine* 1997; **24**: 293–298.

Ho S, Lau W, Leung T *et al.* Tumor-to-normal uptake ratio of Y-90 microspheres in hepatic cancer assessed with Tc-99m macroaggregated albumin. *British Journal of Radiology* 1997; **70**: 823–828.

Ho S, Lau W, Leung T *et al.* Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumors. *European Journal of Nuclear Medicine* 1996; **23**: 947–952.

Fox R, Klemp P, Egan G *et al.* Dose distribution following selective internal radiation therapy. *International Journal of Radiation Oncology, Biology and Physics* 1991; **21**: 463–467.

Gray B, Matz L, Burton M *et al.* Tolerance of the liver to yttrium-90 irradiation. *International Journal of Radiation Oncology, Biology and Physics* 1990; **18**: 619–623.

Burton M, Gray B, Kelleher D *et al.* Selective internal radiation therapy: Validation of intraoperative dosimetry. *Radiology* 1990; **175**: 253–255.

Archer S, Gray B. Vascularization of small liver metastases. *British Journal of Surgery* 1989; **76**: 545–548.

Burton M, Gray B, Klemp P *et al.* Selective internal radiation therapy: Distribution of radiation in the liver. *European Journal of Cancer and Clinical Oncology* 1989; **25**: 1487–1491.

Klemp P, Perry A, Fox R *et al.* Aspects of radiation protection during the treatment of liver cancer using yttrium-90 labeled microspheres. *Radiation Protection in Australia* 1989; **7**: 70–73.

Chamberlain M, Gray B, Heggie J *et al.* Hepatic metastases: A physiological approach to treatment. *British Journal of Surgery* 1983; **70**: 596–598.

Stribley K, Gray B, Chmiel R *et al.* Internal radiotherapy for hepatic metastases: The homogeneity of hepatic arterial blood flow. *Journal of Surgical Research* 1983; **33**: 17–24.

Stribley K, Gray B, Chmiel R *et al.* Internal radiotherapy for hepatic metastases: The blood supply of hepatic metastases. *Journal of Surgical Research* 1983; **33**: 25–32.

Breedis C, Young G. The blood supply of neoplasms in the liver. *American Journal of Pathology* 1954; **30**: 969–977.

Lucke B, Breedis C, Woo ZP *et al.* Differential growth of metastatic tumors in liver and lung; experiments with rabbit V2 carcinoma. *Cancer Research* 1952; **12**: 734–738.

Abstracts on Mechanistic Aspects of Treatment

Cash C, Savin MA, Campbell J *et al.* Yttrium-90 infusion: Incidence and outcomes of delivery catheter occlusion. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S34 Abs. 59.

Lam MG, Louie JD, Abdelmaksoud M *et al.* Dose-response analysis in metastatic colorectal cancer patients treated with hepatic yttrium-90 radioembolization. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S37 Abs. 68.

Tamrazi A, Lam MG, Louie JD *et al.* Management of high hepatopulmonary shunt fractions in patients undergoing radioembolization. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S154 Abs. 359.

Pinjaroen N, Kaufman J, Kolbeck KJ Clinical correlation between hepatic vein opacification and hepatopulmonary shunt fraction for ⁹⁰Y evaluation. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S164 Abs. 385.

- Pacilio M, Botta F, Torres Aroche L *et al.* Impact of voxel S-values calculation method on 3D dosimetry for radionuclide therapy: application to SIRT and IART treatments. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0063.
- Gnesin S, Bertholet J, Boubaker A *et al.* ^{99m}Tc -MAA SPECT-derived tumor-to-normal liver ratios for partition model dosimetry in selective internal radiation therapy (SIRT). *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0068.
- Bagni O, Filippi L, Salvatori R *et al.* Voxel dosimetry with ^{90}Y -PET for the assessment of liver toxicity. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0131.
- D'Arienzo M, Chiacchiararelli L, Filippi L *et al.* Dosimetry with ^{90}Y PET after liver radioembolization: The role of bed and EUD for the assessment of non uniform activity distributions in lesions. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0475.
- Pettinato C, Monari F, Civollani S *et al.* Retrospective dosimetry in patients affected by HCC and treated with SIRT using ^{90}Y -microspheres PET/CT imaging. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. OP476.
- Bailey DL, Willowson KP, Forwood NJ *et al.* Quantitative PET imaging of Y-90. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. OP505.
- Ulrich G, Raatz Y, Furth C *et al.* Prognostic value of Tc-99m-MAA-uptake in patients with cholangiocellular carcinoma undergoing Y-90-radioembolization. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. PO189.
- Dieudonné A, Gardin I, Siebert A *et al.* A Y90-PET/CT for treatment validation of Y90-microspheres SIRT: A 3D dosimetry comparison with pre-therapeutic Tc99m-MAA-SPECT/CT. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. PO190.
- Giancola S, Viscomi D, Pacilio M *et al.* SIRT voxel dosimetry: a 3D computational approach for routine application. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. PO194.
- Ma V, Law M, Ng S *et al.* Experience in Y-90 PET imaging and subsequent dose calculation for selective internal radiation therapy to liver cancer. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. PO196.
- Rosenbaum C, D'Asseler Y, Defreyne L *et al.* Practical aspects of activity prescription for ^{90}Y -microsphere therapy. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. PO198.
- Maleux G, Verslype C, Van Cutsem E *et al.* Comparative study of hydrogel coils versus fibered coils in the prophylactic embolization of the gastroduodenal artery prior to Y-90 radioembolization. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2012; Abs. P-225.
- Bulla K, Loewenthal D, Hubich S *et al.* Advantages of the proximal placement of the Amplatzer Vascular Plug IV[®] for embolization of the gastroduodenal artery prior to Yttrium-90 radioembolization: a comparison with standard pushable coils. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2012; Abs. P-244.
- Kunam V, Shrikanthan S, Srinivas S. Radiation dosimetry of glass versus resin Y-90 microsphere radioembolization in patients with colorectal liver metastases. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2012; **53** (Suppl 1): Abs. 1203.
- Lam MG, Nijssen F, Smits M *et al.* Limitations of the BSA-based dose calculation for Yttrium-90 radioembolization. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S68 Abs. 162.
- Irani FG, Kao Y, Tay K *et al.* Personalized predictive dosimetry by artery-specific SPECT/CT partition modeling: how effective is it? *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S68 Abs. 163.

- Louie JD, Wang EA, Broadwell S *et al.* First in man experience with the surefire infusion system: a dedicated microcatheter system to eliminate reflux during embolotherapy. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S80 Abs. S195.
- Kinsman KA, Kolbeck KJ, Pinjaroen N *et al.* Hepatic vein opacification as an early predictor of pulmonary shunt fraction in radioembolization cases. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S147 Abs. 367.
- McCann JW, Larkin AM, Moore LT *et al.* Multi-center correlation of external exposure rates from ⁹⁰Y radioembolization patients: contact precautions are unnecessary based on nuclear regulatory commission regulations. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S68–69 Abs. 164.
- Nitz MD, Anderson CL, Saad WE *et al.* Preliminary analysis of angiographic contrast density as a predictor of liver perfusion change in radioembolization. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S148–S149 Abs. 371.
- Kennedy A, McNeillie P, Dezarn W *et al.* Development of a tissue-equivalent human liver phantom for ⁹⁰Y-microsphere dosimetry studies and testing of other local ablation therapies. *ASCO Gastrointestinal Cancers Symposium* 2012; Abs. 244.
- Di Dia A, Cremonesi M, Botta B *et al.* Impact of 3D dosimetric and radiobiological estimates methods in radioembolisation of liver metastasis with ⁹⁰Y-microspheres. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. OP020.
- D'Arienzo M, Chiaramida P, Chiacchiararelli L *et al.* ⁹⁰Y-PET based dosimetry after selective internal radiotherapy (SIRT) treatments. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs OP133.
- Arrichiello C, Aloj L, D'Ambrosio L *et al.* Lesion and normal liver absorbed doses based on PET measurements in patients undergoing treatment for liver metastases with ⁹⁰Y SIR spheres. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. OP134.
- Rodriguez M, Maini C, Salvatori R *et al.* Impact of target area (whole-liver, lobar or segmental) in unresectable hepatocellular carcinoma (HCC) patients treated by radioembolization. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. OP021.
- Wilhelmsen S, Ulrich G, Löwenthal D *et al.* Effectiveness of repeat assessment in patients scheduled for radioembolization using yttrium-90 microspheres with extrahepatic ^{99m}Tc-MAA accumulation to the gastrointestinal tract: a single center experience. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2011; Abs. 2107.4.
- Rilling WS, Tutton SM, Hieb RA *et al.* Novel quantitative analysis of tumor to normal liver blood flow ratio: implications for radioembolization dosimetry. *World Conference on Interventional Oncology (WCIO) meeting* 2011; Abs. 47.
- Nichols K, Leveque F, Pugliese P *et al.* Accuracy of pulmonary shunt measurements prior to ⁹⁰Y selective internal radiotherapy: A phantom study. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 90.
- Di Dia GA, Botta F, Marta Cremonesi M *et al.* Voxel-dosimetry as useful tool for optimized administered activity in radioembolization of liver tumors with ⁹⁰Y-microspheres. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 131.
- Civelek A. SIRS-spheres (Y-90 microspheres) therapy for unresectable metastatic liver disease: Pitfalls from tracer preparation for injection to image interpretation. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 1082.
- Kao YH, Tan AEH, Ng DCE, Goh ASW. State-of-the-art Yttrium-90 selective internal radiation therapy: Technical aspects of artery-specific SPECT/CT partition model dosimetry. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs.1084.
- Lambert B, Mertens J, Ravier M *et al.* Urinary excretion of Yttrium-90 following intra-arterial microsphere treatment for liver tumours. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 1744.

- Piana P, McCann JW, Anne R *et al.* Early arterial stasis preventing complete dose delivery during resin based Y90 radioembolization: Incidence and preliminary outcome. *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2011; **22** (Suppl): S87–88 Abs. 205.
- McCann JW, Martino LJ, Larkin AM *et al.* Radiation emission from patients treated with selective hepatic radioembolization using Y90 microspheres: Are contact restrictions necessary? *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2011; **22** (Suppl): S89–90 Abs. 208.
- Barentsz MW, Van den Bosch MAAJ, Lam MGEH *et al.* Technical solutions to ensure safe yttrium-90 radioembolization in patients with initial extrahepatic deposition of ^{99m}Tc-MAA. *European Congress of Radiology* 2011; Abs. C-0363.
- Yu N, Srinivas SM, DiFilippo FA *et al.* Gamma planar scintigraphy based calculation overestimates lung shunt for Y-90 radioembolization of liver tumor. *52nd Annual Meeting American Society for Radiation Oncology* 2010; **78**: S322 Abs. 2265.
- Young R, Shrikanthan S, Levitin A, Grace Cheah G. SPECT/CT detection of extrahepatic shunting in radiomicrosphere therapy. *57th Annual Meeting of the Society of Nuclear Medicine, Journal of Nuclear Medicine* 2010; **51** (Suppl 2): Abs. 2023.
- Dominguez I, Iñarrairaegui M, Rodriguez M *et al.* Tumor vascularity and response to radioembolization using Y90 resin microspheres. *4th International Liver Cancer Association (ILCA) meeting* September 2010; Abs. P-133.
- Chen YW, Lai YC, Lin CY *et al.* Radiation detection in dialysis room for a uremia patient with Y90 microsphere SIRT – initial experience in KMUH, Taiwan. *3rd European International Radiation Protection Association Congress* 2010; Abs. P02-35.
- Abdelmaksoud M, Louie JD, Hwang GL *et al.* Consolidation of hepatic arterial inflow by embolization of variant and parasitized arteries in preparation for ⁹⁰Y radioembolization. *Society of Interventional Radiology (SIR) 35th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2010; **21** (Suppl): S13–14 Abs. 29.
- Rilling WS, Royalty K, Hartmann B *et al.* Quantitative analysis of tumor to normal liver blood flow ratio: Implications for radioembolization dosimetry and comparison to visual estimation. *Society of Interventional Radiology (SIR) 35th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2010; **21** (Suppl): S16 Abs. 36.
- Abdelmaksoud M, Hwang GL, Louie JD *et al.* New hepatico-enteric anastomoses that appear after endovascular skeletonization of the hepatic artery in preparation for radioembolization. *Society of Interventional Radiology (SIR) 35th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2010; **21** (Suppl): S17 Abs. 38.
- Herraiz MJ, Garrastachu P, Iñarrairaegui M *et al.* Yttrium-90 liver radioembolization (Y90-RE): ^{99m}Tc-MAA SPECT/CT tumoral uptake after angiographic redistribution of intrahepatic vessels. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2009; Abs. P-134.
- Cremonesi M, Ferrari M, Bartolomei M *et al.* Radioembolisation with ⁹⁰Y-microspheres: any possible correlation among response, imaging, and dosimetry? *European Association of Nuclear Medicine (EANM) Conference* 2008; Abs. P591.
- Högberg J, Rizell M, Gjertsson P *et al.* Radiation protection considerations in surgery following radioembolization of liver with ⁹⁰Y microspheres. *European Association of Nuclear Medicine (EANM) Conference* 2008; Abs. 268.
- Högberg J, Gjertsson P, Hultborn R *et al.* Dosimetric aspects following radioembolization of liver with ⁹⁰Y microspheres - evaluation of SPECT images and Monte Carlo simulations. *European Association of Nuclear Medicine (EANM) Conference* 2008; Abs. 446.
- Machac J, Heiba S, Zhang Z *et al.* Prediction of yttrium 90 SIR-Spheres deposition by Tc 99m MAA SPECT/CT liver perfusion imaging and their relationship to angiographic flow. Radiomicrosphere Therapy: 4th Annual Symposium May 2008 *Journal of Interventional Oncology* 2009; **2**: 93.
- Dezarn W, Kennedy A. Significant differences exist across institutions in ⁹⁰Y microsphere activities compared to reference standard. *American Association for Physicists in Medicine* July 2007;
- Ferrari M, Cremonesi M, Bartolomei M *et al.* Different evaluations for safe ⁹⁰Y-microspheres in Selective Internal Radiation Therapy (SIRT). *European Association of Nuclear Medicine (EANM) Conference* 2007; Abs. 266.

- Ferrari M, Cremonesi M, Bartolomei M *et al.* Selective Internal Radiation Therapy (SIRT) with ^{90}Y -microspheres: dosimetric and radiobiological considerations for multi-cycle treatments. *European Association of Nuclear Medicine (EANM) Conference 2007*; Abs. 267.
- Monfardini L, Cremonesi M, Ferrari M *et al.* Dosimetric evaluation for safe activity administration of ^{90}Y -microspheres in selective internal radiation therapy (SIRT) for liver metastases. *Cardiovascular and Interventional Radiology 2007*; Abs. P-154.
- Moore S, Park MA, Limpa-Amara N *et al.* Measurement of Y-90 resin microsphere activity using dose calibrators. *Journal of Nuclear Medicine 2007*; **48** (Suppl 2): 74P Abs. 247.
- Gulec S, Mesoloras G, Dezarn W *et al.* Biologic determinants of absorbed dose estimates in Y-90 microsphere treatment of hepatic malignancies: Significance of tumor perfusion measured by Tc-99m MAA imaging. *Journal of Nuclear Medicine 2007*; **48** (Suppl 2): 396P Abs. 1676.
- Kennedy AS, Dezarn W, McNeillie P *et al.* Repeat ^{90}Y -microsphere radioembolization for hepatic malignancies: Safety and patient selection issues. *ASCO Annual Meeting Proceedings Part 1, Journal of Clinical Oncology 2007*; **25** No. 18S (June 20 Supplement): Abs. 15177.
- Lewandowski RJ, Sula S, Sato KT *et al.* Comparison of arteriotomy closure techniques in patients undergoing yttrium radioembolization. *Society of Interventional Radiology (SIR) Conference 2007*; Abs. 423.
- McKay E. Voxel dosimetry of Y-90 micro-spheres in the palliative treatment of neuroendocrine tumours of the liver. *European Association of Nuclear Medicine (EANM) Conference 2006*; Abs. 97.
- Kalogianni E, Towey DJ, Khan S *et al.* ^{90}Y microspheres: Comparison of methods for calculating the administered activity in clinical practice. *European Association of Nuclear Medicine (EANM) Conference 2006*; Abs. P568.
- Lau GBH, Wang SC, Ho YY. Technical aspects in the work up for yttrium 90 SIRsphere radioembolotherapy in the treatment of hepatic tumours. *World Conference on Interventional Oncology (WCIO) meeting 2006*; Abst. 8185.
- Kennedy A, Nutting C, Coldwell D *et al.* Dose selection of resin ^{90}Y -microspheres for liver brachytherapy: A single center review. *Annual American Brachytherapy Society Meeting 2006*; Abs. P76.
- Coldwell D. Selection of patients for treatment of unresectable liver tumours with yttrium-90 microspheres. *Cardiovascular and Interventional Radiology in Europe (CIRSE) 2005 Conference 2005*; Abs. 9.5.3.

Hepatic Arterial Anatomy

Papers on Hepatic Arterial Anatomy

- Chamarthy MR, Hughes TW, Gupta M *et al.* Celiac artery stenting to facilitate hepatic yttrium-90 radioembolization therapy. *Case Reports in Radiology* 2012; **2012**: 236732.
- Theysohn JM, Müller S, Schlaak JF *et al.* Selective internal radiotherapy (SIRT) of hepatic tumors: how to deal with the cystic artery. *Cardiovascular and Interventional Radiology* 2012 Sep 15; ePub doi: 10.1007/s00270-012-0474-1.
- Burgmans MC, Too CW, Kao YH *et al.* Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and ^{99m}Tc-MAA SPECT/CT: Implications for planning ⁹⁰Y radioembolization? *European Journal of Radiology* 2012; **81**: 3979–3984.
- Burgmans MC, Kao YH, Irani FG *et al.* Radioembolization with infusion of Yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe. *Journal of Vascular Interventional Radiology* 2012; **23**: 1294–1301.
- Tapping CR, Dixon S, Little MW *et al.* Liquid embolization of the gastroduodenal artery before selective internal radiotherapy (SIRT). *Clinical Radiology* 2012; **67**: 789–792.
- Gaba RC, Vanmiddlesworth KA. Chemoembolic hepatopulmonary shunt reduction to allow safe Yttrium-90 radioembolization lobectomy of hepatocellular carcinoma. *Cardiovascular and Interventional Radiology* 2012 Apr 19; ePub doi: 10.1007/s00270-012-0371-7.
- Mahvash A, Zaer N, Shaw C *et al.* Temporary balloon occlusion of the common hepatic artery for administration of yttrium-90 resin microspheres in a patient with patent hepatoenteric collaterals. *Journal of Vascular Interventional Radiology* 2012; **23**: 277–280.
- Lenoir L, Edeline J, Rolland Y *et al.* Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. *European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39**: 872–880.
- Gupta A, Levitin A, Shrikanthan S *et al.* Macroaggregated albumin injected in hepatic artery visualized in a recanalized paraumbilical vein. *Clinical Nuclear Medicine* 2012; **37**: 80–81.
- Haggerty JE, Vaidya S, Kooy T *et al.* Identification of the falciform artery on nuclear medicine imaging with successful coil embolization for planned Y-90 therapy. *Clinical Nuclear Medicine* 2012; **37**: 105–107.
- Goryawala M, Guillen M, Cabrerizo M *et al.* A 3D liver segmentation method with parallel computing for Selective Internal Radiation Therapy. *IEEE Transactions on Information Technology in Biomedicine* 2012; **16**: 62–69.
- Salem R. Invited commentary on “Abdelmaksoud MH, Louie JD, Kothary N *et al.* Consolidation of hepatic arterial inflow by embolization of variant hepatic arteries in preparation for yttrium-90 radioembolization. *Journal of Vascular and Interventional Radiology* 2011; **22**: 1364–1371”. *Journal of Vascular and Interventional Radiology* 2011; **22**: 1362–1363.
- Abdelmaksoud MH, Louie JD, Kothary N *et al.* Embolization of parasitized extrahepatic arteries to reestablish intrahepatic arterial supply to tumors before yttrium-90 radioembolization. *Journal of Vascular and Interventional Radiology* 2011; **22**: 1355–1362.
- Abdelmaksoud MH, Louie JD, Kothary N *et al.* Consolidation of hepatic arterial inflow by embolization of variant hepatic arteries in preparation for yttrium-90 radioembolization. *Journal of Vascular and Interventional Radiology* 2011; **22**: 1364–1371.
- Petroziello MF, McCann JW, Gonsalves CF *et al.* Side-branch embolization before ⁹⁰Y radioembolization: rate of recanalization and new collateral development. *AJR – American Journal of Roentgenology* 2011; **197**: W169–174.
- Daghir AA, Gungor H, Haydar AA *et al.* Embolisation of the gastroduodenal artery is not necessary in the presence of reversed flow before yttrium-90 radioembolisation. *Cardiovascular and Interventional Radiology* 2011 Jun 21; ePub doi: 10.1007/s00270-011-0208-9.
- Paprottka PM, Jakobs TF, Reiser MF, Hoffmann RT. Practical vascular anatomy in the preparation of radioembolization. *Cardiovascular and Interventional Radiology* 2012; **35**: 454–462.
- Ahmadzadehfar H, Möhlenbruch M, Sabet A *et al.* Is prophylactic embolization of the hepatic falciform artery needed before radioembolization in patients with ^{99m}Tc-MAA accumulation in the

anterior abdominal wall? *European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38**: 1477–1484.

Kao YH, Tan AE, Khoo LS *et al.* Hepatic falciform ligament Tc-99m-macroaggregated albumin activity on SPECT/CT prior to Yttrium-90 microsphere radioembolization: prophylactic measures to prevent non-target microsphere localization via patent hepatic falciform arteries. *Annals of Nuclear Medicine* 2011; **25**: 365–369.

Abdelmaksoud MH, Hwang GL, Louie JD *et al.* Development of new hepaticocentric collateral pathways after hepatic arterial skeletonization in preparation for yttrium-90 radioembolization. *Journal of Vascular and Interventional Radiology* 2010; **21**: 1385–1395.

Karunanithy N, Gordon F, Hodolic M *et al.* Embolization of hepatic arterial branches to simplify hepatic blood flow before yttrium 90 radioembolization: a useful technique in the presence of challenging anatomy. *Cardiovascular and Interventional Radiology* 2011; **34**: 287–294.

Bilbao JI, Garrastachu P, Herráiz MJ *et al.* Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors. *Cardiovascular and Interventional Radiology* 2010; **33**: 523–531.

Haydar AA, Wasan H, Wilson C, Tait P. ⁹⁰Y radioembolization: embolization of the gastroduodenal artery is not always appropriate. *Cardiovascular and Interventional Radiology* 2010; **33**: 1069–1071.

De Cecco CN, Ferrari R, Rengo M *et al.* Anatomic variations of the hepatic arteries in 250 patients studied with 64-row CT angiography. *European Radiology* 2009; **19**: 2765–2770.

Cosin O, Bilbao JI, Alvarez S *et al.* Right gastric artery embolization prior to treatment with yttrium-90 microspheres. *Cardiovascular and Interventional Radiology* 2007; **30**: 98–103.

Lewandowski RJ, Sato KT, Atassi B *et al.* Radioembolization with ⁹⁰Y microspheres: angiographic and technical considerations. *Cardiovascular and Interventional Radiology* 2007; **30**: 571–592.

Liu D, Salem R, Bui J *et al.* Angiographic considerations in patients undergoing liver-directed therapy. *Journal of Vascular and Interventional Radiology* 2005; **16**: 911–935.

Papers on Reduction of Lung Shunting

Theysohn JM, Schlaak JF, Müller S *et al.* Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. *Journal of Vascular and Interventional Radiology* 2012; **23**: 949–952.

Rose SC, Hoh CK. Hepatopulmonary shunt reduction using chemoembolization to permit yttrium-90 radioembolization. *Journal of Vascular and Interventional Radiology* 2009; **20**: 849–851.

Bester L, Salem R. Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. *Journal of Vascular and Interventional Radiology* 2007; **18**: 1310–1314.

Murata S, Tajima H, Abe Y *et al.* Temporary occlusion of two hepatic veins for chemoembolization of hepatocellular carcinoma with arteriohepatic vein shunts. *American Journal of Roentgenology* 2005; **184**: 415–417.

Abstracts on Hepatic Arterial Anatomy

Koppula R, Weinstein J, Krishnasamy V *et al.* Temporary embolization of the cystic artery in right hepatic lobe Y-90 radioembolization. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S161-S162 Abs. 378.

Fortes MC, Dias AP, Uflacker R *et al.* Importance of the angiographic identification of the right gastric artery anatomic origin in the era of Yttrium-90 liver radioembolization. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S67 Abs. 159.

Hill G, Amesur NB, Zajko AB *et al.* Reconsidering the necessity for prophylactic embolization of the gastroduodenal artery and right gastric artery prior to radioembolization of the liver with Yttrium-90 microspheres. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S67 Abs. 160.

Wang DS, Louie JD, Shah RP *et al.* Prophylactic topically applied ice to prevent cutaneous complications of nontarget chemoembolization and radioembolization of liver tumors. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S84 Abs. 203.

Speer ME, Abdelsalam ME, Chasen B *et al.* The retroportal artery and other less well-known hepatoenteric pathways: moving beyond GDA and right gastric embolization. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S151 Abs. 378.

Wang X, Shah RP, Brown KT *et al.* Cystic artery localization using a three-dimensional angiography vessel tracking system compared with conventional two-dimensional angiography. *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2011; **22** (Suppl): S49–50 Abs. 111.

Farsad K, Ganguli S, Wicky S *et al.* Options to access the hepatic artery for transarterial hepatic therapy in the setting of severe celiac axis stenosis or occlusion. *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2011; **22** (Suppl): S119 Abs. 282.

Imaging

Papers on Imaging

- van den Hoven AF, Prince JF, Samim M *et al.* Erratum to: Posttreatment PET-CT-confirmed intrahepatic radioembolization performed without coil embolization, by using the antireflux Surefire Infusion System. *Cardiovascular and Interventional Radiology* 2013 Aug 17; ePub doi: 10.1007/s00270-013-0720-1.
- Zade AA, Rangarajan V, Purandare NC *et al.* ^{90}Y microsphere therapy: Does ^{90}Y PET/CT imaging obviate the need for ^{90}Y Bremsstrahlung SPECT/CT imaging? *Nuclear Medicine Communications* 2013 Aug 12; ePub doi: 10.1097/MNM.0b013e328364aa4b.
- Mamawan MD, Ong SC, Senupe JM. Post- ^{90}Y radioembolization PET/CT scan with respiratory gating using time-of-flight reconstruction. *Journal of Nuclear Medicine Technology* 2013; **41**: 42.
- Rong X, Frey EC. A collimator optimization method for quantitative imaging: Application to Y-90 bremsstrahlung SPECT. *Medical Physics* 2013; **40**: 082504-1–080504-10.
- Fernández M, Hänscheid H, Mauxion T *et al.* A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculation. *Medical Physics* 2013; **40**: 082502.
- Elschot M, Lam M, van den Bosch M *et al.* Quantitative Monte Carlo-based ^{90}Y SPECT reconstruction. *Journal of Nuclear Medicine* Aug 1 2013; ePub doi:10.2967/jnumed.112.119131.
- Gates VL, Salem R, Lewandowski RJ. Positron emission tomography/CT after yttrium-90 radioembolization: Current and future applications. *Journal of Vascular and Interventional Radiology* 2013; **24**: 1153-1155.
- Kao Y-H, Steinberg JD, Tay Y-S *et al.* Post-radioembolization yttrium-90 PET/CT - part 2: Dose-response and tumor predictive dosimetry for resin microspheres. *EJNMMI Research* 2013; **3**: 57.
- Kao Y-H, Steinberg JD, Tay Y-S *et al.* Post-radioembolization yttrium-90 PET/CT - part 1: Diagnostic reporting. *EJNMMI Research* 2013; **3**: 56.
- Fourkal E, Veltchev I, Lin M *et al.* 3D inpatient dose reconstruction from the PET-CT imaging of ^{90}Y microspheres for metastatic cancer to the liver: Feasibility study. *Medical Physics* 2013; **40**: 081702-1–081702-10.
- Neperud J, Mahvash A, Garg N *et al.* Can imaging patterns of neuroendocrine hepatic metastases predict response yttrium-90 radioembolotherapy? *World Journal of Radiology* 2013; **5**: 241–247.
- Guo Y, Yaghmai V, Salem R *et al.* Imaging tumor response following liver-directed intra-arterial therapy. *Abdominal Imaging* 2013 Jun 27; ePub doi: 10.1007/s00261-013-0017-5.
- Yu N, Srinivas SM, Difilippo FP, Xia P. In reply to Gates and Salem. *International Journal of Radiation Oncology Biology and Physics* 2013; **86**: 211–212. [Reply to Gates and Salem. *International Journal of Radiation Oncology Biology and Physics* 2013; **86**: 211.]
- Gates V, Salem R. In regard to Yu *et al.* *International Journal of Radiation Oncology Biology and Physics* 2013; **86**: 211. [Comment on Yu *et al.* *International Journal of Radiation Oncology Biology and Physics* 2013; **85**: 834–839.]
- Lam MG, Smits ML. Value of $^{99\text{m}}\text{Tc}$ -macroaggregated albumin SPECT for radioembolization treatment planning. *J Nucl Med* 2013 Jun 18; ePub doi: 10.2967/jnumed.113.123281. [Comment on Ulrich *et al.* *Journal of Nuclear Medicine* 2013; **54**: 1–7.]
- Palmowski M, Goedicke A, Vogg A *et al.* Simultaneous dual-isotope SPECT/CT with $^{99\text{m}}\text{Tc}$ - and ^{111}In -labelled albumin microspheres in treatment planning for SIRT. *European Radiology* 2013 Jun 16; ePub doi: 10.1007/s00330-013-2916-9.
- van den Hoven AF, Prince JF, Samim M *et al.* Posttreatment PET-CT-confirmed intrahepatic radioembolization performed without coil embolization, by using the antireflux Surefire Infusion System. *Cardiovascular and Interventional Radiology* 2013 Jun 12; ePub doi: 10.1007/s00270-013-0674-3.
- Wondergem M, Smits ML, Elschot M *et al.* $^{99\text{m}}\text{Tc}$ -macroaggregated albumin poorly predicts the intrahepatic distribution of ^{90}Y resin microspheres in hepatic radioembolization. *Journal of Nuclear Medicine* 2013 Jun 7; ePub doi: 10.2967/jnumed.112.117614.
- Fendler WP, Philippe Tiega DB, Ilhan H *et al.* Validation of several SUV-based parameters derived from ^{18}F -FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. *Journal of Nuclear Medicine* 2013 May 31; ePub doi: 10.2967/jnumed.112.116426.

- Rong X, Ghaly M, Frey EC. Optimization of energy window for ^{90}Y Bremsstrahlung SPECT imaging for detection tasks using the ideal observer with model-mismatch. *Medical Physics* 2013 Jun; **40**: 062502 ePub doi: 10.1118/1.4805095.
- D'Arienzo M, Filippi L, Chiaramida P *et al.* Absorbed dose to lesion and clinical outcome after liver radioembolization with ^{90}Y microspheres: A case report of PET-based dosimetry. *Annals of Nuclear Medicine* 2013 Apr 20; ePub doi: 10.1007/s12149-013-0726-4.
- Yu N, Srinivas SM, Difilippo FP *et al.* Lung dose calculation with SPECT/CT for ^{90}Y trium radioembolization of liver cancer. *International Journal of Radiation Oncology Biology and Physics* 2013; **85**: 834–839.
- Kucuk ON, Soydal C, Araz M *et al.* Prognostic importance of ^{18}F -FDG uptake pattern of hepatocellular cancer patients who received SIRT. *Clinical Nuclear Medicine* 2013 Mar 22; ePub doi: 10.1097/RLU.0b013e3182867f17.
- Soydal C, Kucuk ON, Gecim EI *et al.* The prognostic value of quantitative parameters of ^{18}F -FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer. *Nuclear Medicine Communications* 2013 Mar 7; ePub 10.1097/MNM.0b013e32835f9427.
- Maturen KE, Feng MU, Wasnik AP *et al.* Imaging effects of radiation therapy in the abdomen and pelvis: evaluating "innocent bystander" tissues. *Radiographics* 2013; **33**: 599–619.
- Ulrich G, Dudeck O, Furth C *et al.* Predictive value of intratumoral $^{99\text{m}}\text{Tc}$ -macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with ^{90}Y -microspheres. *Journal of Nuclear Medicine* 2013; **54**: 1–7.
- Kucuk ON, Soydal C, Araz M *et al.* Evaluation of the response to selective internal radiation therapy in patients with hepatocellular cancer according to pretreatment $^{99\text{m}}\text{Tc}$ -MAA uptake. *Clinical and Nuclear Medicine* 2013 Feb 20; ePub doi: 10.1097/RLU.0b013e31828162e8.
- Chang TT, Bourgeois AC, Balius AM, Pasciak AS. Treatment modification of yttrium-90 radioembolization based on quantitative positron emission tomography/CT imaging. *Journal of Vascular Interventional Radiology* 2013; **24**: 333–337.
- Carson JP, Kuprat AP, Colby SM *et al.* Detecting distance between injected microspheres and target tumor via 3D reconstruction of tissue sections. *Conference proceedings: 34th Annual International Conference of the IEEE Engineering in Medicine and Biology Society* 2012; **2012**: 1149–1152.
- Mamawan MD, Ong SC, Senupe JM. Post- ^{90}Y radioembolization PET/CT scan with respiratory gating using time-of-flight reconstruction. *Journal of Nuclear Medicine Technology* 2013 Jan 31; ePub doi: 10.2967/jnmt.112.114413.
- Sharma B, Martin A, Zerizer I. Positron emission tomography-computed tomography in liver imaging. *Seminars in ultrasound CT and MRI* 2013; **34**: 66–80.
- Elschot M, Vermolen BJ, Lam MG *et al.* Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. *PLoS One* 2013; **8**: e55742.
- Carlier T, Eugène T, Bodet-Milin C *et al.* Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. *EJNMMI Research*. 2013; **3**: 11.
- Zerizer I, Al-Nahhas A, Towey D *et al.* The role of early ^{18}F -FDG PET/CT in prediction of progression-free survival after ^{90}Y radioembolization: comparison with RECIST and tumour density criteria. *European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39**: 1391–1399.
- Hicks RJ, Hofman MS. Is there still a role for SPECT–CT in oncology in the PET–CT era? *Nature Reviews Clinical Oncology* 2012; **9**: 712–720.
- Uliel L, Royal HD, Darcy MD *et al.* From the angio suite to the γ -camera: vascular mapping and $^{99\text{m}}\text{Tc}$ -MAA hepatic perfusion imaging before liver radioembolization—A comprehensive pictorial review. *Journal of Nuclear Medicine* 2012; **53**: 1736–1747.
- Roche G, Teo TK, Tan AE *et al.* Intra-arterial CT angiography visualization of arterial supply to inferior vena cava tumor thrombus prior to radioembolization of hepatocellular carcinoma. *Saudi Journal of Gastroenterology* 2012; **18**: 384–387
- Rosenbaum CE, van den Bosch MA, Veldhuis WB *et al.* Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases. *European Radiology* 2012 Oct 31; ePub doi: 10.1007/s00330-012-2693-x.

- Willowson K, Forwood N, Jakoby BW *et al.* Quantitative ^{90}Y image reconstruction in PET. *Medical Physics* 2012; **39**: 7153–7159.
- Goedicke A, Berker Y, Verburg F *et al.* Study-parameter impact in quantitative 90-Yttrium PET imaging for radioembolization treatment monitoring and dosimetry. *IEEE Transactions in Medical Imaging* 2012 Oct 2; ePub doi: 10.1109/TMI.2012.2221135.
- Flamen F, Hendlisz A, Vanderlinden B. Selective internal radiation therapy simulation using $^{99\text{m}}\text{Tc}$ -labelled macroaggregates of albumin and SPECT-CT. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ^{90}Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 54–56.
- Ricke J. Measuring the response to selective internal radiation therapy. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ^{90}Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 57–58.
- Ahmadzadehfar H, Sabet A, Meyer C *et al.* The importance of Tc-MAA SPECT/CT for therapy planning of radioembolization in a patient treated with bevacizumab. *Clinical and Nuclear Medicine* 2012; **37**: 1129–1130.
- Burgmans MC, Too CW, Kao YH *et al.* Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and $^{99\text{m}}\text{Tc}$ -MAA SPECT/CT: Implications for planning ^{90}Y radioembolization? *European Journal of Radiology* 2012; **81**: 3979–3984.
- Zalom M, Yu R, Friedman M *et al.* FDG PET/CT as a prognostic test after ^{90}Y radioembolization in patients with metastatic hepatic disease. *Clinical Nuclear Medicine* 2012; **37**: 862–865.
- Gensure RH, Foran DJ, Lee VM *et al.* Evaluation of hepatic tumor response to Yttrium-90 radioembolization therapy using texture signatures generated from contrast-enhanced CT images. *Academic Radiology* 2012 Jul 26; ePub doi: 10.1016/j.acra.2012.04.015.
- Wu SY, Kuo JW, Chang TK *et al.* Preclinical characterization of ^{18}F -MAA, a novel PET surrogate of $^{99\text{m}}\text{Tc}$ -MAA. *Nuclear Medicine and Biology* 2012 Jul 2; ePub doi: org/10.1016/j.nucmedbio.2012.04.008.
- Kao YH, Tan EH, Lim KY *et al.* Yttrium-90 internal pair production imaging using first generation PET/CT provides high resolution images for qualitative diagnostic purposes. *British Journal of Radiology* 2012; **85**: 1018–1019.
- Tochetto SM, Töre HG, Chalian H *et al.* Colorectal liver metastasis after ^{90}Y radioembolization therapy: Pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response. *AJR American Journal of Roentgenology* 2012; **198**: 1093–1099.
- Weber K, Berger F, Mustafa M *et al.* [SPECT/CT for staging and treatment monitoring in oncology: Applications in differentiated thyroid cancer and liver tumors.] *Der Radiologe* 2012 Jun 20; ePub doi: 10.1007/s00117-011-2267-y. [in German]
- Rong X, Du Y, Frey EC. A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging. *Physics in Medicine and Biology* 2012; **57**: 3711–3725.
- Rong X, Du Y, Ljungberg M *et al.* Development and evaluation of an improved quantitative ^{90}Y Bremsstrahlung SPECT method. *Medical Physics* 2012; **39**: 2346–2358.
- Jiang M, Fischman A, Nowakowski FS *et al.* Segmental perfusion differences on paired Tc-99m macroaggregated albumin (MAA) hepatic perfusion imaging and yttrium-90 (Y-90) Bremsstrahlung imaging studies in SIR-Sphere radioembolization: Associations with angiography. *Journal of Nuclear Medicine and Radiation Therapy* 2012; **3**: 122 ePub doi: 10.4172/2155-9619.1000122.
- Karaman B, Battal B, Alagoz E *et al.* Complete disappearance of uptake of FDG in the multifocal liver hemangioendothelioma after radioembolization therapy using yttrium-90 microspheres. *Annals of Nuclear Medicine* 2012; **26**: 440–443.
- D'Arienzo M, Chiamida P, Chiacchiararelli L *et al.* ^{90}Y PET-based dosimetry after selective internal radiotherapy treatments. *Nuclear Medicine Communications* 2012; **33**: 633–640.
- Kao YH, Tan AEH, Burgmans MC *et al.* Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective ^{90}Y radioembolization. *Journal of Nuclear Medicine* 2012; **53**: 1–8.
- Haug AR, Tiega Donfack BP, Trumm C *et al.* ^{18}F -FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. *Journal of Nuclear Medicine* 2012; **53**: 371–377.

- Gupta A, Levitin A, Shrikanthan S *et al.* Macroaggregated albumin injected in hepatic artery visualized in a recanalized paraumbilical vein. *Clinical Nuclear Medicine* 2012; **37**: 80–81.
- Gupta A, Gill A, Shrikanthan S *et al.* Nontargeted Y-90 microsphere radioembolization to duodenum visualized on Y-90 PET/CT and Bremsstrahlung SPECT/CT. *Clinical Nuclear Medicine* 2012; **37**: 98–99.
- Haggerty JE, Vaidya S, Kooy T *et al.* Identification of the falciform artery on nuclear medicine imaging with successful coil embolization for planned Y-90 therapy. *Clinical Nuclear Medicine* 2012; **37**: 105–107.
- Lenoir L, Edeline J, Rolland Y *et al.* Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. *European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39**: 872–880.
- Bagni O, D'Arienzo M, Chiaramida P *et al.* ⁹⁰Y-PET for the assessment of microsphere biodistribution after selective internal radiotherapy. *Nuclear Medicine Communications* 2012; **33**: 198–204.
- Goryawala M, Guillen M, Cabrerizo M *et al.* A 3D liver segmentation method with parallel computing for Selective Internal Radiation Therapy. *IEEE Transactions on Information Technology in Biomedicine* 2012; **16**: 62–69.
- Galizia MS, Töre HG, Chalian H *et al.* MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: Comparison of two-dimensional and volumetric techniques. *Academic Radiology* 2012; **19**: 48–54.
- Ahmadzadehfar H, Muckle, M, Sabet A *et al.* The significance of Bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects. *European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39**: 309–315.
- Großer OS, Nultsch M, Laatz K *et al.* Radioembolisation mit ⁹⁰Y-markierten mikrosphären: posttherapeutische therapievalidierung mit bremsstrahlungs-SPECT [Radioembolization with ⁹⁰Y-labeled microspheres: post-therapeutic therapy validation with Bremsstrahlung-SPECT]. *Zeitschrift für Medizinische Physik* 2012; **21**: 274–280. [in German]
- Schmidt GP, Paprottka Pa, Jakobs TF *et al.* FDG–PET–CT and whole-body MRI for triage in patients planned for radioembolisation therapy. *European Journal of Radiology* 2012; **81**: e269–276.
- Walrand S, Hesse M, Demonceau G *et al.* Yttrium-90-labeled microsphere tracking during liver selective internal radiotherapy by bremsstrahlung pinhole SPECT: feasibility study and evaluation in an abdominal phantom. *European Journal of Nuclear Medicine and Molecular Imaging Research* 2011; **1**: 32.
- Chalian H, Töre HG, Horowitz JM *et al.* Radiologic assessment of response to therapy: Comparison of RECIST versions 1.1 and 1.0. *Radiographics* 2011; **31**: 2093–2105.
- Kao YH, Tan EH, Ng CE *et al.* Yttrium-90 Time-of-Flight PET/CT is superior to Bremsstrahlung SPECT/CT for postradioembolization imaging of microsphere biodistribution. *Clinical Nuclear Medicine* 2011; **36**: e186–187.
- Lacin S, Oz I, Ozkan E *et al.* Intra-arterial treatment with ⁹⁰yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of ¹¹¹In-octreotide scintigraphy in the evaluation of treatment response. *Cancer Biotherapy & Radiopharmaceuticals* 2011; **26**: 631–637.
- van Elmbt L, Vandenberghe S, Walrand S *et al.* Comparison of yttrium-90 quantitative imaging by TOF and non-TOF PET in a phantom of liver selective internal radiotherapy. *Physics in Medicine and Biology* 2011; **56**: 6759.
- Wong KM, Tan BS, Taneja M *et al.* Cone beam computed tomography for vascular interventional radiology procedures: Early experience. *Annals, Academy of Medicine, Singapore* 2011; **40**: 308–314.
- Dudeck O, Wilhelmsen S, Ulrich G *et al.* Effectiveness of repeat angiographic assessment in patients designated for radioembolization using yttrium-90 microspheres with initial extrahepatic accumulation of technetium-99m macroaggregated albumin: A single center's experience. *Cardiovascular and Interventional Radiology* 2011 Aug 11; ePub doi: 10.1007/s00270-011-0252-5.
- Gartenschlaeger M, Maus S, Buchholz H *et al.* Investigation for extrahepatic shunt before SIRT by PET/CT with ⁶⁸Ga-MAA. *Nuklearmedizin* 2011; **50**: N37–N38.

- Kao YH, Tan EH, Teo TK *et al.* Imaging discordance between hepatic angiography versus Tc-99m-MAA SPECT/CT: A case series, technical discussion and clinical implications. *Annals of Nuclear Medicine* 2011; **25**: 669–676.
- Becker C, Waggshausen T, Tiling R *et al.* C-arm computed tomography compared with positron emission tomography/computed tomography for treatment planning before radioembolization. *Cardiovascular and Interventional Radiology* 2011; **34**: 550–556.
- Vouche M, Vanderlinden B, Delatte P *et al.* New imaging techniques for ⁹⁰Y microsphere radioembolization. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 113 ePub doi: 10.4172/2155-9619.1000113.
- Sabet A, Ahmadzadehfar H, Muckle M *et al.* Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization. *Journal of Nuclear Medicine* 2011; **52**: 1063–1067.
- Willowson K, Bailey DL, Baldock C. Quantifying lung shunting during planning for radio-embolization. *Physics in Medicine and Biology* 2011; **56**: N145–N152.
- Crocetti L, Della Pina C, Cioni D, Lencioni R. Peri-intraprocedural imaging: US, CT, and MRI. *Abdominal Imaging* 2011; **36**: 648–660.
- Haug AR, Heinemann V, Bruns CJ *et al.* ¹⁸F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with ⁹⁰Y microspheres. *European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38**: 1037–1045.
- O'Doherty J, Scuffham J, Hinton P. The importance of scatter correction for the assessment of lung shunting prior to yttrium-90 radioembolization therapy. *Nuclear Medicine Communications* 2011; **32**: 628–634.
- Kim YC, Kim YH, Um SH *et al.* Usefulness of Bremsstrahlung Images after intra-arterial Y-90 resin microsphere radioembolization for hepatic tumors. *Nuclear Medicine and Molecular Imaging* 2011; **45**: 59–67.
- Wissmeyer M, Heinzer S, Majno P *et al.* ⁹⁰Y Time-of-flight PET/MR on a hybrid scanner following liver radioembolisation (SIRT). *European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38**: 1744–1745.
- Bester L, Hobbins PG, Wang SC, Salem R. Imaging characteristics following ⁹⁰yttrium microsphere treatment for unresectable liver cancer. *Journal of Medical Imaging and Radiation Oncology* 2011; **55**: 111–118.
- Walrand S, Flux GD, Konijnenberg MW *et al.* Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: ⁸⁶Y or ⁹⁰Y imaging? *European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** Suppl 1: S57–68.
- Ahmadzadehfar H, Sabet A, Muckle M *et al.* ^{99m}Tc-MAA/⁹⁰Y-Bremsstrahlung SPECT/CT after simultaneous Tc-MAA/⁹⁰Y-microsphere injection for immediate treatment monitoring and further therapy planning for radioembolization. *European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38**: 1281–1288.
- Kim KW, Lee JM, Choi BI. Assessment of the treatment response of HCC. *Abdominal Imaging* 2011; **36**: 300–314.
- Gates VL, Esmail AA, Marshall K *et al.* Internal pair production of ⁹⁰Y permits hepatic localization of microspheres using routine PET: Proof of concept. *Journal of Nuclear Medicine* 2011; **52**: 72–76.
- Morgan B, Kennedy AS, Lewington V *et al.* Intra-arterial brachytherapy of hepatic malignancies: watch the flow. *Nature Reviews Clinical Oncology* 2011; **8**: 115–120.
- Lambert B, Mertens J, Sturm EJ *et al.* ^{99m}Tc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with ⁹⁰Y microspheres. *European Journal of Nuclear Medicine and Molecular Imaging* 2010; **37**: 2328–2333.
- Pua BB, Sofocleous CT. Imaging to optimize liver tumor ablation. *Imaging in Medicine* 2010; **2**: 433–443.
- Monsky WL, Garza AS, Kim I *et al.* Treatment planning and volumetric response assessment for yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy. *Cardiovascular and Interventional Radiology* 2011; **34**: 306–318.
- Ahmadzadehfar H, Sabet A, Biermann K *et al.* The significance of ^{99m}Tc-MAA SPECT/CT liver perfusion imaging in treatment planning for ⁹⁰Y-microsphere selective internal radiation treatment. *Journal of Nuclear Medicine* 2010; **51**: 1206–1212.

- Dudeck O, Zeile M, Wybranski C *et al.* Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. *European Radiology* 2010; **20**: 2699–2706.
- Rault E, Staelens S, Van Holen R *et al.* Fast simulation of yttrium-90 bremsstrahlung photons with GATE. *Medical Physics* 2010; **37**: 2943–2950.
- Tochetto SM, Rezaei P, Rezvani M *et al.* Does multidetector CT attenuation change in colon cancer liver metastases treated with ⁹⁰Y help predict metabolic activity at FDG PET? *Radiology* 2010; **255**: 164–172.
- Lhommel R, van Elmbt L, Goffette P *et al.* Feasibility of ⁹⁰Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres. *European Journal of Nuclear Medicine and Molecular Imaging* 2010; **37**: 1654–1662.
- Knesaurek K, Machac J, Muzinic M *et al.* Quantitative comparison of yttrium-90 (⁹⁰Y)-microspheres and technetium-99m (^{99m}Tc)-macroaggregated albumin SPECT images for planning ⁹⁰Y therapy of liver cancer. *Technology in Cancer Research & Treatment* 2010; **9**: 253–262.
- Wong CY, Gates VL, Tang B *et al.* Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography predicts extrahepatic metastatic potential of colorectal metastasis: a practical guide for yttrium-90 microsphere liver-directed therapy. *Cancer Biotherapy and Radiopharmaceuticals* 2010; **25**: 233–236.
- Heusner TA, Hamami ME, Ertle J *et al.* Angiography-based C-Arm CT for the assessment of extrahepatic shunting before radioembolization. *RoFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin* 2010; **182**: 603–608.
- Werner MK, Brechtel K, Beyer T *et al.* PET/CT for the assessment and quantification of ⁹⁰Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases. *European Journal of Nuclear Medicine and Molecular Imaging* 2010; **37**: 407–408.
- Pasciak AS, Erwin WD. Effect of voxel size and computation method on Tc-99m MAA SPECT/CT-based dose estimation for Y-90 microsphere therapy. *IEEE Transactions on Medical Imaging* 2009; **28**: 1754–1758.
- Mesoloras G, Sandison GA, Gulec SA. Measurement of functional tumor volume for fluorodeoxyglucose-positive primary and metastatic liver tumors: validation of optimal threshold value technique. *Journal of Interventional Oncology* 2009; **2**: 95–104.
- Vasamillette J, Hohenberger P, Schoenberg S *et al.* Treatment monitoring with ¹⁸F-FDG PET in metastatic thymoma after ⁹⁰Y-Dotatoc and selective internal radiation treatment (SIRT). *Hellenic Journal of Nuclear Medicine* 2009; **12**: 271–273.
- Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. *Journal of Nuclear Medicine* 2009; **50** (Suppl 1): 122S–150S.
- Dierckx R, Maes A, Peeters M, Van De Wiele C. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. *Quarterly Journal of Nuclear Medicine and Molecular Imaging* 2009; **53**: 336–342.
- Sato KT, Omary RA, Takehana C *et al.* The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. *Journal of Vascular and Interventional Radiology* 2009; **20**: 1564–1569.
- Lhommel R, Goffette P, Van den Eynde M *et al.* Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. *European Journal of Nuclear Medicine and Molecular Imaging* 2009; **36**: 1696.
- Campbell JM, Wong CO, Muzik O *et al.* Early dose response to Yttrium-90 microsphere treatment of metastatic liver cancer by a patient-specific method using single photon emission computed tomography and positron emission tomography. *International Journal of Radiation Oncology, Biology and Physics* 2009; **74**: 313–320.
- Allen-Auerbach M, Weber WA. Measuring response with FDG-PET: methodological aspects. *The Oncologist* 2009; **14**: 369–377.
- Fabbri C, Sarti G, Cremonesi M *et al.* Quantitative analysis of ⁹⁰Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. *Cancer Biotherapy & Radiopharmaceuticals* 2009; **24**: 145–154.
- Hamami ME, Poeppel TD, Müller S *et al.* SPECT/CT with ^{99m}Tc-MAA in radioembolization with ⁹⁰Y microspheres in patients with hepatocellular cancer. *Journal of Nuclear Medicine* 2009; **50**: 688–692.

- Louie JD, Kothary N, Kuo WT *et al.* Incorporating cone-beam CT into the treatment planning for Yttrium-90 radioembolization. *Journal of Vascular and Interventional Radiology* 2009; **20**: 606–613.
- Murthy R, Mutha P, Madoff DC *et al.* Establishment of the radiation effect of yttrium-90 microspheres: Role of C-arm CT. *Journal of Vascular and Interventional Radiology* 2009; **20**: 422–424.
- Eisenhauer EA, Therasse P, Bogaerts J *et al.* New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *European Journal of Cancer* 2009; **45**: 228–247.
- Ibrahim SM, Nikolaidis P, Miller FH *et al.* Radiologic findings following Y90 radioembolization for primary liver malignancies. *Abdominal Imaging* 2009; **34**: 566–581.
- Rose SC, Iussich G, Casola G *et al.* Comparison of CT angiography and digital subtraction angiography for displaying extrahepatic arterial anatomy relevant to planning regional arterial therapy for liver cancers. *Journal of Interventional Oncology* 2008; **1**: 19–27.
- Flamen P, Vanderlinden B, Delatte P *et al.* Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. *Physics in Medicine and Biology* 2008; **53**: 6591–6603.
- Atassi B, Bangash AK, Bahrani A *et al.* Multimodality imaging following ⁹⁰Y radioembolization: a comprehensive review and pictorial essay. *Radiographics* 2008; **28**: 81–99.
- Sebastian AJ, Szyszko T, Al-Nahhas A, Nijran K, Tait NP. Evaluation of hepatic angiography procedures and bremsstrahlung imaging in selective internal radiation therapy: a two-year single-center experience. *Cardiovascular and Interventional Radiology* 2008; **31**: 643–649.
- Fletcher JW, Djulbegovic B, Soares HP *et al.* Recommendations on the use of ¹⁸F-FDG PET in oncology. *Journal of Nuclear Medicine* 2008; **49**: 480–508.
- Lin M, Shon IH, Wilson R *et al.* Treatment response in liver metastases following ⁹⁰Y SIR-spheres: an evaluation with PET. *Hepato-Gastroenterology* 2007; **54**: 910–912.
- Szyszko T, Khodjibekova M, Singh A, AL-Nahhas A. Role of nuclear medicine in the treatment and follow-up of unresectable liver tumours treated with yttrium-90 microspheres. *RAD Magazine* June 2007; **33**: 25.
- Tehranipour N, Al-Nahhas A, Canelo R *et al.* Concordant F-18 FDG PET and Y-90 Bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: Confirmation with histopathology. *Clinical Nuclear Medicine* 2007; **32**: 371–374.
- Welsh JS. Radiographically identified necrosis after ⁹⁰Y microsphere brachytherapy: A new standard for oncologic response assessment? *American Journal of Roentgenology* 2007; **188**: 765–767.
- Keppke AL, Salem R, Reddy D *et al.* Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. *American Journal of Roentgenology* 2007; **188**: 768–775.
- Miller FH, Keppke AL, Reddy D *et al.* Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. *American Journal of Roentgenology* 2007; **188**: 776–783.
- Szyszko T, AL-Nahhas A, Canelo R *et al.* Assessment of response to treatment of unresectable liver tumours with ⁹⁰Y microspheres: Value of FDG PET versus computed tomography. *Nuclear Medicine Communications* 2007; **28**: 15–20.
- Das CJ, Paul SB, Madhusudhan KS, Gulati MS. Update in liver imaging. *Tropical Gastroenterology* 2007; **28**: 149–154.
- Boppudi S, Wickremesekera S, Nowitz M *et al.* Evaluation of the role of CT in the assessment of response to selective internal radiation therapy in patients with colorectal liver metastases. *Australasian Radiology* 2006; **50**: 570–577.
- Rivet M. Monitoring ⁹⁰Y-SIRsphere treatment response with ¹⁸F-FDG-PET. *ANZ Nuclear Medicine* 2006; September: 3–4.
- Rhee TK, Omary RA, Gates V *et al.* The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. *Journal of Vascular and Interventional Radiology* 2005; **16**: 1085–1091.
- Bienert M, McCook B, Carr B *et al.* Sequential FDG PET/CT in ⁹⁰Y microsphere treatment of unresectable colorectal liver metastases. *European Journal of Nuclear Medicine and Molecular Imaging* 2005; **32**: 723.
- Bienert M, McCook B, Carr B *et al.* ⁹⁰Y microsphere treatment of unresectable liver metastases: changes in ¹⁸F-FDG uptake and tumour size on PET/CT. *European Journal of Nuclear Medicine and Molecular Imaging* 2005; **32**: 778–787.

Wong C, Qing F, Savin M *et al.* Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [¹⁸F]Fluorodeoxyglucose positron emission tomographic imaging. *Journal of Vascular and Interventional Radiology* 2005; **16**: 1101–1106.

Sarfraz M, Wul X, Lodge MA, Yu CX. Automatic CT-SPECT registration of livers treated with radioactive microspheres. *Physics in Medicine and Biology* 2004; **49**: N131–137.

Therasse P, Arbuck SG, Eisenhauer EA *et al.* New guidelines to evaluate the response to treatment in solid tumors. *Journal of the National Cancer Institute* 2000; **92**: 205–216.

Abstracts on Imaging

Camacho JC, Kokabi N, Schuster DM *et al.* PERCIST criteria to predict survival at 3 months following intra-arterial resin-based yttrium-90 (Y-90) radioembolization therapy of unresectable intrahepatic cholangiocarcinoma refractory to standard chemotherapy: A proof of concept study. *ASCO Annual Meeting 2013, Journal of Clinical Oncology* **31** (suppl): Abs. e15141.

Lam MG, Goris ML, Iagaru A *et al.* Fusion MAA-sulfur colloid spect imaging for yttrium-90 radioembolization: towards customized physiology-based dose planning. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S34 Abs. 60.

Sánchez-Martínez M, Collantes M, Rodríguez-Fraile M *et al.* Fluorine-18 radiolabelling of SIR-Spheres[®] as biodistribution surrogate marker of radiospheres treatment: IN VIVO micro-PET and IN VITRO stability studies. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. OP080.

Sabet A, Ezziddin S, Muckle M *et al.* ¹⁸F-FDG-PET/CT in planning of selective internal radiation therapy of colorectal liver metastases. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. OP173.

Filippi L, D'Arienzo M, Salvatori R *et al.* Planning sequential bilobar treatment with Y90 microspheres: usefulness of parametric imaging with ¹⁸FDG PET/CT. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. OP175.

Rangarajan V, Zade A, Jha A *et al.* Comparative analysis of ⁹⁰Y Bremsstrahlung SPECT/CT and ⁹⁰Y PET/CT imaging of ⁹⁰Y microsphere therapy. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0031.

Demir M, Tanyıldızı H, Çavdar I *et al.* Optimization of physical parameters and quantification of clinical data in SPECT and PET/CT imaging with Y-90. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0034.

Hooker C.A, Ruiz D, Kalogianni E *et al.* Y-90 Bremsstrahlung post therapy imaging for patients treated with Y-90 microspheres. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0036.

Lin K, Lee R, Liu C *et al.* The value of whole-body FDG-PET/CT in detection of extrahepatic metastases in hepatocellular carcinoma patients treated with Yttrium-90 radioembolization. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0508.

Uslu L, Gulsen F, Sager S *et al.* Radioembolization with Yttrium-90 microspheres in unresectable primary and metastatic liver tumors. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0510.

Bagni O, Filippi L, Salvatori R *et al.* Voxel dosimetry with ⁹⁰Y-PET for the assessment of liver toxicity. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0131.

Rangarajan V, Zade A, Kulkarni M *et al.* ⁹⁰Y microsphere therapy: Comparative analysis of pre therapeutic ^{99m}Tc MAA scintigraphy and post therapeutic ⁹⁰Y PET/CT imaging. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0133.

De Cicco C, Cremonesi M, Colandrea M *et al.* Response assessment after radioembolization with ⁹⁰Y-microspheres for liver metastases: Comparing outcomes with FDG-PET Imaging. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. P0132.

Sciuto R, Annovazzi A, Rea S *et al.* ¹⁸F-FDG PET/CT role in predicting clinical outcome after ⁹⁰Y-labeled resin microspheres treatment (⁹⁰Y-RE) in advanced hepatocellular carcinoma (HCC). *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. OP471.

D'Arienzo M, Chiacchiararelli L, Filippi L *et al.* Dosimetry with ⁹⁰Y PET after liver radioembolization: The role of bed and EUD for the assessment of non uniform activity distributions in lesions. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. O0475.

Pettinato C, Monari F, Civollani S *et al.* Retrospective dosimetry in patients affected by HCC and treated with SIRT using ⁹⁰Y-microspheres PET/CT imaging. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. OP476.

Bailey DL, Willowson KP, Forwood NJ *et al.* Quantitative PET imaging of Y-90. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. OP505.

Ulrich G, Raatz Y, Furth C *et al.* Prognostic value of Tc-99m-MAA-Uptake in patients with cholangiocellular carcinoma undergoing Y-90-radioembolization. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. PO189.

Dieudonné A, Gardin I, Siebert A *et al.* A Y90-PET/CT for treatment validation of Y90-microspheres SIRT: A 3D dosimetry comparison with pre-therapeutic Tc99m-MAA-SPECT/CT. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. PO190.

Ma V, Law M, Ng S *et al.* Experience in Y-90 PET imaging and subsequent dose calculation for selective internal radiation therapy to liver cancer. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2012; **39** (Suppl 2): Abs. PO196.

Paxton A, Nickles R, DeWerd L. Activity assay of a Y-90 microsphere sample using a coincidence detection system. *American Association of Physicists in Medicine Annual Meeting, Medical Physics* 2012; **6**: 3856 Abs. SU-F-BRB-2.

Clinthorne N, Kison P, Rothley J, Dewaraja Y. Comparison of Bremsstrahlung SPECT/CT and PET/CT for Y90 quantification. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2012; **53** (Suppl 1): Abs. 445.

Arrichiello C, Aloj L, D'Ambrosio L *et al.* PET based dosimetry in patients undergoing ⁹⁰Y-SIR-spheres treatment for liver metastases: Correlation with response. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2012; **53** (Suppl 1): Abs. 571.

Shrikanthan S, Kunam V, Srinivas S. Y-90 PET/CT for localization of Yttrium-90 microspheres - Post radioembolization. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2012; **53** (Suppl 1): Abs. 1202.

MacLellan C, Hobbs B, Chasen B *et al.* Absorbed dose differences in ⁹⁰Y microsphere therapy between pre-treatment ^{99m}Tc-MAA and post-treatment ⁹⁰Y scans. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2012; **53** (Suppl 1): Abs. 1494.

Erwin W, Cooney S, Santiago G *et al.* A measured Bremsstrahlung dose rate constant for Yttrium-90 microsphere liver-directed brachytherapy. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2012; **53** (Suppl 1): Abs. 2230.

Irani FG, Kao Y, Tay K *et al.* Personalized predictive dosimetry by artery-specific SPECT/CT partition modeling: how effective is it? *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S68 Abs. 163.

Savin MA, Vartanian SA, Metz T *et al.* Early imaging accuracy post Y90 radioembolization for liver metastases from colorectal cancer. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S70-S71 Abs. 169.

- Chang T, Owen R, McKinney JM *et al.* Treatment modification of Y90 selective internal radionuclide therapy based on quantitative PET/CT imaging. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S80 Abs. 194.
- Rosenbaum CE, Smits M, Seinstra BA *et al.* Diffusion-weighted magnetic resonance imaging for early tumor response assessment after Yttrium-90 radioembolization in patients with colorectal cancer liver metastases. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S84 Abs. 204.
- Kucuk ON, Soydal C, Lacin S *et al.* Intra-arterial radioembolization with Y-90 for unresectable primary and metastatic liver tumors and evaluation of treatment response by FDG PET/CT. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. P470.
- Bagni O, D'Arienzo M, Salvatori R *et al.* Can ⁹⁰Y-PET predict the outcome of lesions after SIRT? Biodistribution assessment and preliminary data of Voxel Based Dosimetry. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. OP023.
- Di Dia A, Cremonesi M, Botta B *et al.* Impact of 3D dosimetric and radiobiological estimates methods in radioembolisation of liver metastasis with ⁹⁰Y-microspheres. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. OP020.
- Walrand S, Lhommel R, Goffette P *et al.* Tumor dose-response relationship based on ⁹⁰Y and FDG TOF-PET imaging in liver-SIRT. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. OP024.
- Volkan-Salanci B, Bozkurt MF, Cil B *et al.* Can perfusion pattern in pre-therapy hepatic artery perfusion scintigraphy predict radiomicrosphere therapy response? *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. OP131.
- Arrichiello C, Aloj L, D'Ambrosio L *et al.* Lesion and normal liver absorbed doses based on PET measurements in patients undergoing treatment for liver metastases with ⁹⁰Y SIR spheres. *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. OP134.
- Ulrich G, Zeile M, Großer OS *et al.* Does the intratumoral uptake pattern of Tc-99m-MAA allow a prediction of response to yttrium-90-radioembolization in patients with colorectal liver metastases? *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. P743.
- Chalaye J, Bernardini M, Smadja C *et al.* Combining ^{99m}Tc-MAA SPECT/CT and ¹⁸F-FDG PET/CT for planning liver ⁹⁰Y radioembolization (SIRT). *European Association of Nuclear Medicine (EANM) Annual Meeting, European Journal of Nuclear Medicine and Molecular Imaging* 2011; **38** (Suppl 2): Abs. P744.
- Rosenbaum C, Lam M, van den Bosch M *et al.* Pre-treatment intra-hepatic distribution of technetium-99m MAA does not correlate with the post-treatment distribution of yttrium-90 in radioembolization patients. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2011; Abs. 2107.1.
- Wilhelmsen S, Ulrich G, Löwenthal D *et al.* Effectiveness of repeat assessment in patients scheduled for radioembolization using yttrium-90 microspheres with extrahepatic ^{99m}Tc-MAA accumulation to the gastrointestinal tract: a single center experience. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2011; Abs. 2107.4.
- Burgmans MC, Irani FG, Soh LJM *et al.* Super-selective Y-90 infusion guided by intra-arterial CT enables safe selective internal radiation therapy with a low coiling rate. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2011; Abs. P-294.
- Burgmans MC, Irani FG, Soh LJM *et al.* The use of intra-arterial CT in addition to angiography and TC99-MAA to guide infusion of yttrium-90 for selective internal radiation therapy. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2011; Abs. 2107.5.
- Too CW, Irani FG, Tay KH *et al.* Comparison of diagnostic quality of intra-arterial CT images obtained using cone beam CT and multidetector CT systems for hepatic radioembolisation. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2011; Abs. P-352.
- Jiang M, F. Nowakowski S, Aaron Fischman A *et al.* Segmental perfusion differences (SPD) on paired Tc-99m MAA hepatic perfusion imaging (HPI) and Yttrium-90 microsphere (Y-90) imaging:

- Associations with angiography. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 88.
- Cremonesi M, Di Dia GA, Bonomo G *et al.* Comparing outcomes from CT and PET imaging after tumor liver radioembolization with ⁹⁰Y-microspheres might suggest more appropriate choice of response evaluation. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 89.
- Nichols K, Leveque F, Pugliese P *et al.* Accuracy of pulmonary shunt measurements prior to ⁹⁰Y selective internal radiotherapy: A phantom study. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 90.
- Ahmadzadehfar H, Sabet A, Reichmann K *et al.* Imaging of Y90 distribution with PET/CT and bremsstrahlung SPECT/CT after radioembolization: A patient based study. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 92.
- Di Dia GA, Botta F, Marta Cremonesi M *et al.* Voxel-dosimetry as useful tool for optimized administered activity in radioembolization of liver tumors with ⁹⁰Y-microspheres. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 131.
- Lodge M, Rong X, Frey E, Geschwind JF, Wahl R. Quantitative potential of Y-90 PET. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 601.
- Civelek A. SIRS-spheres (Y-90 microspheres) therapy for unresectable metastatic liver disease: Pitfalls from tracer preparation for injection to image interpretation. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 1082.
- Kao YH, Tan AEH, Ng DCE, Goh ASW. Controversy in Yttrium-90 selective internal radiation therapy: Imaging discordance between catheter-directed CT hepatic angiography versus Tc-99m-MAA SPECT/CT as a possible first human demonstration of in-vivo microparticle trajectory selection for specific daughter vessel targeting. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 1083.
- Haug A, Zech C, Bartenstein P, Hacker M. FDG PET/CT in the prediction of survival in patients after radioembolization of hepatic metastases from breast cancer. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 368.
- Kao YH, Tan AEH, Ng DCE, Goh ASW. State-of-the-art Yttrium-90 selective internal radiation therapy: Technical aspects of artery-specific SPECT/CT partition model dosimetry. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs.1084.
- Ahmadzadehfar H, Muckle M, Sabet A *et al.* The effectiveness of Bremsstrahlung SPECT-CT of the abdomen after radioembolization in the prediction of radiation induced gastroduodenal side effects. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 1361.
- Dieudonné A, Garin E, Sophie Laffont S *et al.* Fast 3D dosimetry of Y90 selective internal radiation treatment (SIRT) using voxel S-values. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 1681.
- Giesel F, Wulfert S, Zechmann C *et al.* Short-term follow-up using contrast-enhanced ultrasound in patients with hepatic metastases under selective internal radiation therapy (SIRT). *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 1726.
- Gupta A, DiFilippo F, Shrikanthan S *et al.* PET/CT imaging for localization of Yttrium-90 microspheres post radioembolization - Initial experience. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 1728.
- Baechler S, Camus F, Hobbs R *et al.* Quantitative imaging of ⁹⁰Y with PET/CT for reliable 3D patient-specific dosimetry after selective internal radiation therapy (SIRT). *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 1798.
- Wang X, Shah RP, Brown KT *et al.* Cystic artery localization using a three-dimensional angiography vessel tracking system compared with conventional two-dimensional angiography. *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2011; **22** (Suppl): S49–50 Abs. 111.
- Sardari A, Sweeney J, Biebel B *et al.* Radiation related computed tomographic benign findings after radioembolization with Yttrium-90. *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2011; **22** (Suppl): S90 Abs. 209.
- Schmidt G, Paprottka P, Jakobs T *et al.* FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolization therapy. *European Congress of Radiology* 2011; Abs. C-0624.

- Seidel R, Fries P, Farmakis G *et al.* MR evaluation of hepatic lesions after radioembolization by unenhanced and hepatobiliary phase MR imaging using Gd-BOPTA. *European Congress of Radiology* 2011; Abs. C-1187.
- Vouche M, Lemort M, Flamen P *et al.* Correlation study of structural and metabolic response of hepatic metastasis from colorectal cancer after a ⁹⁰Y radio-embolization treatment. *European Congress of Radiology* 2011; Abs. C-1382.
- Irani FG, Tan BS, Yoong G *et al.* Comparison of diagnostic quality of intra-arterial CT images obtained using cone-beam CT and multi-detector CT systems for hepatic radioembolization. *European Congress of Radiology* 2011; Abs. C-1862.
- Patel A, Tay KH, Lo RHG *et al.* Usefulness of catheter directed intra-arterial CT hepatic angiography (CDCTHA) using an hybrid angiography - computed tomography system in radio-embolization of hepatocellular carcinoma. *European Congress of Radiology* 2011; Abs. C-1968.
- Wulfert S, Zechmann C, Kratochwil C *et al.* Short-term follow-up using contrast-enhanced ultrasound in patients with hepatic metastases under selective internal radiation therapy (SIRT). *European Congress of Radiology* 2011; Abs. C-1985.
- Rothe JH, Grieser C, Schnapauff D *et al.* MR-volumetry of functional liver tissue before selective intraarterial radiotherapy (SIRT): evaluation of a threshold based approach using hepatobiliary contrast media (Gd-EOB) and fat saturated T1w 3D-sequences with different flip angles. *European Congress of Radiology* 2011; Abs. C-1991.
- Yu N, Srinivas SM, DiFilippo FA *et al.* Gamma planar scintigraphy based calculation overestimates lung shunt for Y-90 radioembolization of liver tumor. *53rd Annual Meeting of American Society for Radiation Oncology (ASTRO), International Journal of Radiation Oncology, Biology and Physics* 2010; **78** (2 Suppl): S322 Abs. 2265.
- Dominguez I, Iñarrairaegui M, Rodriguez M *et al.* Tumor vascularity and response to radioembolization using Y90 resin microspheres. *4th International Liver Cancer Association (ILCA) meeting* September 2010; Abs. P-133.
- Baechler S, Camus F, Haag G *et al.* SPECT and PET imaging of yttrium-90 in targeted radionuclide therapy. *Schweizerische Gesellschaft für Strahlenbiologie und Medizinische Physik (SGSMP – Swiss Society of Radiobiology and Medical Physics) Annual Conference* 2010; Abs. 32.
- Riaz A, Lewandowski RJ, Gupta R *et al.* Imaging response in the primary index lesion: A standardizable, reproducible and novel biomarker for hepatocellular carcinoma. *Society of Interventional Radiology (SIR) 35th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2010; **21** (Suppl): S11 Abs. 23.
- Riaz A, Ryu RK, Gupta R *et al.* A novel scoring system combining anatomic size and enhancement characteristics for assessing response to locoregional therapies. *Society of Interventional Radiology (SIR) 35th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2010; **21** (Suppl): S11–12 Abs. 24.
- Louie JD, Kothary N, Kuo WT *et al.* Impact of using C-arm CT on treatment planning for yttrium-90 radioembolization. *Society of Interventional Radiology (SIR) 35th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2010; **21** (Suppl): S14 Abs. 31.
- Ulrich G, Ruf J, Großer O *et al.* Pretherapeutic evaluation of extra-hepatic accumulation in SIRT-patients by Tc-99m-MAA-perfusion-scintigraphy: Is there an impact of SPECT-MRI/CT-image fusion? *European Association of Nuclear Medicine (EANM) Conference* 2009; Abs. OP437.
- Aloj L, Arrichiello C, Izzo F *et al.* Tumor dosimetry in the treatment of liver metastases with Sirtex does not correlate with therapeutic response. *European Association of Nuclear Medicine (EANM) Conference* 2009; Abs. OP510.
- Dasgupta DJ, Kalogianni E, Corcoran BJ *et al.* The value of additional SPECT in ^{99m}Tc-MAA perfusion imaging pre therapy, and ⁹⁰Y Bremsstrahlung imaging post therapy, in the management of patients treated with ⁹⁰Y microspheres. *European Association of Nuclear Medicine (EANM) Conference* 2009; Abs. OP622.
- Garrastachu P, Rodriguez-Fraile M, Herraíz M *et al.* Liver radioembolization. The tumoral uptake of ^{99m}Tc albumine macroaggregates in SPECT/CT after the angiographic redistribution. *European Association of Nuclear Medicine (EANM) Conference* 2009; Abs. OP623.
- Sze DY, Louie JD, Iagaru AH, Goris ML *et al.* Survival after ⁹⁰Y radioembolization is predicted by dose distribution scintigraphy. *European Association of Nuclear Medicine (EANM) Conference* 2009; Abs. OP625.

- Bozkurt MF, Peynircioglu B, Cil B *et al.* Impact of image co-registration on the treatment planning of Y-90 microsphere therapy. *European Association of Nuclear Medicine (EANM) Conference 2009*; Abs. PW048.
- Mustafa M, Hoffmann R, Haug A *et al.* The value of SPECT/CT in diagnosing aberrant abdominal vessels in pre – SIRT evaluation with ^{99m}Tc-MAA. *European Association of Nuclear Medicine (EANM) Conference 2009*; Abs. P274.
- Herraiz MJ, Garrastachu P, Iñarrairaegui M *et al.* Yttrium-90 liver radioembolization (Y90-RE): ^{99m}Tc-MAA SPECT/CT tumoral uptake after angiographic redistribution of intrahepatic vessels. *Cardiovascular and Interventional Radiology in Europe (CIRSE) 2009*; Abs. P-134.
- Rodriguez-Fraile M, Arbizu J, Iñarrairaegui M *et al.* Evaluation of ^{99m}Tc-MAA SPECT as a biomarker of liver tumor response to radioembolization with 90-yttrium. *European Association of Nuclear Medicine (EANM) Conference 2008*; Abs. P206.
- Cremonesi M, Ferrari M, Bartolomei M *et al.* Radioembolisation with ⁹⁰Y-microspheres: any possible correlation among response, imaging, and dosimetry? *European Association of Nuclear Medicine (EANM) Conference 2008*; Abs. P591.
- Ahmadzadehfar H, Biermann K, Sabet A *et al.* Significance of Bremsstrahlung scans in patients treated by selective internal radiation therapy (SIRT). *European Association of Nuclear Medicine (EANM) Conference 2008*; Abs. PW104.
- Campbell J, Wong O, Muzik O *et al.* Dose response to Y-90 microsphere treatment of metastatic liver cancer by quantitative analysis SPECT and PET images. *Journal of Nuclear Medicine* 2008; **49** (Suppl 1): 43P Abs. 170.
- Campbell J, Mahajan P, Savin M, Wong O. Benefits of SPECT and SPECT-CT liver perfusion imaging in treatment planning for Y-90 radioembolization. *Journal of Nuclear Medicine* 2008; **49** (Suppl 1): 345P. Abs. 1460.
- Machac, J, Heiba, S, Zhang Z *et al.* Prediction of yttrium 90 SIR-Spheres deposition by Tc 99m MAA SPECT/CT liver perfusion imaging and their relationship to angiographic flow. Radiomicrosphere Therapy: 4th Annual Symposium May 2008 *Journal of Interventional Oncology* 2009; **2**: 93.
- Machac, J, Heiba, S, Zhang Z *et al.* The value of planar and SPECT/CT Tc 99m MAA liver perfusion imaging in the planning of yttrium 90 SIR-Spheres therapy of tumors of the liver. Radiomicrosphere Therapy: 4th Annual Symposium May 2008 *Journal of Interventional Oncology* 2009; **2**: 94.
- Campbell J, Wong CO, Muzik O *et al.* Analysis of SPECT and PET images for the development of dose response curves in ⁹⁰Y microsphere radiotherapy. Radiomicrosphere Therapy: 4th Annual Symposium May 2008 *Journal of Interventional Oncology* 2009; **2**: 94.
- Campbell J, Mahajan P, Savin P, Wong CO. SPECT-CT liver perfusion imaging in treatment planning for ⁹⁰Y microsphere radiotherapy. Radiomicrosphere Therapy: 4th Annual Symposium May 2008 *Journal of Interventional Oncology* 2009; **2**: 94.
- Gulec S, Mesoloras G, Dezarn W *et al.* Biologic determinants of absorbed dose estimates in Y-90 microsphere treatment of hepatic malignancies: Significance of tumor perfusion measured by Tc-99m MAA imaging. *Journal of Nuclear Medicine* 2007; **48** (Suppl 2): 396P Abs. 1676.
- Machac J, Weintraub J, Nowakowski F *et al.* Variations in liver perfusion patterns in patients with liver tumors undergoing therapy with yttrium-90 microspheres, studied with SPECT/CT. *Journal of Nuclear Medicine* 2007; **48** (Suppl 2): 396P Abs. 1677.
- Machac J, Weintraub J, Nowakowski F *et al.* Does perfusion imaging of the liver with Tc-99m MAA reliably predict the pattern of therapeutic deposition of Yttrium-90 SirSpheres? *Journal of Nuclear Medicine* 2007; **48** (Suppl 2): 399P. Abs. 1686.1
- Lazar B, Gates V, McDonald N *et al.* Hepatic volume analysis using SPECT and CT as a clinical tool for microsphere treatment planning. *Journal of Nuclear Medicine* 2007; **48** (Suppl 2): 473P Abs. 2214.
- Renshaw J, Gates V, Spies S *et al.* Effect of elapsed time between Tc-99m MAA preparation and patient imaging on evaluation of lung shunting. *Journal of Nuclear Medicine* 2007; **48** (Suppl 2): 476P Abs. 2225.
- Burdette AS, Carlisle JG, Morton KA. Fusion of Tc-99m MAA SPECT images to CT or MR images in yttrium-90 microsphere radioembolization treatment planning. *Society of Interventional Radiology (SIR) conference 2007*; Abs. 402.

Denecke T, Lopez Hänninen E, Rühl R *et al.* Planning transarterial radioembolisation of colorectal liver metastases with Y90-microspheres: diagnostic imaging approach. *European Association of Nuclear Medicine (EANM) Conference 2006*; Abs. 180.

Rose SC, Iussich G, Casola G. Comparison of computed tomography-angiography and digital subtraction-angiography for displaying vascular anatomy relevant to regional therapy for liver cancers. *Cardiovascular and Interventional Radiology 2006*. Abs. P68.

Sebastian AJ, Szyszko T, Al-Nahhas A, Tait NP. Value of hepatic angiography and Brehmstrahlung imaging in selective internal radiation therapy. *Cardiovascular and Interventional Radiology 2006*. Abs. P88.

Gulec S, Mesoloras G, Dezarn A *et al.* Safety and efficacy evaluation of Y-90 microsphere treatment of liver malignancies using medical internal radiation dosimetry (MIRD). *Journal of Nuclear Medicine 2006*; **47** (Suppl 1): 493P Abs. 1812.

Managing Side Effects and Complications

Papers on Managing Side Effects and Complications

Smits ML, van den Hoven AF, Rosenbaum CE *et al.* Clinical and laboratory toxicity after intra-arterial radioembolization with ⁹⁰Y-microspheres for unresectable liver metastases. *PLoS One* 2013; **24**; 8: e69448.

Tan AE, Kao YH, Xie W. Excessive hepatic arterial-portal venous shunting may predict failure of microparticle localization in hepatocellular carcinomas. *World Journal of Nuclear Medicine* 2013; **12**: 48–50.

Peterson JL, Vallow LA, Johnson DW *et al.* Complications after ⁹⁰Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients. *Brachytherapy* 2013 Aug 14; ePub doi: 10.1016/j.brachy.2013.05.008.

Kurian RR, Preston SR, Bagwan IN. Iatrogenic gastric ulceration. *Virchows Arch* 2013; **462**: 685–686.

Kosiek O, Strach K, Pech M *et al.* [Finding-specific minimally invasive approach for acute radiation-induced cholecystitis after (⁹⁰)Y-radioembolisation of intrahepatic metastases]. *Zentralblatt für Chirurgie* 2013; **138**: 84–87. [Article in German]

Lam MG, Abdelmaksoud MH, Chang DT *et al.* Safety of ⁹⁰Y radioembolization in patients who have undergone previous external beam radiation therapy. *International Journal of Radiation Oncology, Biology and Physics* 2013 Jul 9; ePub doi: 10.1016/j.ijrobp.2013.05.041.

Stiven P, Frizelle FA. The importance of anatomy in a new iatrogenic disease: Yttrium microsphere-induced gastritis. *New Zealand Medical Journal* 2013 Jun 28; **126**: 65–66.

Rodríguez-Lago I, Carretero C, Herráiz M *et al.* Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumors. *World Journal of Gastroenterology* 2013; **19**: 2935–2940.

Luo DL, Chan JK. Basophilic round bodies in gastric biopsies little known by pathologists: Iatrogenic yttrium ⁹⁰ microspheres deriving from selective internal radiation therapy. *International Journal of Surgery and Pathology* 2013 Apr 5; ePub doi: 10.1177/1066896913481057.

Veloso N, Brandão C, Gonçalves B *et al.* Gastroduodenal ulceration following liver radioembolization with yttrium-90. *Endoscopy* 2013; **45**: E108–109.

Wang DS, Louie JD, Kothary N *et al.* Prophylactic topically applied ice to prevent cutaneous complications of nontarget chemoembolization and radioembolization. *Journal of Vascular and Interventional Radiology* 2013; **24**: 596–600.

Gil-Alzugaray B, Chopitea A, Iñarrairaegui M *et al.* Prognostic factors and prevention of radioembolization-induced liver disease. *Hepatology* 2013; **57**: 1078–1087.

Lam MG, Banerjee S, Louie JD *et al.* Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization. *Cardiovascular and Interventional Radiology* 2013 Feb 22; ePub doi: 10.1007/s00270-013-0579-1.

Lam MG, Louie JD, Iagaru AH *et al.* Safety of repeated Yttrium-90 radioembolization. *Cardiovascular and Interventional Radiology* 2013 Jan 26; ePub doi: 10.1007/s00270-013-0547-9.

Gil-Alzugaray B, Chopitea A, Iñarrairaegui M *et al.* Prognostic factors and prevention of radioembolization-induced liver disease. *Hepatology* 2012 Dec 10. ePub doi: 10.1002/hep.26191.

Seidensticker R, Seidensticker M, Damm R *et al.* Hepatic toxicity after radioembolization of the liver using ⁹⁰Y-microspheres: Sequential lobar versus whole liver approach. *Cardiovascular and Interventional Radiology* 2012; **35**: 1109–1118.

Metyko J, Williford J, Erwin W *et al.* Long-lived impurities of ⁹⁰Y-labeled microspheres, TheraSphere and SIR-Spheres, and the impact on patient dose and waste management. *Health Physics* 2012; **103**: S204–S208.

Bilbao J. Maximising effects and minimising complications of selective internal radiation therapy. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 51–52.

Kennedy A. Calculating yttrium-90 activity with clinical considerations. *Proceedings of the 4th European Symposium on Liver-Directed Therapy Using ⁹⁰Y Microspheres*, *European Journal of Cancer Supplements* 2012; **10** (3): 59–61.

- Theysohn JM, Müller S, Schlaak JF *et al.* Selective internal radiotherapy (SIRT) of hepatic tumors: how to deal with the cystic artery. *Cardiovascular and Interventional Radiology* 2012 Sep 15; ePub doi: 10.1007/s00270-012-0474-1.
- Sabet A, Ahmadzadehfar H, Schäfer N *et al.* Survival after accidental extrahepatic distribution of Y90 microspheres to the mesentery during a radioembolization procedure. *Cardiovascular and Interventional Radiology* 2012; **35**: 954–957.
- Garg M, Strauchen JA, Warner RR, Divino CM. Radioembolization-induced gastroduodenal ulcer. *The American Surgeon* 2012; **78**: 621–623.
- Wright CL, Werner JD, Tran JM *et al.* Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. *Journal of Vascular and Interventional Radiology* 2012; **23**: 669–674.
- Kosiek O, Strach K, Pech M *et al.* Situativ und befundadaptiertes, minimalinvasives management einer akuten radiogenen cholezystitis nach ⁹⁰Y-radioembolisation intrahepatischer metastasen. [Finding-specific minimally invasive approach for acute radiation-induced cholecystitis after ⁹⁰Y-radioembolisation of intrahepatic metastases.]. *Zentralblatt für Chirurgie* 2012 Mar 2; ePub doi: 10.1055/s-0031-1283811. [in German]
- Gupta A, Gill A, Shrikanthan S *et al.* Nontargeted Y-90 microsphere radioembolization to duodenum visualized on Y-90 PET/CT and Bremsstrahlung SPECT/CT. *Clinical Nuclear Medicine* 2012; **37**: 98–99.
- Wallstabe I, Bakos G, Plötner A *et al.* Gastroduodenal ulceration after selective internal radiation therapy of liver tumor. *Endoscopy* 2012; **44**: E354–355.
- Latif E, Chua TC, Morris DL. Damage control surgery for liver rupture following selective internal radiation therapy for unresectable colorectal liver metastases. *ANZ Journal of Surgery* 2011; **81**: 570–572.
- Brown DB. Hepatic artery dissection in a patient on bevacizumab resulting in pseudoaneurysm formation. *Seminars in Interventional Radiology* 2011; **28**: 142–146.
- Nosher JL, Ohman-Strickland PA, Jabbour S *et al.* Changes in liver and spleen volumes and liver function after radioembolization with yttrium-90 resin microspheres. *Journal of Vascular and Interventional Radiology* 2011; **22**: 706–716.
- Lance C, McLennan G, Obuchowski N *et al.* Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. *Journal of Vascular and Interventional Radiology* 2011; **22**: 1697–1705.
- Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. *Seminars in Radiation Oncology* 2011; **21**: 256–263.
- Piana PM, Gonsalves CF, Sato T *et al.* Toxicities after radioembolization with yttrium-90 SIR-Spheres: Incidence and contributing risk factors at a single center. *Journal of Vascular and Interventional Radiology* 2011; **22**: 1373–1379.
- Paprottka PM, Schmidt GP, Trumm CG *et al.* Changes in normal liver and spleen volume after radioembolization with ⁹⁰Y-resin microspheres in metastatic breast cancer patients: Findings and clinical significance. *Cardiovascular and Interventional Radiology* 2011; **34**: 964–972.
- Liu DM. Interventional oncology – avoiding common pitfalls to reduce toxicity in hepatic radioembolization. *Journal of Nuclear Medicine & Radiation Therapy* 2011; **2**: 106 ePub doi: 10.4172/2155-9619.1000106.
- Meer AB, Louie JD, Abdelmaksoud MHK *et al.* Intrahepatic collateral supply to the previously embolized right gastric artery: a potential pitfall for nontarget radioembolization. *Journal of Vascular and Interventional Radiology* 2011; **22**: 575–577.
- Ahuja C, Chadha M, Critchfield JJ. Intraoperative carcinoid hypertensive crisis precipitated by yttrium 90 microsphere radioembolotherapy. *Endocrine Practice* 2010; **16**: 1074–1075.
- Yang CW, Yen HH, Su WW *et al.* Profound transient thrombocytopenia associated with ⁹⁰yttrium microsphere therapy for inoperable hepatoma. *Southern Medical Journal* 2010; **103**: 1264–1268.
- Nair J, Liu C, Caridi J *et al.* Gastroduodenal ulcerations as a delayed complication of hepatic metastasis radioembolization. *Journal of Clinical Oncology* 2010; **28**: e735–736.
- Sjoquist KM, Goldstein D, Bester L. A serious complication of selected internal radiation therapy: case report and literature review. *The Oncologist* 2010; **15**: 830–835.

- Kubisch CH, Beigel F, Ihrler S *et al.* Oesophageal ulceration after selective internal radiation therapy in a patient with carcinoma of unknown primary. *Zeitschrift für Gastroenterologie / German Journal of Gastroenterology* 2010; **48**: 546–550.
- Naymagon S, Warner RR, Patel K *et al.* Gastroduodenal ulceration associated with radioembolization for the treatment of hepatic tumors: an institutional experience and review of the literature. *Digestive Diseases and Sciences* 2010; **55**: 2450–2458.
- Ulenaers M, Dedeurwaerdere F, Christiaens P. Gastric ulceration complicating selective internal radiation therapy of liver metastases. *Clinical Gastroenterology and Hepatology* 2010; **8**: A18.
- Jazwinski A, Bentley R, Teitelman M. Gastric ulceration in a patient treated with Sir-Spheres. *Clinical Gastroenterology and Hepatology* 2010; **8**: A22.
- Aloia TA, Barakat O, Connelly J *et al.* Gastric radiation enteritis after intra-arterial yttrium-90 microsphere therapy for early stage hepatocellular carcinoma. *Experimental and Clinical Transplantation* 2009; **7**: 141–144.
- Schultz CC, Campbell J, Bakalyar D *et al.* Y-90 microsphere therapy: prevention of adverse events. *Cancer Biotherapy & Radiopharmaceuticals* 2009; **24**: 427–333.
- Silvanto A, Novelli M, Lovat L. SIRT--an uncommon cause of gastroduodenal ulceration. *Histopathology* 2009; **55**: 114–115.
- Riaz A, Lewandowski RJ, Kulik LM *et al.* Complications following radioembolization with Yttrium-90 microspheres: A comprehensive literature review. *Journal of Vascular and Interventional Radiology* 2009; **20**: 1121–1130.
- Konda A, Savin MA, Cappell MS, Duffy MC. Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity. *Gastrointestinal Endoscopy* 2009; **70**: 561–567.
- Rühl R, Seidensticker M, Peters N *et al.* Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy. *Digestive Diseases* 2009; **27**: 189–199.
- Schleipman AR, Gallagher PW, Gerbaudo VH. Optimizing safety of selective internal radiation therapy (SIRT) of hepatic tumors with ⁹⁰Y resin microspheres: a systematic approach to preparation and radiometric procedures. *Health Physics* 2009; **96** (2 Suppl): S16–S21.
- Leong QM, Lai HK, Lo RGH *et al.* Radiation dermatitis following radioembolization for hepatocellular carcinoma: A case for prophylactic embolization of a patent falciform artery. *Journal of Vascular and Interventional Radiology* 2009; **20**: 833–836.
- Siddiqi NH, Khan AJ, Devlin PM. Palonosetron – A single-dose antiemetic adjunct for hepatic artery radioembolization: A feasibility study. *Cardiovascular and Interventional Radiology* 2009; **32**: 47–51.
- Kennedy AS, McNeillie P, Dezarn WA *et al.* Treatment parameters and outcome in 680 treatments of internal radiation with resin ⁹⁰Y-Microspheres for unresectable hepatic tumors. *International Journal of Radiation Oncology, Biology and Physics* 2009; **74**: 1494–1500.
- Zimmermann L, Dudeck O, Schmitt J, Ricke J, Roessner A, Malfertheiner P, Mönkemüller K. Duodenal ulcer due to yttrium microspheres used for selective internal radiation therapy of hepatocellular cancer. *Gastrointestinal Endoscopy* 2009; **69**: 977–978.
- Crowder CD, Grabowski C, Inampudi S *et al.* Selective internal radiation therapy-induced extrahepatic injury: an emerging cause of iatrogenic organ damage. *American Journal of Surgical Pathology* 2009; **33**: 963–975.
- Cao C, Yana TD, Baillie T, Bester L. Radiation cholecystitis—A case report after Yttrium-90 microsphere therapy. *European Journal of Radiology Extra* 2009; **72**: e73–e74.
- Nelson K, Vause PE Jr, Koropova P. Post-mortem considerations of Yttrium-90 ⁹⁰Y microsphere therapy procedures. *Health Physics* 2008; **95** (5 Suppl): S156–S161.
- Ogawa F, Mino-Kenudson M, Shimizu M *et al.* Gastroduodenitis associated with yttrium 90-microsphere selective internal radiation: an iatrogenic complication in need of recognition. *Archives of Pathology and Laboratory Medicine* 2008; **132**: 1734–1738.
- Chernyak I, Bester L, Freund J, Richardson M. Anterior abdominal wall uptake in intrahepatic arterial brachytherapy with yttrium-90 Sir Spheres for hepatic malignancy. *Clinical Nuclear Medicine* 2008; **33**: 677–680.
- South CD, Meyer MM, Meis G *et al.* Yttrium-90 microsphere-induced gastrointestinal tract ulceration. *World Journal of Surgical Oncology* 2008; **6**: 93.

Hoffman MA, Rubin JI, Vinceguerra VP, Nowakowski FS, Warner RPR. Severe coagulopathy after ⁹⁰Y microsphere administration: Resemblance to the Kasabach-Merritt syndrome. *Journal of Vascular and Interventional Radiology* 2008; **19**: 1099–1102.

Townsend A, Price TJ, Patterson K, Pittman K. Fluorouracil-induced hepatic artery spasm preventing yttrium-90 microsphere administration. *Clinical Nuclear Medicine* 2008; **33**: 528–530.

Ng SS, Yu SC, Lai PB, Lau WY. Biliary complications associated with selective internal radiation (SIR) therapy for unresectable liver malignancies. *Digestive Diseases and Sciences* 2008; **53**: 2813–2817.

Newland L, Walsh A, Gilbert D *et al.* Selective Internal Radiation Therapy: A case of SIR-Sphere associated duodenal ulceration. *Pathology* 2007; **39**: 526–528.

Mallach S, Ramp U, Erhardt A *et al.* An uncommon cause of gastro-duodenal ulceration. *World Journal of Gastroenterology* 2008; **14**: 2593–2595.

Thamboo TP, Wai CT, Lim LG, Wang SC. Late gastric ulceration and cytomegalovirus infection following selective internal radiation therapy (SIRT) of the liver. *Pathology* 2008; **40**: 303–305.

Sangro B, Gil-Alzugaray B, Rodriguez J *et al.* Liver disease induced by radioembolization of liver tumors. *Cancer* 2008; **112**: 1538–1546.

Price TJ, Townsend A. Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. *Archives of Surgery* 2008; **143**: 313–314.

Neff R, Abdel-Misih R, Khatri J *et al.* The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors. *Cancer Investigation* 2008; **26**: 173–177.

Gulec SA and Siegel JA. Posttherapy radiation safety considerations in radiomicrosphere treatment with ⁹⁰Y-microspheres. *Journal of Nuclear Medicine* 2007; **48**: 2080–2086.

Murthy R, Brown DB, Salem R *et al.* Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. *Journal of Vascular and Interventional Radiology* 2007; **18**: 553–562.

Yarze JC, Hoffman MM. Another case of severe, chronically symptomatic, nonhealing gastroduodenal injury after radioembolization of hepatic tumor. *American Journal of Gastroenterology* 2007; **102**: 2863. [Comment on: Carretero *et al.* *American Journal of Gastroenterology* 2007 Jun; **102**: 1216–1220.]

Carretero C, Munoz-Navas M, Betes M *et al.* Gastroduodenal injury after radioembolization of hepatic tumors. *American Journal of Gastroenterology* 2007; **102**: 1–5.

Szyszkowski T, AL-Nahhas A, Tait P *et al.* Management and prevention of adverse effects related to treatment of liver tumours with ⁹⁰Y microspheres. *Nuclear Medicine Communications* 2007; **28**: 21–24.

Stubbs R. Portal hypertension and liver surgery following selective internal radiation therapy with ⁹⁰Yttrium microspheres. *Journal of Clinical Oncology* 2006; **24**: 15e. [Comment on Ayav *et al.* *Journal of Clinical Oncology* 2005; **23**: 8275–8276.]

Ayav A, Habib N, Jiao L. Portal hypertension secondary to ⁹⁰Yttrium microspheres: An unknown complication. *Journal of Clinical Oncology* 2005; **23**: 8275–8276.

Brock H; Günther RW; Haage P. Leberzirrhose als folge selektiver hepatischer radioembolisation mit ⁹⁰Yttrium-mikrosphären. *Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren* 2006; **178**: 538–549. [in German]

Yip D, Allen R, Ashton C *et al.* Letter: Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. *Journal of Gastroenterology and Hepatology* 2004; **19**: 347–349.

Thamboo T, Tan K, Wang S *et al.* Extra-hepatic embolisation of Y-90 microspheres from selective internal radiation therapy (SIRT) of the liver. *Pathology* 2003; **35**: 351–353.

Wickremesekera J, Chen W, Cannan R *et al.* Serum proinflammatory cytokine response in patients with advanced liver tumors following selective internal radiation therapy (SIRT) with yttrium-90 microspheres. *International Journal of Radiation Oncology, Biology and Physics* 2001; **49**: 1015–1021.

Dancey JE, Goin J. *J Nucl Med* 2001; **42**: 1588–1589. [Comment on Ho *et al.* *Journal of Nuclear Medicine* 2001; **42**: 1587–1588.]

Ho S, Lau J, Leung T. Intrahepatic Y-90 microspheres for hepatocellular carcinoma. *Journal of Nuclear Medicine* 2001; **42**: 1587–1588.

Yorke ED, Jackson A, Fox RA, Wessels BW, Gray BN. Can current models explain the lack of liver complications in Y-90 microsphere therapy? *Clinical Cancer Research* 1999; **5**: 3024a–3030a.

Leung T, Lau W, Ho S *et al.* Radiation pneumonitis after selective internal radiation treatment with intraarterial yttrium-90 microspheres for inoperable hepatic tumors. *International Journal of Radiation Oncology, Biology and Physics* 1995; **33**: 919–924.

Gray BN, Burton MA, Kelleher D *et al.* Tolerance of the liver to the effects of Yttrium-90 radiation. *International Journal of Radiation Oncology, Biology and Physics* 1990; **18**: 619–623.

Abstracts on Managing Side Effects and Complications

Lam MG, Louie JD, Banerjee A *et al.* Splenomegaly-associated thrombocytopenia after hepatic Yttrium-90 radioembolization. *Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2013; **24** (Suppl): S34–S35 Abs. 61.

Mahvash A, Moayyad J, Shreyaah S *et al.* Y90 radioembolization in patients with compromise of the Ampulla of Vater. *GEST meeting abstracts, Journal of Vascular and Interventional Radiology* 2012; **23**: 577.e12 Abs.

Gil-Alzugaray B, Iñarrairaegui M, Benito A *et al.* Incidence and risk factors of radioembolization (RE)-induced liver disease: results of global therapeutic strategy aiming to prevention. *47th annual meeting of the European Association for the Study of the Liver (EASL), Journal of Hepatology* 2012; **56** (Suppl 2): S402 Abs. 1028.

McCann JW, Larkin AM, Moore LT *et al.* Multi-center correlation of external exposure rates from ⁹⁰Y radioembolization patients: contact precautions are unnecessary based on nuclear regulatory commission regulations. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S68–69 Abs. 164.

Cholapranee A, Soulen MC. Risk of liver abscess following Y-90 radioembolization in patients with prior biliary intervention. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S71 Abs. 170.

Louie JD, Wang EA, Broadwell S *et al.* First in man experience with the Surefire infusion system: a dedicated microcatheter system to eliminate reflux during embolotherapy. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S80 Abs. S195.

Wang DS, Louie JD, Shah RP *et al.* Prophylactic topically applied ice to prevent cutaneous complications of nontarget chemoembolization and radioembolization of liver tumors. *Society of Interventional Radiology (SIR) 37th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2012; **23** (Suppl): S84 Abs. 203.

Ahmadzadehfar H, Muckle M, Sabet A *et al.* The effectiveness of Bremsstrahlung SPECT-CT of the abdomen after radioembolization in the prediction of radiation induced gastroduodenal side effects. *Society of Nuclear Medicine (SNM) Annual Meeting, Journal of Nuclear Medicine* 2011; **52** (Suppl 1): Abs. 1361.

Abdelmaksoud M, Chang D, Eclov NC *et al.* Safety of Y90 radioembolization in patients who have undergone previous external beam radiation therapy. *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2011; **22** (Suppl): S87 Abs. 201.

Piana P, McCann JW, Anne R *et al.* Toxicities following radioembolization with Y90 SIR-Spheres: Incidence and contributing risk factors at a single center. *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2011; **22** (Suppl): S88 Abs. 206.

Sag AA, Savin MA, Lal NR *et al.* The post-Yttrium-90 microsphere gallbladder: Imaging findings and incidence of cholecystitis. *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2011; **22** (Suppl): S101 Abs. 237.

Underhill MP, Getzen TM, Myers D *et al.* Cholecystitis following hepatic embolization? Appearances may be deceiving. *Society of Interventional Radiology (SIR) 36th Annual Scientific Meeting, Journal of Vascular and Interventional Radiology* 2011; **22** (Suppl): S122 Abs. 289.

Nutting C, Kennedy A, Kortz E. Radioembolization of liver metastases in the setting of a violated Ampulla. *GEST meeting* 2010; Abs.

Rose SC, Nelson KJ, Finch MR. Protecting the gut from toxic hepatic regional therapy. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2009; Abs. P-156.

Rose SC, Nelson KJ, Finch MR. Acute systemic hypertension precipitated by ^{90}Y radioembolization. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2009; Abs. P-167.

McWilliams JP, Lee EW, Kee ST *et al.* Distal protection of the gallbladder through embolization of the cystic artery prior to radioembolization: technical feasibility and safety. *Cardiovascular and Interventional Radiology in Europe (CIRSE)* 2009; Abs. P-150.

Iñarrairaegui M, D'Avola D, Bilbao JI *et al.* Toxicity of Y90-radioembolisation resulting from radiation of non-target tissues. *3rd International Liver Cancer Association (ILCA) meeting* 2009; Abs. O-026.

Alonso-Burgos A, Martinez-Cuesta A, Valero M *et al.* Complications of the radioembolization (RE) of liver tumors: prevention and treatment. *Cardiovascular and Interventional Radiology* 2007; Abs. P-73.

Kennedy AS, Dezarn W, McNeillie P *et al.* Repeat ^{90}Y -microsphere radioembolization for hepatic malignancies: Safety and patient selection issues. ASCO Annual Meeting Proceedings Part I *Journal of Clinical Oncology* 2007; **25** No. 18S (June 20 Suppl): Abs. 15177.

Kennedy AS, Dezarn W, McNeillie P *et al.* Liver tolerance to repeat ^{90}Y -microsphere radioembolization. *ASCO Gastrointestinal Cancers Symposium* 2007; Abs. 191.

Books and Book Chapters

Books

- Kennedy A, Nag S, Murthy R *et al.* Liver-directed radiotherapy using ^{90}Y microspheres (radioembolization) for primary and metastatic cancers: Key concepts & clinical updates. Wake Radiology and Postgraduate Institute for Medicine 2008.
- Hoffmann RT, Reiser M (eds). Selektive interne radiotherapie (SIRT) – Grundlagen und klinische anwendung. Uni-Med Verlag AG, Bremen-London-Boston, 2008; ISBN: 978-3-8374-1033-4. [in German]
- Bilbao JI, Reiser MF (eds). Liver radioembolization with ^{90}Y microspheres. Springer, New York 2008; ISBN 978-3-540-35421-5.

Book Chapters

- Wagman LD, Robertson JM, Raftery L, O'Neil B. Liver, gallbladder, and biliary tract cancers. In: Pazdur, Wagman LD, Camphausen KA, Hoskins WJ (eds.), *Cancer Management: A Multidisciplinary Approach*; 13th Edition. CMP Healthcare Media LLC, 2011.
- Murthy R, Mutha P, Gupta S. Yttrium-90 radioembolotherapy for hepatocellular cancer. In: McMasters KM, Vauthey JN (eds.), *Hepatocellular Carcinoma*, Springer, New York 2011; 319–335.
- Riaz A, Kulik L, Abecassis M, Salem R. Internal radiation therapy for liver tumors. In: Clavien PA (ed). *Malignant Liver Tumors: Current and Emerging Therapies*. Wiley-Blackwell, Chichester, UK: 2010; 131–138.
- Georgiades CS, Geschwind JF. Transcatheter Management of Neoplasms. In: Minev BR (ed). *Cancer Growth and Progression, 1, Volume 13, Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures*. Springer, New York 2011; 341–347.
- Kennedy A, Welsh J. Radioembolization with yttrium-90 microspheres for primary and metastatic hepatic cancer. In: Speer TW (ed). *Targeted radionuclide therapy*. Lippincott Williams & Wilkins, 2010; 305–317.
- Riaz A, Salem R. Liver tumors: metastases. In: Kessel D, Ray C (eds). *Transcatheter Embolization and Therapy; Techniques in Interventional Radiology, Part 2*, 2010; 197–203.
- 069: Radioembolization for Hepatocellular Carcinoma; and 071: Radioembolization for Other Hepatic Malignancies. In: Mauro MA, Murphy K, Thomson K, Venbrux A and Zollikofer CL (eds). *Image-Guided Interventions: Expert Radiology Series*. Elsevier, New York: 2008.
- Stubbs RS, Correia MM. Selective internal radiation therapy for liver tumours. In: Blumgart L (Org.). *Surgery of the liver, biliary tract and pancreas*. 4th ed. New York: Elsevier, 2006; 567–577.
- Al-Nahhas A, Szyszko T, Tait P, Damrah O, Canelo R. Selective internal radiation therapy (SIRT) in the management of liver tumours. In Karaliotas C, Broelsch C, Habib N (eds): *Liver and biliary tract surgery*. Springer, New York 2006; 409–418.
- Zacharoulis D, Habib NA, Jiao R. The use of Sirtex in inoperable liver tumours. A surgeon's view. In Karaliotas C, Broelsch C, Habib N (eds): *Liver and biliary tract surgery*. Springer, New York 2006; 419–420.
- Thomadsen B, Welsh J, Hammes R. Microspheres as microbrachytherapy, in Thomadsen B, Rivard M, Butler W (eds): *Brachytherapy physics (2nd Edition)*. Madison, Wisconsin, Medical Physics Publishing 2005; 955–965.
- Stubbs R. Local radio ablative techniques for liver tumors. 2nd ed. Sudbury, Massachusetts: Jones and Bartlett; 2003.
- Stubbs R, Cannan R. Selective internal radiation therapy with ^{90}Y microspheres for primary or metastatic cancer confined to the liver. In: Habib N, editor. *Multi-treatment modalities of liver tumours*. New York: Kluwer Academic/Plenum Publishers; 2002. pp. 305–321.
- Lau W, Ho S, Leung T. Internal radiation therapy through the hepatic artery. In: Habib N, editor. *Multi-treatment modalities of liver tumours*. New York: Kluwer Academic/Plenum. 2002.
- Willmott N, Daly J, Gray B. Perspectives in the management of liver metastases. In: Willmott N, Daly J, editors. *Microspheres and regional cancer therapy*: CRC Press Inc. 1994; 229–235.